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Substandard and falsified medicines (SF) are a major global public health problem and occur 
throughout healthcare systems worldwide. With an average occurrence of 10% of all medicines 
globally, the specific levels range from ~1% of all medicines in high-income countries (HIC) to 
as much as 30-40% in low-income countries (LIC) and low-middle income countries (LMIC). 
Current detection methods for SF medicines range from ‘low tech’ approaches, for example, 
visual appearance, thin layer chromatography (TLC) to those that are technically refined, such as, 
Raman spectroscopy, Near Infrared (NIR) spectroscopy and Mass Spectrometry (MS). In order 
to counteract the increasing complexity of anti-counterfeit measures, counterfeiters are finding 
ever more sophisticated ways to bypass existing screening techniques. Therefore, the aim of this 
research is to develop a novel rapid screening method to identify SF medicines. 
The performance of seven different benchtop instruments has been investigated with respect to 
their potential to deliver rapid assessment of the identity and to quantify the level of Active 
Pharmaceutical Ingredient’s (API’s) present in tablet samples. 
The materials used in this research comprised of 29 reference samples and 64 individual group 
samples from 8 countries, totaling some 867 tablets. Tablets were analysed in both whole and 
powdered forms. 
Mass Spectrometry provided the least complex data, followed by Raman and then Attenuated 
Total Reflectance Fourier Transform Infrared (ATR FTIR). The mass spectrometer was the least 
reliable instrument, but provided the greatest sensitivity.  
Successful identification of the API was obtained from ATR FTIR and Raman analysis and from 
Direct Insertion Probe (DIP) Mass Spectrometry. 
Quantitative levels of API could be obtained from Ultraviolet (UV) and ATR FTIR 
measurements, whilst some excipient levels could be determined by Elemental Dispersive X-ray 
(EDX) spectroscopy. Handheld Raman systems produced some erroneous quantitative 
information. 
The majority of samples examined were within ±10% of the stated level, as per the British 
Pharmacopeia specifications; however, there was some evidence of substandard medication. 
Substandard medication was suspected in 2 of the 64 pharmaceutical products assessed. 
At the present state of development, the Raman and ATR FTIR equipment could be used in 






I would like to thank my supervisors, Dr Graham Lawson and Prof. Sangeeta Tanna, for their 
advice and guidance throughout the project. 
This study would not have been possible without the support of those that have helped me during 
this time. My thanks go to those that were there at the start of the journey and encouraged me to 
undertake this research who have since left DMU; Dr Mike Needham and Carl Winfield. I am 
very grateful for the support of my line manager Zahoor Ul-Haq, whose support has been 
invaluable and all of those chats have now come to fruition and to the technical services manager 
Dr Richard Webster who has supported me throughout this process, which was undertaken 
alongside my job. 
Thanks go to all the members of DMU staff who have helped support my research along the way; 
Angela Ferguson, Belinda Sone, Alan Hogg, Leonie Hough, Krishna Nama, Richard Brawn, Jinit 
Masania, and Liz O’Brien. 
Special thanks go to all of the students and staff who collected samples for me, without you this 
study would have not been possible. 
Thanks go to Dr Owen Wilkin at Bruker UK, for all his help and support with ATR FTIR and 
Raman spectroscopy. 
To my family who have supported me all the way, I appreciate all of the help and support you 
have given me. To my husband, Dave and daughter Jessica, your love and continued support has 
kept me going through everything, this would not have been possible without you. And, yes Jess, 
mummy has finally finished!  
I also have to thank my friends Liz and Emma, who have kept me going throughout everything 





Peer Reviewed Journal Publications 
Lawson G., Turay E., Armitage R., Goodyer L., Tanna S. (2014) Is it what it says on the 
packet? ATR FTIR provides a rapid answer to counterfeit tablet formulations. British 
Global and Travel Health Association Journal, 23, p. 55-57. 
Conference Oral Presentations 
Armitage, R. (2017) Identification of Counterfeit Medicines – A Truly Global Issue. 
Health and Life Sciences Conference, De Montfort University, Leicester, March 2017. 
Lawson, G., Armitage, R. and Tanna, S. (2012) Identification of Counterfeit Drugs. 
Invited lecture at Cafe Scientifique, Nanjing, China, November 2012. 
Lawson, G., Armitage, R. and Tanna, S. (2012) Identification of counterfeit medicines. 
7th Annual Pharmaceutical Anti-Counterfeiting Meeting. 2012, Visiongain Conference 
Centre, Barbican, London, UK. 26-27 June. 
Conference Poster Presentations 
Armitage, R., Lawson, G. and Tanna, S. (2017) Counterfeit or just poor quality control? 
Presented at 8th APS International PharmSci conference, University of Hertfordshire, 
Hatfield. 5th – 7th September 2017. 
Tanna, S., Lawson, G., Armitage, R. and Ogwu, J. (2017) #DMU engage – Helping 
people in Africa stay clear of fake and substandard medicines #DMU engage and #DMU 
global trip to Nairobi, 19 June-26 June 2017. 
Lawson, G., Ogwu, J., Armitage, R., Alcroft, C. and Tanna, S. (2016) Fast identification 
of counterfeit medicines – a comparison of two MS methods. Proceedings of the 21st 
International Mass Spectrometry conference, Toronto, Canada. 20 – 26 August 2016. 
Tanna S., Armitage R., Lawson G. (2013) Identification of counterfeit pills - Is rapid 
instrumental analysis possible? Proceedings of the 24th International Symposium on 
Pharmaceutical and Biomedical Analysis, 30 June-3 July 2013. 
v 
 
Keeling, R., Lawson, G., Needham, M., Tanna, S., (2011) A Microscopic Approach to a 
Big Problem… … Analysing Counterfeit Drugs. Presented at the 6th annual Vitae 
Midlands Hub Regional PhD Poster Competition, Nottingham Trent University, 
Nottingham, July 2011.  
Keeling, R., Lawson, G., Needham, M., Tanna, S., (2011) A Microscopic Approach to a 
Big Problem… … Analysing Counterfeit Drugs. Presented at De Montfort University 
Research Degree Students’ Poster competition and Research Open Day, De Montfort 
University, Leicester, May 2011. Awarded 3rd Prize. 
Keeling, R., Lawson, G., Tanna, S., Needham, M., (2010) It’s not what it says on the 
packet… …Counterfeit drugs. Presented at the FIRN Midlands regional student forensic 
science conference, De Montfort University, Leicester, April 2010. 
Conference Proceedings 
Lawson, G., Armitage, R., Alhedethe, A. and Tanna, S. (2013) Rapid identification of 
counterfeit pills by ATR FT/IR analysis of crushed samples. Journal of Analytical and 













Abstract ..................................................................................................................................... ii 
Acknowledgements .................................................................................................................. iii 
Outputs Resulting from this Research ..................................................................................... iv 
Timeline of PhD Study ............................................................................................................ vi 
List of Figures .......................................................................................................................... ix 
List of Tables ........................................................................................................................... xi 
Abbreviations ......................................................................................................................... xiii 
Glossary ................................................................................................................................... xi 
1 Introduction ......................................................................................................................... 12 
1.1 Background ................................................................................................................. 12 
1.2 Counterfeits become substandard or falsified medicines ............................................ 13 
1.3 The Extent of the Problem .......................................................................................... 15 
 Lower and Lower Middle-Income Countries (LIC and LMIC) .......................... 17 
 High Income Countries (HIC) ............................................................................. 19 
 Internet Pharmacies ............................................................................................. 21 
 Generic Medicines .............................................................................................. 22 
1.4 Growth of the Substandard and Falsified Medicines market ...................................... 23 
1.5 Combating Substandard and Falsified Medicines ....................................................... 24 
2 Tablet Formulation .............................................................................................................. 26 
2.1 Selection of Target Medication Forms ........................................................................ 26 
2.2 Components of a Tablet .............................................................................................. 26 
 Diluents ............................................................................................................... 29 
 Binding Agents ................................................................................................... 29 
 Lubricants ........................................................................................................... 30 
 Disintegrants ....................................................................................................... 30 
 Glidants ............................................................................................................... 31 
 Colourants (Pigments) ......................................................................................... 31 
viii 
 
2.3 Tablet Formulations for this research ......................................................................... 31 
 Atenolol ............................................................................................................... 32 
 Metformin Hydrochloride ................................................................................... 33 
 Antimalarials ....................................................................................................... 34 
2.4 Study Aims .................................................................................................................. 36 
3 Detection of Substandard and Falsified Medicines ............................................................. 37 
3.1 Spectroscopic Methods ............................................................................................... 40 
 Ultraviolet (UV) analysis .................................................................................... 40 
 Infrared Spectroscopy ......................................................................................... 41 
3.2 Chromatographic Methods .......................................................................................... 50 
 GPHF-Minilab .................................................................................................... 50 
3.3 Mass Spectrometry ...................................................................................................... 51 
 Direct Insertion Probe (DIP) Mass Spectrometry (MS) ...................................... 52 
 Atmospheric Solid Analysis Probe (ASAP) Mass Spectrometry (MS) .............. 53 
3.4 Electron Microscopy ................................................................................................... 54 
 Scanning Electron Microscopy (SEM) ................................................................ 54 
3.5 Comparison of Techniques ......................................................................................... 56 
 General reliability of methods ............................................................................. 57 
4 Instruments, Materials and Experimental Methods ............................................................ 59 
4.1 Instrumentation ........................................................................................................... 59 
4.2 Materials ..................................................................................................................... 60 
 Excipient and Reference Samples ....................................................................... 60 
 Tablet Samples .................................................................................................... 62 
4.3 Sample Preparation and Analysis ............................................................................... 66 
 Calibration Standard Preparation ........................................................................ 66 
 UV Sample Preparation and Analysis ................................................................. 69 
 ATR FTIR Specimen Preparation and Analysis ................................................. 69 
 Raman Sample Preparation and Analysis ........................................................... 72 
 DIP Sample Preparation and Analysis ................................................................ 73 
ix 
 
 ASAP Sample Preparation and Analysis ............................................................ 74 
 SEM/EDX Specimen Preparation and Analysis ................................................. 74 
5 API Identification and Discussion ...................................................................................... 75 
5.1 Spectroscopic .............................................................................................................. 75 
 Reference Spectra of API and Excipients ........................................................... 75 
 Whole Tablet Studies .......................................................................................... 91 
 Powered Tablet Sample Studies ........................................................................ 111 
5.2 DIP Mass Spectrometry ............................................................................................ 133 
 Reference Spectra ............................................................................................. 133 
 Powdered Tablet Sample Studies ...................................................................... 135 
 Discussion ......................................................................................................... 142 
5.3 Summary ................................................................................................................... 144 
6 API Quantification and Discussion ................................................................................... 146 
6.1 UV Analysis .............................................................................................................. 146 
 Atenolol ............................................................................................................. 146 
 Metformin Hydrochloride ................................................................................. 149 
6.2 ATR FTIR Spectroscopy .......................................................................................... 150 
 Atenolol ............................................................................................................. 150 
 Metformin Hydrochloride ................................................................................. 159 
6.3 Raman spectroscopy ................................................................................................. 167 
 Atenolol ............................................................................................................. 167 
 Paracetamol ....................................................................................................... 167 
6.4 EDX spectroscopy..................................................................................................... 167 
 Atenolol ............................................................................................................. 168 
 Metformin hydrochloride .................................................................................. 179 
6.5 Summary ................................................................................................................... 185 
7 Comparison of Techniques ............................................................................................... 186 
7.1 ATR FTIR and Raman Spectroscopy ....................................................................... 186 
 Raman Instrument Comparisons ....................................................................... 194 
x 
 
7.2 UV and ATR FTIR Spectroscopy ............................................................................. 198 
7.3 Mass spectrometry .................................................................................................... 200 
7.4 Elemental Analysis ................................................................................................... 201 
7.5 Discussion ................................................................................................................. 202 
7.6 Application of this research to LIC and LMIC ......................................................... 204 
8 Conclusion ........................................................................................................................ 206 
8.1 Identification of a Mislabelled or Possibly Falsified Pharmaceutical Product ......... 206 
 Raman Analyses ................................................................................................ 206 
 ATR-FT/IR Analyses ........................................................................................ 208 
 SEM/EDX Analyses ......................................................................................... 209 
 Discussion ......................................................................................................... 210 
9 Further Work ..................................................................................................................... 211 
References ................................................................................................................................. 212 







Figure 2.1: Frequency of excipient usage for the top 200 tablets (Dave, 2008) ......................... 28 
Figure 2.2: Molecular structure of atenolol ................................................................................ 33 
Figure 2.3: Molecular structure of metformin hydrochloride ..................................................... 34 
Figure 2.4: Molecular structure of chloroquine phosphate ......................................................... 35 
Figure 2.5: Molecular structure of quinine sulphate ................................................................... 35 
Figure 3.1: Levels of sample preparation for some analytical techniques, with those to be 
investigated highlighted .............................................................................................................. 38 
Figure 3.2: Electromagnetic spectrum and Infrared region (Chromacademy, undated) ............. 41 
Figure 3.3: Schematic of a Near Infrared spectrometer (Buchi, 2017) ....................................... 42 
Figure 3.4: ATR principle (Tanna et al, 2013) ........................................................................... 44 
Figure 3.5: Schematic of a Raman spectrometer (Andor, 2017) ................................................. 47 
Figure 3.6: Jablonski Diagram (Horiba, 2017) ........................................................................... 48 
Figure 3.7: Analysis of TiO2 anatase, a) NIR Spectroscopy; b) Raman Spectroscopy (Shimadzu, 
2016) ........................................................................................................................................... 49 
Figure 3.8: Analysis of lactose monohydrate, a) NIR Spectroscopy; b) Raman Spectroscopy 
(Shimadzu, 2016) ........................................................................................................................ 49 
Figure 3.9: Schematic of a DIP system ....................................................................................... 52 
Figure 3.10: Schematic of an ASAP system ............................................................................... 53 
Figure 3.11: Schematic diagram showing some of the signals that are generated when a primary 
electron beam interacts with a specimen in the Scanning Electron Microscope (Nichols, 2012)55 
Figure 4.1: ATR FTIR Spectra of atenolol analytical reference, 1 (Blue), 2 (Red), 3 (Green), 4 
(Purple) and 5 (Cyan) .................................................................................................................. 70 
Figure 4.2: ATR FTIR spectrum of atenolol with integration areas highlighted ........................ 71 
Figure 4.3: ATR FTIR spectrum of metformin hydrochloride with integration areas highlighted
 .................................................................................................................................................... 71 
Figure 4.4: Different Integration Methods, a) Method A, b) Method B and c) Method K ......... 72 
Figure 5.1: ATR FTIR spectra for common excipients in atenolol tablets, A) calcium carbonate, 
B) dicalcium phosphate, C) lactose monohydrate, D) magnesium stearate, E) maize starch, F) 
MCC, G) povidone, H) silicon dioxide (colloidal) and I) titanium dioxide ................................ 76 
Figure 5.2: ATR FTIR spectra for common excipients in metformin hydrochloride tablets, A) 
hypromellose, B) magnesium stearate, C) maize starch, D) MCC, E) PEG, F) povidone, G) silicon 
dioxide (colloidal) H) sodium starch glycolate and I) titanium dioxide ..................................... 77 
x 
   
Figure 5.3: ATR FTIR spectra for common excipients in antimalarial tablets, A) croscarmellose 
sodium, B) hypromellose, C) lactose monohydrate, D) magnesium stearate, E) maize starch, F) 
MCC, G) povidone, H) silicon dioxide (colloidal) and I) SLS ................................................... 78 
Figure 5.4: ATR FTIR spectrum of atenolol (analytical standard) ............................................. 79 
Figure 5.5: ATR FTIR spectrum of metformin hydrochloride (analytical standard) .................. 79 
Figure 5.6: ATR FTIR spectrum of chloroquine phosphate (analytical standard) ...................... 82 
Figure 5.7: ATR FTIR spectrum of quinine sulphate (analytical standard) ................................ 82 
Figure 5.8: Raman spectra for common excipients, A) calcium carbonate, B) croscarmellose 
sodium, C) dicalcium phosphate, D) lactose monohydrate, E) magnesium stearate, F) MCC, G) 
sodium starch glycolate, H) starch and I) titanium dioxide ........................................................ 85 
Figure 5.9: Raman spectra of atenolol (analytical standard) using BRAVO handheld spectrometer 
(Red), FORAM-2 spectrometer (Blue) and MIRA handheld spectrometer (Green) .................. 86 
Figure 5.10: Raman spectrum of metformin hydrochloride (analytical standard) using MIRA-3 
handheld spectrometer ................................................................................................................ 88 
Figure 5.11: Raman spectrum of chloroquine phosphate (analytical standard) using FORAM-2 
benchtop spectrometer ................................................................................................................ 89 
Figure 5.12: Raman spectrum of quinine sulphate (analytical standard) using FORAM-2 benchtop 
spectrometer ................................................................................................................................ 90 
Figure 5.13: A) ATR FTIR Spectra of At/UK/3 edge (Blue) and At/UK/3 centre (Green), B) ATR 
FTIR Spectra of At/UK/3 centre (Green) and atenolol analytical reference (Red)..................... 92 
Figure 5.14: A) ATR FTIR Spectra of At/IND/6 edge (Blue) and At/IND/6 centre (Green), B) 
ATR FTIR Spectra of At/IND/6 centre (Green) and atenolol analytical reference (Red) .......... 93 
Figure 5.15: A) ATR FTIR Spectra of At/SA/1 edge (Blue) and At/SA/1 centre (Green), B) ATR 
FTIR Spectra of At/SA/1 centre (Green) and atenolol analytical reference (Red) ..................... 94 
Figure 5.16: ATR FTIR Spectra of Met/UK/1 (Blue) and metformin hydrochloride analytical 
reference (Red) ............................................................................................................................ 95 
Figure 5.17: A) ATR FTIR Spectra of Met/IND/2 (Blue) and metformin hydrochloride analytical 
reference (Red), B) ATR FTIR Spectra of Met/IND/4 (Blue) and metformin hydrochloride 
analytical reference (Red) ........................................................................................................... 96 
Figure 5.18: ATR FTIR Spectra of Met/IND/11 (Blue) and metformin hydrochloride analytical 
reference (Red) ............................................................................................................................ 97 
Figure 5.19: ATR FTIR Spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple) 
and tablet 4 (Yellow) .................................................................................................................. 97 
Figure 5.20: ATR FTIR Spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple), 
tablet 4 (Yellow) and quinine sulphate reference (Red) ............................................................. 98 
xi 
   
Figure 5.21: Raman Spectra of At/UK/3, BRAVO (Green) and atenolol analytical reference, 
BRAVO (Red) ............................................................................................................................ 99 
Figure 5.22: Raman spectra for At/UK/2 using BRAVO (Red) and MIRA-3 (Green) handheld 
spectrometers ............................................................................................................................ 100 
Figure 5.23: Raman spectra for At/UK/1 (Green), At/UK/2 (Blue) and At/UK/3 (Red) using the 
BRAVO spectrometer ............................................................................................................... 101 
Figure 5.24: Raman Spectra of At/IND/1 25mg (Green) and At/IND/5 50mg (Blue) tablets using 
the BRAVO spectrometer ......................................................................................................... 101 
Figure 5.25: Raman Spectra of At/IND/6, BRAVO (Green) and atenolol analytical reference, 
BRAVO (Red) .......................................................................................................................... 102 
Figure 5.26: Raman Spectra of At/PAK/1 (Green) and At/PAK/2 (Blue) using the BRAVO 
spectrometer .............................................................................................................................. 103 
Figure 5.27: Raman Spectra of At/SA/1, BRAVO (Green) and atenolol analytical reference, 
BRAVO (Red) .......................................................................................................................... 104 
Figure 5.28: Raman Spectra of AT/NEP/1 (Green) and At/NEP/2 (Blue) tablets using the BRAVO 
spectrometer .............................................................................................................................. 105 
Figure 5.29: Raman Spectra of At/SA/1 (Green) and At/NEP/1 (Purple) using the BRAVO 
spectrometer .............................................................................................................................. 106 
Figure 5.30: Raman Spectra of Met/UK/1 (Green) and Met/UK/2 (Blue) using the FORAM-2 
spectrometer .............................................................................................................................. 107 
Figure 5.31: Raman Spectra for Met/IND/6 (Blue) and Met/IND/11 (Red) tablets using the 
FORAM-2 spectrometer ........................................................................................................... 108 
Figure 5.32: Raman Spectra of Met/IND/6 (Blue), score line (Red) using FORAM-2 spectrometer
 .................................................................................................................................................. 109 
Figure 5.33: A) Raman spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple), 
tablet 4 (Yellow) and tablet 5 (Red) .......................................................................................... 110 
Figure 5.34: Raman spectra of AM/ZIM/4 tablet 1 (Green), and tablet 5 (Red) ...................... 110 
Figure 5.35: ATR FTIR Spectra of At/UK/2 (pre-2016) (50mg) (Blue) and At/UK/3 (pre-2016) 
(100mg) (Green) and atenolol analytical reference (Red) ........................................................ 112 
Figure 5.36: ATR FTIR Spectra of At/UK/1 (25 mg) (Green) overlaid with atenolol analytical 
reference (Red) .......................................................................................................................... 113 
Figure 5.37: ATR FTIR spectra of At/UK/2 pre-2016 (Green) and At/UK/2 post-2016 (Blue)
 .................................................................................................................................................. 114 




Figure 5.39: ATR FTIR Spectra of At/IND/1 (Green) and At/IND/2 (Blue) (25 mg) overlaid with 
atenolol analytical reference (Red) ........................................................................................... 115 
Figure 5.40: ATR FTIR spectrum of At/IND/5 (50mg) ........................................................... 116 
Figure 5.41: ATR FTIR spectra of At/IND/5 (Blue), At/IND/6 (Green), At/IND/7 (Purple), 
At/IND/8 (Yellow), At/IND/9 (Red) and At/IND/10 (Pink) Atenolol (50 mg) ........................ 117 
Figure 5.42: ATR FTIR Spectra of At/IND/17 (Green) and atenolol analytical reference (Red)
 .................................................................................................................................................. 118 
Figure 5.43: ATR FTIR Spectra of At/PAK/1 (Green) and atenolol analytical reference (Red)
 .................................................................................................................................................. 119 
Figure 5.44: ATR FTIR Spectra of At/PAK/2 (Green) and atenolol analytical reference (Red)
 .................................................................................................................................................. 120 
Figure 5.45: ATR FTIR Spectra of At/SA/1 (Green), At/SA/2 (Blue) and atenolol analytical 
reference (Red) .......................................................................................................................... 120 
Figure 5.46: ATR FTIR Spectra of At/SA/3 (Green) and atenolol analytical reference (Red) . 121 
Figure 5.47: ATR FTIR Spectra of At/NEP/1 (Green) and atenolol analytical reference (Red)
 .................................................................................................................................................. 122 
Figure 5.48: ATR FTIR Spectra of At/NEP/2 (Green) and atenolol analytical reference (Red)
 .................................................................................................................................................. 122 
Figure 5.49: ATR FTIR Spectra of At/SA/1 (Green), At/SA/2 (Blue), At/UK/7 (Purple) and 
At/NEP/1 (Yellow) ................................................................................................................... 123 
Figure 5.50:  ATR FTIR Spectra of Met/UK/1 (Green), Met/UK/2 (Blue) and metformin 
hydrochloride analytical reference (Red) .................................................................................. 124 
Figure 5.51:  ATR FTIR Spectra of Met/IND/4 (Green), Met/IND/5 (Blue) and metformin 
hydrochloride analytical reference (Red) .................................................................................. 125 
Figure 5.52: ATR FTIR Spectra of Met/IND/6 (Green) and metformin hydrochloride analytical 
reference (Red) .......................................................................................................................... 126 
Figure 5.53: ATR FTIR Spectra of Met/SA/1 (Green) and metformin hydrochloride analytical 
reference (Red) .......................................................................................................................... 127 
Figure 5.54: ATR FTIR Spectra of AM/UK/1 (Green) and chloroquine phosphate analytical 
reference (Red) .......................................................................................................................... 128 
Figure 5.55: ATR FTIR Spectra of AM/ZIM/4 (Green) and quinine sulphate reference (Red) 128 
Figure 5.56: ATR FTIR Spectra of AM/NEP/1 (Green) and chloroquine phosphate analytical 
reference (Red) .......................................................................................................................... 129 




Figure 5.58: Raman Spectra of Met/IND/6 (Blue) and score line (Red) whole tablet using the 
FORAM-2 and crushed (Green) tablet using the MIRA-3 spectrometer .................................. 131 
Figure 5.59: Raman Spectra for Met/IND/2 tablets using the MIRA-3 (Green) and FORAM-2 
(Blue) spectrometers ................................................................................................................. 131 
Figure 5.60: Raman Spectra for AM/ZIM/4 whole tablet (Blue) and powdered (Red) using the 
FORAM-2 spectrometer ........................................................................................................... 132 
Figure 5.61: DIP MS spectra for atenolol analytical reference ................................................. 133 
Figure 5.62: DIP MS spectra for chloroquine phosphate analytical reference ......................... 134 
Figure 5.63: DIP MS spectra for quinine sulphate analytical reference ................................... 135 
Figure 5.64: DIP MS spectra for At/UK/5 ................................................................................ 135 
Figure 5.65: DIP MS spectra for At/IND/5 ............................................................................... 136 
Figure 5.66: DIP MS spectra for AM/UK/1 ............................................................................. 137 
Figure 5.67: DIP MS spectra for AM/GHA/1 ........................................................................... 138 
Figure 5.68: DIP MS spectra for AM/NEP/1 ............................................................................ 138 
Figure 5.69: DIP MS spectra for AM/NIG/1 ............................................................................ 139 
Figure 5.70: DIP MS spectra for AM/NIG/2 ............................................................................ 139 
Figure 5.71: DIP MS spectra for AM/NIG/3 ............................................................................ 140 
Figure 5.72: Representative DIP MS spectra for AM/ZIM/1 and AM/ZIM/2 .......................... 141 
Figure 5.73: DIP MS spectra for AM/ZIM/3 ............................................................................ 141 
Figure 5.74: DIP MS spectra for AM/ZIM/4 ............................................................................ 142 
Figure 5.75: ASAP MS spectra for atenolol analytical reference ............................................. 143 
Figure 5.76: ASAP MS spectra for a sulphadoxine/ pyrimethamine tablet from Zimbabwe ... 144 
Figure 6.1: Percentage of stated dosage of UK atenolol tablets as calculated by UV with EMA 
(90-110%) (--) and FDA (80-125%) (--) limits ........................................................................ 146 
Figure 6.2: Percentage of stated dosage of At/IND/1-18 tablets as calculated by UV with EMA 
(90-110%) (--) and FDA (80-125%) (--) limits ........................................................................ 147 
Figure 6.3: Percentage of stated dosage of Pakistani, Saudi Arabian and Nepalese atenolol tablets 
as calculated by UV EMA (90-110%) (--) and FDA (80-125%) (--) limits ............................. 148 
Figure 6.4: Percentage of stated dosage of UK metformin hydrochloride tablets as calculated by 
UV with EMA (90-110%) (--) and FDA (80-125%) (--) limits ................................................ 149 
Figure 6.5: Percentage of stated dosage of Indian and Saudi Arabian metformin hydrochloride 
tablets as calculated by UV with EMA (90-110%) (--) and FDA (80-125%) (--) limits .......... 149 
Figure 6.6: Met/IND/7 tablets within the blister packaging ..................................................... 150 
Figure 6.7: ATR FTIR Spectra of standard calibration mixtures, A) 5% atenolol, B) 25% atenolol, 
C) 50% atenolol and D) 75% atenolol ...................................................................................... 151 
xiv 
   
Figure 6.8: ATR FTIR spectrum of atenolol with integration areas highlighted ...................... 153 
Figure 6.9: Calibration plot using integration method A and peak area 4 for atenolol with error 
bars ............................................................................................................................................ 154 
Figure 6.10: Percentage of stated dosage of UK atenolol Tablets as calculated by UV (X) and 
ATR FTIR (X) with EMA (90-110%) (--) and FDA (80-125%) (--) limits ............................. 156 
Figure 6.11: Percentage of stated dosage of Indian atenolol tablets as calculated by UV (X) and 
ATR FTIR (X) with EMA (90-110%) (--) and FDA (80-125%) (--) limits ............................. 158 
Figure 6.12: Percentage of stated dosage of Pakistani, Saudi Arabian and Nepalese atenolol tablets 
as calculated by UV (X) and ATR FTIR (X) EMA (90-110%) (--) and FDA (80-125%) (--) limits
 .................................................................................................................................................. 158 
Figure 6.13: SEM Images for atenolol A) raw and B) ground. ................................................. 159 
Figure 6.14: ATR FTIR spectrum of metformin hydrochloride with integration areas highlighted
 .................................................................................................................................................. 161 
Figure 6.15: Percentage of stated dosage of UK metformin hydrochloride tablets as calculated by 
UV (X) and ATR FTIR (X) with EMA (90-110%) (--) and FDA (80-125%) (--) limits ......... 163 
Figure 6.16: Percentage of stated dosage of Indian and Saudi Arabian metformin hydrochloride 
tablets as calculated by UV (X) and ATR FTIR (X) EMA (90-110%) (--) and FDA (80-125%) (-
-) limits ...................................................................................................................................... 165 
Figure 6.17: SEM images for metformin hydrochloride A) raw and B) ground ...................... 165 
Figure 6.18: SEM images for maize starch A) raw and B) ground ........................................... 166 
Figure 6.19: SEM images for 50:50 metformin hydrochloride: maize starch. ......................... 166 
Figure 6.20: Composite image of elemental maps for a cross section of an ibuprofen tablet 
(titanium (blue), magnesium/ silicon (green), carbon (yellow), sodium (red) and iron (pink)) 168 
Figure 6.21: EDX Map for At/UK/3 ......................................................................................... 170 
Figure 6.22:  EDX Map of At/UK/6 ......................................................................................... 172 
Figure 6.23: EDX map showing distribution of titanium for At/UK/7 ..................................... 173 
Figure 6.24: Elemental maps of Calcium and Phosphorous for At/IND/5 ............................... 175 
Figure 6.25: Elemental maps of Sodium for A) At/IND/14, B) At/IND/15 and C) At/IND/16 176 
Figure 6.26: Elemental maps of silicon and magnesium for At/SA/5 ...................................... 178 
Figure 6.27: Elemental map of Chlorine for Met/UK/2 ............................................................ 180 
Figure 6.28: Elemental map of Titanium and Magnesium for Met/UK/2 ................................ 180 
Figure 6.29: Elemental maps of Sodium and Chlorine for Met/IND/15 tablet. ........................ 184 
Figure 7.1: ATR FTIR spectra of At/IND/1 (Green) and At/IND/5 (Blue ............................... 187 
Figure 7.2: Raman spectra of At/IND/1 (Green) and At/IND/5 (Blue) .................................... 188 
xv 
   
Figure 7.3: A) Raman spectra of At/IND/1 (Blue) and ATR FTIR spectra of At/IND/1 (Red), B) 
Raman spectra of At/IND/5 (Blue) and ATR FTIR spectra of At/IND/5 (Red) ....................... 189 
Figure 7.4: A) ATR FTIR spectra of At/SA/1 (Green), At/SA/2 (Blue), At/UK/7 (Purple) and 
At/NEP/1 (Yellow), B) Raman spectra of At/SA/1 (Green), and At/NEP/1 (Purple) .............. 190 
Figure 7.5:  A) ATR FTIR spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple) 
and tablet 4 (Yellow), B) ATR FTIR spectra of AM/ZIM/4 whole (Blue) and crushed (Green)
 .................................................................................................................................................. 192 
Figure 7.6: Raman spectra of AM/ZIM/4 tablet 1 (Green), and tablet 5 (Red) ........................ 193 
Figure 7.7: Raman Spectra for AM/ZIM/4 whole tablet (Blue) and powdered (Red) using the 
FORAM-2 spectrometer ........................................................................................................... 193 
Figure 7.8: Raman spectra of atenolol (analytical standard) using BRAVO handheld spectrometer 
(Red) and FORAM-2 spectrometer (Blue) ............................................................................... 195 
Figure 7.9: Raman spectra of metformin hydrochloride (analytical standard) using FORAM-2 
spectrometer (Blue) and MIRA-3 handheld spectrometer (Green) ........................................... 196 
Figure 7.10: Raman spectra of Met/IND/13 (Green) and metformin hydrochloride analytical 
standard (Red) using MIRA-3 handheld spectrometer ............................................................. 196 
Figure 7.11: A) ATR FTIR spectra of Met/IND/2 (Blue) and Met/IND/4 (Green), B) Raman 
spectra of Met/IND/2 (Blue) and Met/IND/4 (Green) using MIRA-3 handheld spectrometer . 197 
Figure 7.12: Percentage of stated dosage of Indian atenolol tablets as calculated by UV (X) and 
ATR FTIR (X) with EMA (--) and FDA (--) limits .................................................................. 199 
Figure 7.13: Elemental maps of Calcium and Phosphorous for At/IND/1 ............................... 201 
Figure 8.1: PCA Plot of the Raman spectra for whole At/UK/7 (Yellow), At/SA/1 (Yellow), 
At/SA/2 (Yellow), At/NEP/1 (Yellow) and other generic atenolol tablets (Blue) .................... 207 
Figure 8.2: Raman Spectra of At/SA/1 (Green) and At/NEP/1 (Purple) using the BRAVO 
spectrometer .............................................................................................................................. 207 
Figure 8.3: Raman Spectra of whole At/UK/7 (Yellow), At/SA/1 (Yellow), At/SA/2 (Yellow), 
and At/NEP/1 (Red) tablets ...................................................................................................... 208 
Figure 8.4: ATR FTIR Spectra of crushed At/SA/1 (Green), At/SA/2 (Blue), At/UK/7 (Purple) 





Table 1.1: Recalls and interceptions relating to counterfeit medicines (Almuzani, 2013; European 
Compliance Academy, 2016; MHRA, 2011a and US Attorney 2014, 2016a, 2016b) ............... 20 
Table 2.1: Different excipient components of typical tablet formulations ................................. 28 
Table 3.1: Advantages and Disadvantages for the analytical techniques analysed .................... 39 
Table 3.2: Comparison of various analytical techniques ............................................................ 58 
Table 4.1: Manufacturer and batch numbers of excipients used ................................................. 61 
Table 4.2: Manufacturer and batch numbers of analytical reference APIs used ......................... 62 
Table 4.3: Manufacturer and batch numbers of solvents used .................................................... 62 
Table 4.4: Atenolol tablet samples analysed ............................................................................... 64 
Table 4.5: Metformin Hydrochloride tablet samples analysed ................................................... 65 
Table 4.6: Antimalarial tablet samples analysed......................................................................... 65 
Table 4.7: Calibration standard mixture concentrations of atenolol for ATR FTIR analysis ..... 66 
Table 4.8: Calibration standard mixture concentrations of metformin hydrochloride for ATR 
FTIR analysis .............................................................................................................................. 67 
Table 4.9: Calibration standard mixture concentrations of atenolol for Raman spectroscopy ... 68 
Table 4.10: Calibration standard mixture concentrations of paracetamol for Raman spectroscopy
 .................................................................................................................................................... 68 
Table 5.1: Summary of excipients and their differentiation with characteristic atenolol peaks . 80 
Table 5.2: Summary of excipients and their differentiation with characteristic metformin 
hydrochloride peaks .................................................................................................................... 81 
Table 5.3: Summary of excipients and their differentiation with characteristic chloroquine 
phosphate peaks .......................................................................................................................... 83 
Table 5.4: Summary of excipients and their differentiation with characteristic quinine sulphate 
peaks ........................................................................................................................................... 84 
Table 5.5: Characteristic Raman peaks of atenolol and their assignments ................................. 87 
Table 5.6: Characteristic Raman peaks of metformin hydrochloride and their assignment ....... 89 
Table 6.1: Summary of characteristic atenolol and MCC peaks in calibration mixtures .......... 152 
Table 6.2: Integration methods ranked according to R2 values for atenolol ............................. 154 
Table 6.3: Quantification results for UK atenolol tablets calculated by ATR FTIR ................ 155 
Table 6.4: Quantification Results for Indian Atenolol Tablets as calculated by ATR FTIR .... 157 
Table 6.5: Summary of characteristic metformin and maize starch peaks in calibration mixtures
 .................................................................................................................................................. 160 
Table 6.6: Integration methods ranked accorded to R2 values for metformin hydrochloride ... 162 
xii 
   
Table 6.7: Quantification results for UK metformin hydrochloride tablets as calculated by ATR 
FTIR .......................................................................................................................................... 163 
Table 6.8: Quantification results for Indian and Saudi Arabian metformin hydrochloride tablets 
as calculated by ATR FTIR ...................................................................................................... 164 
Table 6.9: Comparison of EDX quantification data for At/UK/1 -3 tablets ............................. 169 
Table 6.10: Comparison of EDX quantification data for At/UK/4 -6 tablets ........................... 171 
Table 6.11: EDX quantification data for At/UK/7 tablet .......................................................... 173 
Table 6.12: Comparison of EDX quantification data for At/IND/1-2 and At/IND/4-10 .......... 174 
Table 6.13: Comparison of EDX quantification data for At/IND/11 – 13 tablets .................... 175 
Table 6.14: Comparison of Quantification data At/IND/14 – 16 tablets. ................................. 176 
Table 6.15: Comparison of EDX quantification data for At/PAK1 and At/PAK/2 tablets ....... 177 
Table 6.16: Comparison of EDX quantification data for Saudi Arabian tablets ....................... 178 
Table 6.17: Comparison of EDX quantification data for the Nepalese samples ....................... 179 
Table 6.18: Comparison of Quantification data for UK Metformin Hydrochloride tablets. ..... 180 
Table 6.19: Comparison of EDX quantification data for Met/IND/1 -5 tablets ....................... 181 
Table 6.20: Comparison of EDX quantification data for Met/IND/6 - 8 tablets ....................... 182 
Table 6.21: Comparison of Quantification data for Met/IND/9 and Met/IND/10 tablets ......... 182 
Table 6.22: Comparison of EDX quantification data for Met/IND/11. Met/IND/14 – 16 tablets
 .................................................................................................................................................. 183 
Table 6.23: Comparison of Quantification data for Met/IND/12 & 13 tablets ......................... 184 
Table 6.24: Quantification data for Met/SA/1 tablet ................................................................ 185 
Table 7.1: Comparison of various analytical methods with respect to tablet sample analysis . 203 
Table 7.2: Estimated cost of equipment in the UK ................................................................... 204 







ACT  Artemisin based Combination Therapies 
ADR  Adverse Drug Reaction 
API  Active Pharmaceutical Ingredient 
ASAP  Atmospheric Solid Analysis Probe 
ATR  Attenuated Total Reflectance 
BP  British Pharmacopeia  
BSE  Backscattered Electron 
CIS  Counterfeit Incident System 
CL  Cathodoluminscence 
DIP   Direct Insertion Probe  
EAASM European Alliance for Access to Safe Medicines 
EC  European Commission 
EDX  Energy Dispersive X-ray Spectroscopy 
EI  Electron Impact 
EM  Electromagnetic 
EMA  European Medicines Agency 
EP  European Pharmacopeia 
EU  European Union 
FDA  Food and Drug Administration 
FIA   Federal Investigation Agency 
FTIR  Fourier Transform Infrared 
GPHF  Global Pharma Health Fund 
xiv 
   
HIC  High-income countries 
HIV/AIDS Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome   
HPLC  High Performance Liquid Chromatography 
HPMC  Hydroxypropyl methyl cellulose 
IID  Inactive Ingredient Database 
IMPACT International Medical Products Anti-Counterfeiting Taskforce 
INTERPOL International Police 
IP  Intellectual Property 
IPN  International Policy Network 
IR  Infrared 
LC MSMS Liquid Chromatography Tandem Mass Spectrometer 
LIC  Lower income countries 
LMIC  Lower middle-income countries 
MCC  Microcrystalline Cellulose 
MHRA  Medicines and Healthcare Products Regulatory Agency 
MS  Mass Spectrometry  
MSF  Médecins Sans Frontières 
NHS  National Health Service 
NIR  Near Infrared 
NMR  Nuclear Magnetic Resonance  
OTC  Over the Counter 
PCA  Principal Component Analysis 
PEG  Polyethylene glycol 
PIC  Punjab Institute of Cardiology 
xv 
   
PLS  Partial Least Squares 
POM Prescription Only Medicine 
PSI Pharmaceutical Security Institute 
PVP Polyvinylpyrrolidinone 
QC Quality Control 
SE Secondary Electron 
SEM Scanning Electron Microscopy 
SEM/EDX Scanning Electron Microscopy/ Energy Dispersive X-ray Spectroscopy 
SERS Surface Enhanced Raman Spectroscopy    
SF Substandard and falsified medical products 
SP Sulphadoxine - Pyrimethamine 
SSFFC Substandard, spurious, falsely labelled, falsified and counterfeit medical products 
TIC Total Ion Chromatogram 
TLC  Thin Layer Chromatography 
UK  United Kingdom 
UNODC United Nations Office on Drugs and Crimes 
US  United States 
USA  United States of America 
UV  Ultraviolet 
WADA  World Anti-Doping Agency 





Atlas Conversion Factor: For any given year, it is the average of a country’s exchange rate for 
the preceding two years, adjusted for the difference between the rate of inflation in the country 
and international inflation. 
Artesunate: A water-soluble hemisuccinate derivative of artemisinin. 
Bioavailability: The rate and extent to which the API is absorbed from a pharmaceutical dosage 
form and becomes available in the general circulation. 
Bioequivalence: Two pharmaceutical products are bioequivalent if they are pharmaceutically 
equivalent and their bioavailability after exposure. 
Dosage form: The finished formulation of a pharmaceutical product, for example tablet, capsule 
and suspension. 
Generic product: A multisource pharmaceutical product, which is usually manufactured without 
a licence from the innovator company and marketed after the expiry of a patent. 
High Income Countries: Gross National Income (GNI) per capita calculated using World Bank 
Atlas method of $12,476 or higher per annum.  
Innovator product: A pharmaceutical product that was first authorised for marketing based on 
documentation of quality, safety and efficacy. 
Low Income Countries: GNI per capita calculated using World Bank Atlas method of $1,025 or 
less per annum.  
Lower Middle-Income Countries: GNI per capita calculated using World Bank Atlas method 
of between $1,026 and $4,035 per annum.  
Upper Middle-Income Countries: GNI per capita calculated using World Bank Atlas method 
of between $4,036 and $12,475 per annum.  
World Bank Atlas method: In calculating GNI in US Dollars, the Atlas conversion factor is used 






This Chapter looks at how substandard and falsified (SF) medicines are a global issue that affects 
both High Income Countries (HIC) and Low Income Countries (LIC), spanning across both 
lifesaving and lifestyle medicines. Whilst this issue is more prevalent in LIC and Lower Middle 
Income Countries (LMIC), it is a growing market worldwide and in part due to the rise in internet 
pharmacies. 
Governments and the pharmaceutical industry are trying to stem the tide of SF medicines, with 
the creation of new laws, taskforces and the implementation of the Falsified Medicines Directive 
in the EU. However, before the new laws can be implemented, we need to understand the 
formulation of medicines and in particular tablets. Chapter 2 discusses the selection of target 
medicines and the different components in a tablet. 
	
1.1 		Background	
In January 2012, the city of Lahore in Pakistan experienced what was described by the media as 
a ‘fake medicine crisis’. Over one hundred cardiac patients died during a three-week period, as a 
direct result of taking substandard/falsified cardiovascular medication (BBC, 2012a). The 
contaminated medication had been distributed in mid-December by the Government run Punjab 
Institute of Cardiology (PIC) (BBC, 2012a). It was reported that around forty thousand people 
were at risk from taking the free medication (Hugman, 2012), in particular the less privileged, as 
the medication was mainly supplied to them (Riaz, 2012). The affected patients exhibited 
symptoms similar to dengue fever, these included the rapid depletion of white blood cells and 
blood platelets, bleeding from the mouth and gastrointestinal tract and strange dark marks on the 
skin (WHO, 2013). Doctors initially mistook the outbreak for dengue fever (Riaz, 2012); 
however, there had been reports of zero findings of the dengue mosquito larvae (WHO, 2013) and 
that the symptoms were limited to patients treated by the PIC (Riaz, 2012). The Federal 
Investigation Agency (FIA) found that the medicines supplied to patients were manufactured in 
unhygienic conditions with no adherence to safety regulations (Hao, 2012). Samples of the 
medication were analysed by the Medicines and Healthcare Products Regulatory Agency 
(MHRA) in England and found to contain pyrimethamine, an antiparasitic drug used in the 
treatment of malaria. The presence of this active ingredient was discovered to be toxic to the 
patients (Riaz, 2012). The MHRA also found that this particular batch of cardiovascular 





antimalarial medication (WHO, 2013). Not only was the drug misidentified, but the packaging 
also failed to display any dates of manufacture or expiry (BBC, 2012a). 
Counterfeiting of commercial products is an age-old practice, which flourishes in many countries 
and is motivated mainly by the huge profits that can be made (WHO, 1999). The production of 
substandard and counterfeit medicines is a vast and under reported problem, particularly affecting 
poorer countries (Cockburn et al., 2005; Höllein and Holzgrabe, 2014 and Glass, 2014). High 
costs and increasing public demand for newer medicines means that high profits can be made 
from selling counterfeit medicines. 
Counterfeit medicines are not restricted to specific drug classes, but instead span a broad 
spectrum, including lifestyle and lifesaving medicines (WHO, 2010a). Patients that take such 
medicines as part of their treatment may get no relief from their symptoms and may suffer induced 
illness or death (Attaran et al., 2012).  
1.2 		Counterfeits	become	substandard	or	falsified	medicines	
Despite the increasing awareness on the dangers of the ‘fraudulent drug epidemic’ (Lui and 
Lundin, 2016 and Nayyar et al., 2015) there are still issues when assessing the global problem of 
counterfeit medicines (Fernandez et al., 2008). There was no universally accepted definition of 
counterfeit medicines; this made the exchange of information between countries difficult, as each 
may have had a conflicting definition (WHO, 2011). The lack of a universal definition led to 
difficulties in taking effective and strategic actions to solve the issue, (Clift, 2010), and is thought 
by some sources to be the ‘heart of the problem’ (Lui and Lundin, 2016 and Gostin et al., 2013). 
To address this problem, the World Health Organisation (WHO) developed the following 
definition in the 1990’s. It was seen as the most elaborate, and had gained international acceptance 
(Höllein et al., 2016). 
“A counterfeit medicine is one which is deliberately and fraudulently mislabelled with respect to 
identity and/or source. Counterfeiting can apply to both branded and generic products and 
counterfeit products, may include products with the correct ingredients or with the wrong 
ingredients, without active ingredients, with insufficient active ingredients or with fake 
packaging” (WHO, 2011). 
However, the term counterfeit is now deemed to be controversial by some parties including the 
WHO, who removed the term counterfeits from its definition in early 2017. Although the above 
definition by the WHO remained generally accepted as the worldwide standard (Dégardin et al., 
2014); concerns that the term counterfeit is largely associated and defined, with respect to 





Lundin, 2016). As a result of pressure from stakeholders and criticism that the enforcement of the 
IP issue would empower big pharmaceutical companies and hinder the generic industry in the 
production of equivalent alternative and cheaper medicines (Attaran et al., 2012). The WHO in 
January 2016 updated and modified their definition to include substandard, spurious, falsely 
labelled, falsified and counterfeit (SSFFC) medical products (WHO, 2016). The WHO now 
defined a SSFFC medical product, as one that may contain no active ingredients, the wrong active 
ingredient, or the wrong amount of the correct active ingredient. In general, SSFFC medicines 
can be distinguished into the following five subtypes (Höllein et al., 2016): 
i) Copies of the genuine brand medicines usually with correct amounts of the Active 
Pharmaceutical Ingredient (API). 
ii) Products with the wrong API’s; these can be poor or acceptable quality. 
iii) Preparations containing no API at all. 
iv) Medicines with too high or too low contents of the declared API. 
v) Contamination of products with known and/or unknown purities.  
However, it may not always be possible to discretely assign a sample to one of these subtypes 
(Hölllein et al., 2016). For example, products may contain trace amounts of API alongside an 
incorrect API and may also be contaminated with other material. 
The use of the term SSFFC has now been superseded and from May 2017, the WHO amended 
their definition to Substandard and Falsified (SF) medical products. It is thought that the change 
simplifies the situation, as it was felt that the term SSFFC often confused the phenomenon with 
IP rights (WHO, 2017a). The term substandard is defined by the WHO as “out of specification 
authorised medical products that fail to meet either their quality standards, specifications or both” 
(WHO 2017a). The individual country’s national regulatory medicine authority determines the 
quality standards and specifications that a product must meet. A medicine is deemed falsified if 
the “authorised manufacturer deliberately fails to meet these quality standards or specifications 
due to misrepresentation of identity, composition, or source” (WHO, 2017a). The change in 
definition by the WHO is seen as an “important and crucial milestone” in the prevention and 
detection of these medical products, it is thought that the definition adds clarity and simplification 
to an already complex issue (WHO 2017a). The WHO hope that member states and stakeholders 
adopt the change in definition to permit a more accurate comparison and analysis of data to 
combat this problem.  
This change occurred in the latter stages of this research and the terms ‘substandard and falsified 





change and use the term counterfeit. Similarly, most referenced material includes the word 
‘counterfeit’ and there is no clear distinction between substandard or falsified materials. 
 
1.3 		The	Extent	of	the	Problem	
The falsification of medicines is a global phenomenon that affects lower, lower middle and high-
income countries. In 2015, Mackey et al., investigated incidents of counterfeit medicines 
penetrating the global legitimate supply chain. The study analysed data from the Pharmaceutical 
Security Institute (PSI) Counterfeit Incident System (CIS) over a 36-month period, 2009-2011. It 
discovered that globally there were 1,510 reports of counterfeit incidents, of which 1,799 different 
counterfeit medicine detections entered the legitimate supply chain (Mackey et al., 2015). The 
report found that China was responsible for approximately a quarter of detections (27.6%) in the 
legitimate supply chain. The top five countries represented a total of 65.7% of detections, which 
consisted of China (27.6%), Peru (11.6%), Uzbekistan (10.9%), Russia (8.4%) and Ukraine 
(7.2%) (Mackey et al., 2015). Other studies have been carried out; the results of which tend to be 
limited to individual therapeutic classes for example cardiovascular and antiparasitic (Kelesidilis 
and Falagas, 2015). 
There is considerable literature to be sourced from investigative journalism (Bogdanich and 
Hooker, 2008; Bosely, 2011; BBC, 2011; Baibhav, 2016; Pitts, 2016 and Piervincenzi, 2016), 
with little public health enquiry relative to the size of this criminal enterprise (Cockburn et al., 
2005). Details of these enquiries can be excessively delayed or supressed for legal, political, 
communication and economic reasons (Mackey et al., 2015). 
Several systematic reviews of the literature have been reported, with some analysing a single 
therapeutic class (Almunzaini et al., 2013) and others spanning a broad spectrum of classes 
(Alghannam et al., 2014). The study by Alghannam et al., (2014), analysed studies that used 
chemical identification/ quantification of an API. The group found that few studies reported 
evidence of counterfeits medicines (8%) whilst 55% of studies reported instances of substandard 
medicines, with the most reported problem adherence to specified API limits (Alghannam et al., 
2014). A study by Koczwara and Dressman (2017), debated the figure reported by the WHO in 
2006 for the prevalence of counterfeits globally, but concluded based on scientific literature from 
the last decade, that it was impossible to make reliable estimations on the prevalence of counterfeit 
medicines globally due to a lack of data. The group also found that the terms counterfeit and 
substandard were used synonymously and that the terms were not sufficiently differentiated 





2017). This confusion between the terms counterfeit and substandard has also been reported by 
Grech et al., (2018). 
The WHO estimates that a 30 – 40% of all medicines in lower and lower-middle income countries 
are substandard and falsified (Lui and Lundin, 2016) and up to 1% of medicines available in high 
income countries are likely to be, with this figure rising to 10% globally (Rebiere et al, 2017). It 
has also been reported that in some former Soviet Union countries, the figure for counterfeit 
medicines is as high as 20% of the pharmaceutical market (IMPACT, 2008). Data from the PSI 
has shown that, globally over the period of 2005 to 2010, the theft of pharmaceuticals increased 
66% whilst counterfeiting instances increased 122% (Mackey et al., 2015). A current assessment 
in Kenya (Tanna et al., 2017) suggested that the level of substandard and falsified medicines was 
between 40 – 50% of the total with substandard material being the greater component (Tanna et 
al., 2017). 
The effects of counterfeit medicines on patients range from the difficult to detect and quantify, to 
an important cause of unnecessary morbidity, mortality and loss of public confidence in medicines 
and health systems (Cockburn et al., 2005). Substandard and falsified medicines are usually first 
identified when problems with the medication are identified by the public, often resulting in an 
adverse reaction or a fatality. A study by Newton et al., found that counterfeiters are able to 
produce high quality replica holograms (Newton et al., 2008), by purchasing them from specialist 
suppliers at competitive prices, the internet also enables the holograms to be obtained rapidly.  
High-income countries are not immune from this problem; Pfizer have reported that 80% of 
Viagra purchased from the internet was falsified (Rushe, 2013) and in the United States of 
America (USA), there is a growing problem of fake medicines. In the UK healthcare is provided 
by the National Health Service (NHS) and is highly regulated, with all medicines monitored and 
licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) and European 
Medicines Agency (EMA) (NHS, 2014). Medicines are procured for the NHS through a national 
buying group (UK Government, 2017), meaning that the supply chain is tightly controlled. 
Medicines are available to patients via the NHS in three different ways, these are: 
 Prescription Only Medicines – patients need a prescription issued by a Doctor or suitably   
qualified healthcare professional, these are available via a pharmacy at a fixed price or 
no cost to the patient, 
 Pharmacy Medicines – available from a pharmacy, but under the supervision of a 
pharmacist, 
 Over the Counter Medicines – can be purchased without the supervision of a pharmacist 





However, despite this, substandard and falsified medicines still occur in both the NHS supply 
chain and those sold on the internet. In many countries, none of these controls exist and medicines 




The counterfeiting of medicines is a major issue and has a profound impact on lower income 
countries (LIC) and lower middle-income countries (LMIC) (Almuzanini et al., 2013); these 
countries also bear the brunt of the problem (Bandiera and Marmo 2017). In this area of the 
world counterfeiters target lifesaving medicines, as these offer a higher profit (WHO, 2010b). 
This is because the demand for these medicines outweighs the financial ability of the country to 
pay. The most commonly targeted medicines in developing countries are antimalarials, 
antituberculosis, antiretrovirals and antibiotics (Höllein et al., 2016). 
A United Nations Office on Drugs and Crimes (UNODC) report in 2009 stated that there were 
83 million cases of treatment with antimalarials in the private sector, if half of these cases were 
treated with counterfeit medicines it would represent a market worth just under half a billion US 
dollars (UNODC, 2009). The same study also found that the ramifications of trafficking inert or 
substandard medicines into Western Africa were vast and extended beyond the region. However, 
due to lack of legislation and regulations, the counterfeiting of medicines is not generally 
regarded as a major organised crime activity (UNODC, 2009). 
 
According to a report by INTERPOL, the deaths of six million people a year can be attributed 
to malaria, tuberculosis and HIV/AIDS (Selgelid, 2007). The International Policy Network 
(IPN) estimates that counterfeit antimalarial and antituberculosis drugs cause 700,000 deaths a 
year (Harris, 2009). Counterfeit antimalarials are of particular concern amongst healthcare 
bodies; the Food and Drug Administration (FDA) suggests that more than half the antimalarials 
in Africa are counterfeit (Atemnkeng et al., 2007). The New York Times reported that due to 
the scale and severity of the disease, malaria kills more than 2,000 children a day in Africa 
(Fuller, 2009). A report by INTERPOL also estimated that 200,000 children die annually after 
taking counterfeit antimalarial medication (Fenoff and Wilson, 2009). 
 
Studies conducted by the WHO, UNODC and the Wellcome Trust found several instances of 
counterfeit antimalarials reaching the legitimate supply chain. These include, but not limited to 





prepared with sulphadoxine-pyrimethamine (SP) (which is an older less effective anti-
malarial, that is still in use in some countries for example Zimbabwe, 2016), which 
was sold as artesunate (a water-soluble derivative of artemisinin) (Mukhopadhyay, 
2007). 
 In 2001 in South East Asia, out of 104 antimalarial drugs that were on sale in 
pharmacies, 38% did not contain any active ingredients (Mukhopadhyay, 2007). 
 
A joint operation (Operation Jupiter) in 2008 between the WHO, INTERPOL, the Wellcome 
Trust and Chinese authorities, found that half of all artesunate tablets were counterfeit in South 
East Asia (Brierley, 2008). Of those found to be counterfeit, most tablets contained no 
artesunate, of which some contained a potentially toxic range of chemicals replacing the active 
ingredient (Brierley, 2008). Another case that demonstrates the danger of counterfeit medicines 
containing lethal ingredients is the death of 500 children in Bangladesh after ingesting 
paracetamol containing a renal toxin (diethylene glycol) (Newton et al., 2010). 
Surveys conducted in South East Asia found that between 33% and 53% of artesunate purchased 
from pharmacies were counterfeit, containing either no or sub therapeutic quantities of the active 
pharmaceutical ingredient (API) (Newton et al., 2008).  Studies also found that some counterfeit 
antimalarials contained active ingredients for other conditions; one such example is Sildenafil, 
the active ingredient in Viagra (Newton et al., 2001). Ricci et al., (2008) analysed the 
antimalarial artesunate by Raman spectroscopy and mass spectrometry and found that samples 
contained other APIs, these included acetaminophen, artemisinin, dipyrone, erythromycin and 
erucamide (Ricci et al., 2008). 
 
Counterfeit medicines aggravate the growing problem of drug resistance (Atemnkeng et al., 
2007 and Newton et al., 2008); the use of sub therapeutic levels of API is fueling this issue. 
Whilst the low amounts of API are high enough to pass qualitative screening tests, the dosages 
are too low to be effective. This exposure to sub therapeutic doses results in the malaria parasite 
becoming resistance to particular classes of drug (Brierley, 2008; BBC, 2012b and Noedl et al., 
2008). Low API concentrations kill the weaker strains of the parasite but allow survival of more 
resistant mutations; thereby accelerating the evolution of the resistant strains.  
 
There are several reasons for the growth of counterfeit medicines in LIC and LMIC. It is thought 
that inadequate access to health services, health insurance and the availability of a reliable 
pharmaceutical supply contribute to the problem (Mukhopadhyay, 2007). There is also the 
healthcare dilemma of quality (few tablets at a prohibitive cost) versus quantity (high volume of 





Governments who need to be seen to be doing something to provide healthcare for the 
population. Another reason may be due to the lack of monitoring of medicines, due to the 
relatively immature healthcare systems, restricted laboratory capacity, weak analytical 
infrastructures and chaotic logistical distribution (Höllein et al., 2016 and Kovacs et al., 2014). 
Counterfeits are more prevalent in countries where regulatory oversight is weak and where there 
is a minimal fear of prosecution. A report by the UNODC quoted the head of corporate security 
at Novartis as “If you get caught with a pound of cocaine, you can expect to do serious time. But 
if you are found with counterfeit medicines, you might do only six months.” (UNODC, 2009). 
This emphasises the point of minimal fear of enforcement and prosecution. 
 
Counterfeiters take advantage of the high cost of medication (IMPACT, 2008); in LIC, the cost 
of medicines can consume a significant portion of an individual’s income incentivising patients 
to seek a cheaper alternative. It is common for some pharmacies in Africa to stock a cheaper 
substandard drug copy next to the original or generic brand (Atemnkeng et al., 2007). In Nairobi 
in 2017, different atenolol and metformin hydrochloride tablets with significant differences in 
cost were purchased. Unlike in high-income countries (HIC), patients in LIC rarely have health 




In contrast to LIC and LMIC, lifestyle drugs are more commonly targeted in HIC (Russo et al., 
2016). The most common counterfeited drugs are weight loss, anti-erectile dysfunction and 
cholesterol lowering drugs (MHRA, 2011a). Although the occurrence of counterfeit medicines 
reaching the legitimate supply chain in the UK via the NHS is low (ca 1%), the consequences can 
still be potentially life threatening (Jackson et al., 2012). This situation is similar in the USA (PSI, 
2016). 
Substandard and falsified products can affect both medicines and medical devices; the most 
common dosage form that is counterfeited are tablets. This is because tablets are the most popular 
and common route of oral drug administration (Jaimini and Rawat, 2013). 
There have been several recalls of medicines found to be counterfeit in the UK between 2004 and 
2009, of which four products had reached both pharmacy and patient levels and the other products 
were intercepted at wholesale level (MHRA, 2011a). Table 1.1 highlights recalls and interceptions 






Table 1.1: Recalls and interceptions relating to counterfeit medicines (Almuzani, 2013; European 
Compliance Academy, 2016; MHRA, 2011a and US Attorney 2014, 2016a, 2016b) 
Year Country Product Treatment 
2004 UK Cialis Erectile Dysfunction 
2004 UK Reductil Weight Loss 
2005-2006 UK Lipitor Cholesterol Lowering 
2007 UK Zyprexa Schizophrenia and Bipolar Disorder 
2007 UK Plavix Prevention of Blood Clots – Cardiac 
2009 UK Seretide  Asthma 
2010 USA Tamiflu Antiviral 
2011 UK Nurofen Plus Pain relieving 
2011 UK Truvada Antiretroviral  
2011 UK Viread  Antiretroviral 
2012 USA Avastin Anticancer 
2013 UK Unknown Type 2 Diabetes 
2014 Germany Sutent Anticancer 
2014 USA Unbranded Antiretroviral 
2015 USA Botox Cosmetic 
2015 USA  Unbranded Anticancer  
2015 Germany Tenofavir Antiretroviral 
2015 Germany Humira Solution for pre-filled syringes 
2016 UK Medikinet ADHD 
2016 Germany Cialis Erectile Dysfunction 
 
During 2005 to 2006, particular batches of Lipitor, a cholesterol lowing medicine, manufactured 
by Pfizer, were found to contain counterfeit material; stocks of Lipitor were removed from sale. 
The counterfeit batches carried the same batch number as a genuine Pfizer batch (MHRA, 2011a). 
In May and June 2007, batches of Plavix, a cardiac medicine, manufactured by Sanofi-Aventis 
and Bristol Myers Squibb, were found to have been repackaged into English language cartons, 
which displayed the same batch numbers as those that were intended for the French market and 
packaged with French livery (MHRA, 2011a), Plavix was withdrawn from sale. 
It is not just Prescription Only Medicine’s (POM’s) that are counterfeited; in August 2011, 
Nurofen Plus, a pain-relieving medicine that is available Over the Counter (OTC), was recalled 
due two or more batches containing the wrong API (BBC, 2011). Batches affected were found to 
contain Seroquel, an anti-psychotic medicine and Neurontin, an anti-epileptic medicine (BBC, 
2011 and MHRA, 2011a). 
In other countries, instances of substandard and falsified medicines are increasing and this trend 
looks to continue, whether this is the result of detection methods becoming more advanced and 
therefore able to detect more occurrences, or if the counterfeit market is growing. In America 
cases of counterfeit medicines almost doubled (30 cases to 58 cases) in 2003 and 2004 





counterfeit Viagra, the seized tablets contained, but not limited to contaminated paint, heavy 
metals, rat poison, chalk and anti-freeze (Bandiera and Marmo, 2017). 
 
 	Internet	Pharmacies	
Due to the popularity of people ‘self-diagnosing’ using the internet, individuals are now buying 
medicines at the same time to complement their diagnosis regardless if it is correct, reinforcing 
the illusion of the internet being cost effective and time saving. Because of this, it is becoming 
more and more common for counterfeiters to use the internet as a means for selling and 
distributing counterfeit medicine. In the last decade in the UK, there has been rapid expansion in 
the number of websites offering medicines for sale via the internet (MHRA, 2011a). Surveys 
conducted by the WHO and other regulatory bodies have found that around 50% of medicines 
purchased on the internet from websites that conceal their physical address are counterfeit 
(EAASM, 2012). 
There has been an increase in the UK in recent years of people buying prescription drugs online 
(BBC, 2010). These flourishing internet pharmacies have transformed the conventional method 
of medicine distribution (Lui and Lundin, 2016); allowing people in the UK to buy anything from 
lifestyle to lifesaving medicines, often without prescription. These unregulated websites, further 
facilitate the availability of counterfeit medicines (Lui and Lundin, 2016). The risk in the UK is 
that many of these websites originate from abroad and are therefore not subjected to British 
regulations (MHRA, 2011a). In 2015, the police and MHRA raided the premises of a UK online 
pharmacy, 60,000 units of potentially dangerous medicines worth an estimated 2.4 million US 
dollars were seized (INTERPOL, 2015). In 2010, it was estimated that the European counterfeit 
drugs market was worth 10.5 billion Euros each year, with 1 in 5 Europeans buying counterfeit 
medicines (Grogan, 2010). It was also believed that as many 2.5 million men in Europe had taken 
counterfeit Viagra (Gardner, 2010). This has resulted in an annual increase in sales of counterfeit 
medicines of 15%; evidence of this includes the seizure of 11.4 million counterfeit medicines at 
EU borders in 2009, representing a 422% increase since 2006 (Mackey and Liang, 2011). 
The European Alliance for Access to Safe Medicines (EAASM) investigated the purchase of 
POM from the internet (Fake Britain, 2010). Results showed that not only could POM’s be easily 
purchased, but also an alarming lack of patient care or information was provided. Examples 
included supplying free Viagra with cardiac medication, counterfeit Lipitor and supplying a hair 
loss drug that can cause infertility in women to a female recipient without any checks taking place 
(Fake Britain, 2010). In the UK, all the medicines that were obtained by the programme required 





online pharmacy. However non-registered online pharmacies do not require a valid prescription 
or any form of medical history to supply a POM. It is illegal in the UK to obtain a POM without 
a valid prescription (UK Government, 1997) and could have life threatening consequences for the 
patients. 
The International Medical Products Anti-Counterfeiting Taskforce (IMPACT), a joint venture 
between the WHO, INTERPOL and other stakeholders established in 2006; believe that 
companies whose websites conceal their real identity sell counterfeit medicines (IMPACT, 2008). 
These companies tend to be international, sell POM’s without a valid prescription and often 
deliver products with unknown origins (IMPACT, 2008). In June 2015, INTERPOL carried out 
Operation Pangea VIII, an annual operation targeting the online sales of medicines and medical 
devices (INTERPOL, 2015). A record 20.17 million units of medicines were seized in just one 
week, worth 81 million US dollars (Lundin, 2015). These medicines included blood pressure, 
anti-erectile dysfunction and cancer medication, as well as nutritional supplements (INTERPOL, 
2015). In the UK, 6.2 million units of medicines were seized worth £15.8 million (Gallagher, 
2015).  
Nevertheless, non-registered internet pharmacies are on the increase (Fittler et al., 2013); the main 
driver is the growth of the internet, which stimulates the growth in internet pharmacies. In 
particular, POMs can be purchased from non-registered internet sites without prescriptions, 
creating a fake belief that time and money can be saved without having to visit a doctor and often 
to avoid embarrassment for some complaints.  
 
 	Generic	Medicines	
The usage of generic medicines can complicate the already complex issue of substandard and 
falsified medicines. Generic medicines enter the market after the patent expires on the innovator 
product. In order for a generic formulation to obtain approval from the relevant regulatory body, 
the formulation must be validated and shown to be bioequivalent and biopharmaceutically 
equivalent to the innovator product (Dharmalingam et al., 2014). It must also be identical in API 
release profile, purity, quality, dosage form and route of administration (Olusola et al., 2012). 
The introduction of generic medicines into health care systems, in particular in LIC and LMIC is 
aimed at reducing costs and therefore improving the overall delivery of healthcare in these 
countries (Olusola et al., 2012). However, the quality control (QC) and effective monitoring of 
generic medicines in LIC and LMIC is often absent. The QC issue itself raises concerns with the 





sources quoting that substandard medicines pose a greater threat to public health than falsified 
medicines (Odeniyi et al., 2003 and Davidson, 2011).  
Therefore, it is important that the relevant healthcare agencies and regulatory bodies monitor the 
quality of generic formulations. It is thought that effective monitoring of medicines can lessen the 
financial burden on countries caused by health issues, resulting from the usage of substandard and 
falsified medicines (Dharmalingam et al., 2014 and Blackstone et al., 2014). 
Studies in Kuala Lumpur and Nigeria assessed the quality of generics against the innovator brand 
for atenolol and metformin hydrochloride tablets using the methodologies from the British 
Pharmacopeia (Dharmalingam et al., 2014 and Olusola et al., 2012). The aim of the studies was 
to evaluate and establish the quality of most used generics against the innovator product 
(Dharmalingam et al., 2014 and Olusola et al., 2012). Both studies used a “working reference 
standard”, which was an analytical grade API powder, as opposed to a reference tablet. The 
studies established that all of the atenolol tablets analysed passed the pharmacopeia tests and were 
found to be bioequivalent to the innovator drug; whereas only four of the eight metformin 
hydrochloride brands tested could be classed as bioequivalent and passed the relevant 
pharmacopoeia tests (Dharmalingam et al., 2014 and Olusola et al., 2012). These studies showed 
that there is variation amongst generic formulations and some could even be classed as 
substandard, as not all of the metformin hydrochloride generics met the specifications outlined 
by the pharmacopeia. 
 
1.4 		Growth	of	the	Substandard	and	Falsified	Medicines	market	
Several factors make falsifying medicines attractive. Counterfeiting is a lucrative business, 
medicines are high value items in relation to their bulk and the demand for medicines is 
continually increasing (WHO, 2011). There are greater profits to be made in falsifying medicines 
than from smuggling Class A drugs (WHO, 1999); also, the penalty if caught is considerable less 
than that of Class A substances. The cost of ingredients can be very low if expensive active 
ingredients are omitted or cheap substitutions used (WHO, 2011; Kelesidils and Falagas, 2015). 
Legitimate pharmaceutical manufacturers must ensure product quality and are carefully regulated, 
which results in considerable overheads. Counterfeiters have little quality assurance and no 
regulation to adhere to; hence their profit margins are very high (WHO, 2011; Krakowska et al., 
2016). 
The production of falsified medicines does not require large infrastructure or facilities; many 





and adulterants vary from batch to batch. Jackson et al., (2010) reported contaminants used in the 
falsification of Viagra tablets seized in the UK; these included caffeine and bulk lactose in one 
batch and in another subset talcum powder, commercial grade paints and API’s for other 
pharmaceutical products (paracetamol and metronidazole) were identified. The group also 
reported that in some cases printer ink was used to produce the blue colour of the tablets (Jackson 
et al., 2010).  Furthermore, counterfeiters have also been found to use pharmaceutical companies 
that manufacture genuine medicines during business hours and at night manufacture counterfeits 
(Mukhopadhyay, 2007). Instances in China, where a large proportion of counterfeits are 
manufactured, have shown that counterfeiters take advantage of European and US patent laws not 
being recognized to manufacture medicines which are classed as legal in China. These medicines 
only become illegal once they are exported (MHRA, 2011b). 
Counterfeiters have also set up companies providing a service to dispose of expired medicines, 
only to repackage and resell them (Mukhopadhyay, 2007; Kamba et al., 2017). 
The falsification of medicines is greater in those regions were the regulatory oversight is weak. 
In some countries, the counterfeiting of medicines is not treated as a criminal offence, as there is 
no legislation or regulations that exist for the proper control of medicines (WHO, 2011). Where 
sanctions are imposed on counterfeiters these are often not a significant deterrent and create a 
minimal fear of prosecution (WHO, 2011). 
The growth in the international trade of pharmaceutical ingredients and medicines only adds 
another complexity to this issue (Consoli, 2010). As many pharmaceutical companies seek to 
outsource production of excipients and/ or medicines to reduce costs, the quality and purity of 
these can be compromised and the risk of counterfeiters accessing the supply chain increases. 
 
1.5 	 Combating	Substandard	and	Falsified	Medicines	
Healthcare and regulatory bodies are now working with governments to implement new laws and 
task forces to combat the problem of counterfeit medicines. 
In America, the Counterfeit Drug Enforcement Act 2014 was introduced in December 2014 
however it was not enacted, with previous revisions of the act also being rejected by congress; 
this act seeks to increase penalties for the sale and trade of counterfeit drugs (Anon, 2014). The 
FDA also have a voluntary agreement with pharmaceutical companies, in which companies are 
expected to report suspected counterfeit medicines to the FDA within 5 days of discovery (Food 





The European Union (EU) has issued directives of the European Parliament to combat the issue 
of counterfeit medicines. In 2011, the directive 2001/83/EC relating to medical products for 
human use and prevention of entry of falsified medicinal products into the supply chain was 
amended and now requires all member states to have a system in place to detect such medicinal 
products. This involves introducing an electronic system containing registration details of 
manufacturers, importers and distributors (Merks et al., 2016). Further to this in 2016, a new 
European Commission (EC) regulation (EC 2016/161) dictates that by February 2019, all member 
states must have implemented two safety features on human medicine packaging. These include 
a unique identifier and an anti-tampering device (European Medicines Agency, 2016). The 
directive mandates that all POM’s be serialised with a unique code printed on the packaging that 
can be verified and authenticated at the point of supply to the patient (Naughton et al., 2016) 
In 2009 in Kenya, the Anti-Counterfeit Act 2008 became law clamping down on fake products. 
Critics believed that this act would blur the lines between generic, substandard and counterfeit 
medicines. One such critic is Médecins Sans Frontières (MSF), who believes this anti counterfeit 
measure could potentially deprive Africa of cheap medicines (Chatterjee, 2010). MSF depend 
mainly on low cost generic versions of essential medicines to treat patients around the world. In 
2010, the Constitutional Court in Kenya barred its Government from implementing the new law, 
as the law applied to generic medicines (Gathigah, 2010). For many years, the newer antimalarial 
medicines were not used in Kenya, because the healthcare authorities could afford only generic 
medicines and these might have been considered counterfeit. This unusual situation has been 
rectified and discussed at length by the Kenyan Government. Petitioners to the new law believe 
the act confuses quality and intellectual property rights, therefore making legitimate generic drugs 
counterfeit (Gathigah, 2010). This is due to the term counterfeit being deemed controversial as 
discussed earlier in this chapter. 
Other East African countries look to follow Kenya, Uganda has a draft anti counterfeit bill and 
Tanzania, Rwanda and Burundi are currently in talks over these issues. 
There is still significant resistance to discuss the occurrence of counterfeit or falsified medicines. 
For example at the recent 15th International Association of Therapeutic Drug Monitoring & 
Clinical Toxicology Conference in Kyoto, Japan, there was not a single reference to counterfeit 







The most common oral dosage form is the tablet, the manufacturing process and formulation of 
the tablet can vary depending on the medicine. Excipients are the main constituents of a tablet, 
excluding the API and are often included to aid manufacture, administration or adsorption and 
even enhance the colour of the tablet. Excipients can vary between the innovator product and 
generic formulations, however any excipient used in the product is tightly controlled by regulatory 
bodies. 
Illnesses of global concern were identified (cardiovascular disease and diabetes) and appropriate 
tablet formulation medicines were acquired opportunistically from around the world. The overall 
aim for this research was to examine a range of analytical methods, which could identify and 
potentially quantify the API present in a single tablet. Chapter 3 discusses a range of analytical 
techniques and assesses the ability to detect SF medicines. 
 
2.1 		Selection	of	Target	Medication	Forms	
All healthcare providers look to supplying optimum care in the most cost-effective way. 
The oral route of drug administration is the most common and frequently used with tablets 
accounting for the majority of all dosage forms (Jivraj et al., 2000; Yasmeen et al., 2005; Jaimini 
and Rawat, 2013). The cost, convenience of dosing and stability compared to other dosage forms, 
controlled release of the API, allowance of the incorporation of more than one API and the ability 
to self-administer, make tablets the most popular dosage form (Jivraj et al., 2000; Jaimini and 
Rawat, 2013). This research has therefore focused on developing qualitative and quantitative 




The British Pharmacopeia (BP) define tablets as ‘solid preparations each containing a single dose 
of one or more active substances. They are obtained by compressing uniform volumes of particles 
or by another suitable manufacturing technique… The particles consist of one or more active 
substances with or without excipients.’ (British Pharmacopeia, 2017a). 
Excipients are the main constituents of a dosage form excluding the API (European Commission, 





Martini, 2001). Excipients are sometimes included for other reasons, such as product 
differentiation, appearance enhancement or retention of quality (Crowley and Martini, 2001). 
The selection of excipients within a tablet formulation plays an important role in the overall 
quality of the product (Haywood and Glass, 2011); along with the grade and quality of the 
excipients and the drug manufacturing process (Srinivasan, 2014). This is significant, as many 
pharmaceutical companies outsource the manufacture of their products to reduce overheads and 
production costs. This can sometimes result in a poorer quality product, often substandard, as 
some countries do not have robust quality control measures compared to the UK, Europe and 
America.  
The range of excipients used in the top 200 prescription tablets, in the USA, was investigated 
(Dave 2008), and the results are shown in Figure 2.1. For simplicity, chemically similar and hence 
spectroscopically similar, excipients have been grouped together. These are: 
 Cellulose: MCC, methyl, ethyl, HPMC, cellulose and carboxymethylcellulose. 
 Calcium Phosphate: dibasic, tribasic, anhydrous, diphosphate and hydrogen phosphate 
dehydrate. 
 Cross povidone: povidone and PVP. 
 Lactose: hydrous, anhydrous, monohydrate and spray dried. 
 Silicon dioxide: colloidal  
 Starch: corn, potato, sodium, and pregelantised. 







Figure 2.1: Frequency of excipient usage for the top 200 tablets (Dave, 2008) 
The excipients shown in Figure 2.1 can be categorised into the following types as summarised in 
Table 2.1. 
Table 2.1: Different excipient components of typical tablet formulations 
Excipient Amount in Tablet (%) Mg/Tablet 
Diluents (Fillers) 5 – 80  20 – 400  
Binding Agents 0.5 – 5  2 – 20  
Lubricants 0.3 – 2  1.5 – 10  
Disintegrants 5 – 20  20 – 100  
Glidants < 0.2 < 1 
Colourants (Pigments) 0. 1 – 0.5 < 2 
API 2 – 85  1 – 500  
 
It is important to note that generic formulations of the innovator product may differ in the 
excipient usage. Whilst the physical appearance and bioavailability is tightly controlled (Food 
and Drug Administration, 2015), manufacturers may use different excipients from those in the 
innovator product; however, any excipient used in the proposed formulation must be included in 
the FDA Inactive Ingredient Database (IID or IIG) in the USA (Srinivasan, 2014). In the UK, any 


































Diluents are commonly used as fillers in a tablet and more often added as a bulking agent to aid 
compression and improve bulk powder flow (Mills, 2007). Diluents have a strong influence over 
powder flow and can enable blended powders to flow quickly (Mills, 2007). They are often 
carbohydrate based, but can also contain phosphates; common diluents include lactose, sucrose, 
starch, cellulose, microcrystalline cellulose (MCC) and dicalcium phosphate dihydrate (Aulton, 
2007, Gohel, 2016a). The concentration of diluents in a tablet can range from 5% to 80% (Gohel, 
2016a). 
Lactose is the most common filler used in the manufacture of tablets (Aulton, 2007), with varying 
forms used in the different manufacturing processes. These include spray-dried lactose, which has 
been specifically designed for direct compression (Jivraj et al., 2000) and anhydrous lactose, 
which is commonly used in wet and dry granulation. 
MCC is widely used in the pharmaceutical industry as a diluent, this because it acts as both a filler 
and a binder (Jivraj et al., 2000). Alongside spray dried lactose, MCC is one of the most useful 
fillers for direct compression (Jivraj et al., 2000), this is due to it exhibiting excellent 
compactability at low pressures, high dilution potential and superior disintegration properties 
(Jivraj et al., 2000).  
 
 	Binding	Agents	
Binding agents are added to the tablet to act as an adhesive and bind together the powder and 
granules (Mills, 2007). Binders can be added either ‘dry’ or dissolved in granulation fluid (either 
solvent or water based) (Aulton, 2007). If a granulating fluid is used, it needs to be evaporated 
off, leaving the binder in place to adhere to the granules. Dry binders are often used in the direct 
compression process, as solutions cannot be used (Aulton, 2007). 
The amount of binder added is important, as it affects the overall mechanical strength of the tablet 
(Aulton, 2007). Too much binder results in very hard tablets and an increase in disintegration 
time, with too little binder resulting in a weak tablet that may not withstand further processes. 
Common binding agents are typically polymeric based, for example polyvinylpyyrolidone (PVP) 





and gelatin (Mills, 2007 and Aulton, 2007). The concentration of which binders are added is 
dependent upon the molecular weight, with concentrations ranging between 0.5% to 5% w/w. 
 
 	Lubricants	
Lubricants are used in the formulation of tablets, as they prevent the adherence of 
granules/powders to the punch die/faces and promote smooth ejection from the die after 
completion (Mills, 2007), therefore reducing the effect of pitting on the tablet surface. Most 
lubricants are hydrocarbon based and may be either insoluble or soluble in water. 
Common insoluble lubricants include magnesium stearate and stearic acid, with magnesium 
stearate being the most extensively used tabletting lubricant (Mills, 2007). Soluble lubricants 
include polyethylene glycol (PEG) and lauryl sulphate salts (sodium or magnesium) (Aulton, 
2007). The efficacy of PEG is less then magnesium stearate, so insoluble (hydrophobic) lubricants 
are often preferred. 
The hydrophobic concentration level (typically 0.3% to 2%) needs to be optimised (Mills, 2007), 
as it can affect the tablet quality. If under lubricated, the blend flows poorly and can have 
compression sticking problems, whereas over lubricating can adversely affect the tablet hardness 
and dissolution rate (Mills, 2007). Effective lubrication alongside powder flow is important in the 
pharmaceutical industry for high throughput of product (Mills, 2007). 
 	Disintegrants	
Disintegrants are added to aid de-aggregation of compacted tablets (Mills, 2007). The presence 
of a disintegrant causes a more rapid break-up of the tablet upon exposure to moisture (Mills, 
2007). It is important that the tablet be broken down, to facilitate dissolution in the gastrointestinal 
tract prior to absorption into the blood stream. 
Disintegrants react on contact with moisture and in most instances water uptake alone will cause 
disintegration. This occurs when the interparticle cohesive forces that hold the tablet together are 
ruptured (Mills, 2007). Some disintegrants work by swelling on contact with moisture, in this 
case the tablets are broken down by physical rupturing, as the channels of penetration are widened, 
thereby increasing the rate of water uptake into the tablet (Mills, 2007). 
The most common disintegrants are maize starch, sodium starch glycolate (Primogel) and 
celluloses, for example methylcellulose (Aulton, 2007). The concentration of these ranges from 







Glidants can enhance powder flow, but are not a standard excipient and are only added if 
necessary (Mills, 2007). Glidants can be difficult to work with, as they are very voluminous, 
therefore controlling the level of glidant can be challenging (Mills, 2007). 
Glidants improve powder flow by adhering to particles, thus reducing interparticle function 
(Mills, 2007). They are most commonly used in dry powder formulations and in the direct 
compression manufacturing process.  
The most common glidant used is colloidal silicon dioxide and is required in very low levels, 
usually less than 0.2% (Mills, 2007). 
 
 Colourants	(Pigments)	
Colourants are often used to achieve a certain visual effect and to a less extent to influence the 
mechanical properties of the coating (Aulton, 2007). Acceptable colourants for use 
pharmaceutically are available as both pigments (insoluble in water) and dyes (water-soluble). 
Pigments are often used in film-coated formulations, as they are more chemically stable; provide 
better coverage and a means of optimising permeability in film-coated formulations (Aulton, 
2007).  
The most common pigments used are iron oxides, titanium dioxide and aluminium lakes (Aulton, 
2007). Lake colorants are formed by chemically reacting straight dyes with precipitants and salts. 
Lakes are often used as colour additives for tablet coatings due to their stability (FDA, 2003). 
 
2.3 	 	Tablet	Formulations	for	this	research	
In Low and Middle Income countries, there has been a shift from infectious to non-communicable 
disease, as the leading cause of morbidity and mortality (Antignac et al., 2017), with 
cardiovascular (CV) disease and diabetes a global burden (Al-Hamid et al., 2016). In recent years 
there has been a transfer from HIC to LIC for CV deaths, in HIC the rate of deaths caused by CV 
disease has significantly decreased, whilst in LIC the frequency of CV deaths has been on the rise 
(Antignac et al., 2017). It is thought that more than 80% of deaths globally from CV disease occur 
in LIC and LMIC (Antignac et al., 2017). The WHO state that by 2020, the major sources of 
morbidity globally will be CV disease and diabetes (Al-Hamid et al., 2016). Therefore, atenolol 
(cardiovascular disease), metformin hydrochloride (diabetes) and a range of antimalarials were 





The samples were acquired opportunistically via interested colleagues, PhD students and 
undergraduates studying on the Pharmacy and Pharmaceutical and Cosmetic Science courses at 
De Montfort University. 
This research assesses the ability of various analytical techniques to detect/identify SF medicines 
in a single tablet. Standard assay tests by the British Pharmacopeia (BP) can often use ~20 tablets 
per assay (British Pharmacopeia 2017b); in reality this is not feasible in LIC and LMIC, as there 
are often not 20 tablets to spare per test, as the cost of medicines is expensive. When performing 
analysis of a batch, the concentration of API is often averaged out over the 20 tablets, the patient 
however only takes a single tablet, and any fluctuation in dosage would affect the patient. The 




Atenolol [4-[2-hydroxy-3 isopropyl–aminopropoxy]-phenyl-acetamide] is a β1-receptor 
antagonist belonging to the β blocker category. Figure 2.2 shows the molecular structure of 
atenolol. Atenolol is primarily used for the treatment of cardiovascular diseases, including 
hypertension, arrhythmias and for longer-term management of angina pectoris (Khataee et al., 
2016 and Dharmalingam et al., 2014)). The use of atenolol in sport is prohibited and is included 
on the World Anti-Doping Agency’s (WADA) List of Prohibited Methods and Substances. This 
is due to atenolol being a misused as a doping agent, as it has a calming effect on the athlete 
(Farcaş et al., 2016 and Khataee et al., 2016). Although atenolol is used for the treatment of 
hypertension, it can lead to severe hypotension if taken excessively (Khataee et al., 2016).  
Common excipients used in the formulation of atenolol tablets include, but not limited to calcium 
hydrogen phosphate dehydrate, silica colloidal anhydrous, magnesium carbonate, magnesium 







Figure 2.2: Molecular structure of atenolol 
 
 	Metformin	Hydrochloride	
Metformin hydrochloride belongs to the biguanide class of drugs and is often used as the first line 
agent for the treatment of type 2 diabetes (Olusola et al., 2012). It is one of only two antidiabetic 
tablets included in the WHO’s Model List of Essential Medicines, as it has very few adverse 
effects (Diabetes, 2017). It is often prescribed for the management of type 2 diabetes, particularly 
in cases where the patients are also overweight, obese or suffer from polycystic ovary syndrome 
(Olusola et al., 2012). Metformin hydrochloride works by supressing hepatic glucose production, 
increasing insulin sensitivity therefore enhancing peripheral glucose uptake. This then increases 
the oxidation of fatty acids and results in lower absorption of glucose in the gastrointestinal tract 






Figure 2.3: Molecular structure of metformin hydrochloride 
Common excipients used in the formulation of metformin hydrochloride tablets include, but not 
limited to magnesium stearate, maize starch, povidone and sodium starch glycolate. 
 
 Antimalarials	
Antimalarials are used in the prevention and treatment of malaria (NHS, 2015). Antimalarials are 
used to eliminate the Plasmodium parasite from the patient’s blood. The WHO recommends 
artemisinin based combination therapies (ACT) for the treatment of malaria caused by the P. 
falciparum parasite, these include: 
 Artemether and lumefantrine, 
 Artesunate and amodioquine, 
 Artesunate and mefloquine, 
 Dihydroartemisinin and piperaquine, 
 Artesunate and sulphadoxine – pyrimethamine (SP) (WHO, 2017b). 
Chloroquine or ACT is used for infections caused by P. vivax, in chloroquine resistant areas 
quinine is used to treat the infection (WHO, 2017b). Figure 2.4 shows the molecular structure of 






Figure 2.4: Molecular structure of chloroquine phosphate 
 
Figure 2.5: Molecular structure of quinine sulphate 
Common excipients used in the formulation of antimalarial tablets include, but not limited to 
croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, maize starch, 








All tablets have complex formulations, typically of three or more components and any suitable 
analytical method must be able to either 
 Identify the analyte in a complex mixture 
Or 
 Selectively isolate the target analyte prior to identification. 
In both cases, subsequent quantification would be advantageous. 
The aim of this study is to examine a range of analytical methods, which can identify and possibly 
subsequently quantify the API’s present in a single unknown tablet sample. 
This can be achieved by the following objectives: 
i) Systematic review of the literature. 
ii) Assessment of analytical equipment for the ability to identify and quantify an API in a 
tablet, with respect to LIC’s and LMIC’s. 
iii) To consider the reliability and validity of the equipment/ methods. 






A range of analytical techniques were assessed for their capability to detect SF medicines in 
particular the identification and quantification of the API. 
Instrumental selection criteria for this study included the potential ability to use these techniques 
in LMIC’s and the need for little or no sample preparation. Different analytical techniques require 
different levels of sample preparation as summarised in Figure 3.1. Some techniques were 
discounted on being beyond the scope of LMIC’s and not fitting the criteria of single tablet 
capacity.  
Spectroscopic, chromatographic and microscopic methods were assessed with relation to the 
criteria and ability to identify SF medicines. Chapter 4 outlines the methods and instruments 
selected to identify potential rapid screening methodologies. 
Methods for detecting substandard and falsified medicines vary from ‘low tech’ approaches, for 
example visual appearance, Thin Layer Chromatography (TLC), Minilab and colourimetric tests, 
to those that are technically refined, for example Raman, Near Infrared (NIR) and Mass 
Spectrometry (MS). However, counterfeiters are fast to react to new methods to stop them 
(Mukhopadhyay, 2007), so the need to develop new robust techniques is important. A significant 
consideration for any new technique that is developed is that it can be employed in both HIC’s 
and LIC’s. Much of the infrastructure that is taken for granted in HIC’s is absent or unreliable in 
LMIC and LIC’s. In many parts of the world, power and water supplies can be uncertain and 
specialist analytical equipment and trained staff will be in short supply (Höllein et al., 2016). 
Many counterfeiters will use a small amount of active ingredient in order to bypass some 
qualitative tests, for example TLC and colourmetric tests. Most techniques are often used in 
combination with others to build a profile, including chemical, biological and packaging evidence 
(Newton et al., 2008). This provides the correct identification at the sample screening stage, but 
provides insufficient dosage of the API to the patient, resulting in absence of any therapeutic 
benefit. 
In this work, a rapid screening process capable of identification and quantification of an API will 
be investigated. Substandard and falsified medicines can be analysed by a variety of techniques; 
the techniques available fall into the following general categories and methodologies: 
 Spectroscopic – light absorbance (IR, UV), light emission (Raman) at specific         
frequencies 





 Mass Spectrometry – ionisation giving specific m/z values 
 Microscopy – SEM and X-ray analysis for elemental composition 
 Nuclear Magnetic Resonance – energy absorbance to give structural data 
Whilst considering the range of techniques available the potential to use the technique in a LMIC 
with few trained staff and facilities must be kept in mind. Furthermore, techniques requiring little 
or no sample preparation would be preferred. Each of the techniques referred to above requires 
different degrees of sample preparation, ranging from non-destructive techniques to those needing 
crushing and or dissolution of the dosage form. Figure 3.1 summarises the level of sample 
preparation of medicines for some analytical techniques. 
 
 
Figure 3.1: Levels of sample preparation for some analytical techniques, with those to be 
investigated highlighted 
Sections 3.1 to 3.4 discuss both current and evolving techniques that can be used to analyse 
counterfeit medicines. The focus is on rapid data output generated by relative non-specialists. 
Within the criteria, information is needed that has a high degree of specificity to minimise the 
number of false positives identified with the analyst and the loss of revenue. 

























Table 3.1: Advantages and Disadvantages for the analytical techniques analysed 
Technique Advantage(s) Disadvantage(s) 
UV  Quantification of the API. Requires solvents to extract the API. 
Time Consuming. 
ATR FTIR  Sample preparation is minimal. 
Can identify API’s in a whole tablet 
formulation when compared to a 
reference. 
Able to quantify the amount of API. 
Surface technique. 
Cannot analyse whole tablets. 
Mixing can be an issue. 
 
Raman  Non-destructive, sample 
preparation is minimal if at all. 
Can analyse whole and powdered 
samples. 
Can identify API’s in a whole tablet 
formulation when compared to a 
reference. 
Some samples are prone to the effect of 
fluorescence, which can affect results. 
Requires multivariant analysis to 
quantify. 
DIP MS Sample preparation is minimal. 
Can identify the target API, as it is 
selective technique. 
 
Difficult to quantify amount of API. 
Source can easily become contaminated, 
as inserted directly into it. 
ASAP MS Sample preparation is minimal. 
Can identify the target API, as it is 
selective technique. 
Spectra is generally simple, due 
limited fragmentation (M+H+). 
Difficult to quantify amount of API. 
 
SEM/EDX Can analyse the morphology of a 
tablet. 
Can identify and quantify inorganic 
components readily using EDX. 
Can map the distribution of 
elements using EDX. 
 
Surface technique. 
EDX limited in that it cannot detect the 
lighter elements, e.g. H, He, Li and B. 
  
The techniques that meet these requirements are Near Infrared (NIR) Spectroscopy, Raman 
Spectroscopy, Fourier Transform Infrared (FTIR) with Attenuated Total Reflectance (ATR) 
accessory, Atmospheric Solids Probe (ASAP) Mass Spectrometry, Direct Insertion Probe (DIP) 
Mass Spectrometry and Scanning Electron Microscopy (SEM) / Energy Dispersive X-ray 
Spectroscopy (EDX). 
Costlier techniques such as Liquid Chromatography Tandem Mass Spectrometry (LC-MSMS) 
and Nuclear Magnetic Resonance (NMR), which are common in HIC, were excluded on being 
beyond the scope of laboratories in LMIC’s. The British Pharmacopeia (BP) was used as a 
reference test and it should be remembered that the methodology was designed to test multiple 
tablets in lengthy procedures.  On this basis, the BP methods do not fit the criteria for a rapid 










Ultraviolet (UV) and visible radiation constitute a small part of the Electromagnetic spectrum. 
This radiation then interacts with matter and a variety of processes can occur including 
absorbance, this is important for the purpose of UV-Vis spectroscopy. UV-Vis is often used for 
the quantification analysis of all molecules that absorb UV-Vis radiation (RSC, 2017). 
The principle of UV analysis is that in the case of a single beam spectrophotometer; light is 
emitted from a source and is separated into narrow bands of specific wavelengths selected by a 
monochromator, this then passes through the sample and is measured by the detector (Harris, 
2003). Depending on the spectrometer, both a tungsten and deuterium lamp can be used; this is 
due to the optimum performance of the lamps at a given wavelength. Tungsten lamps are often 
used as a continuous source of visible and Near Infrared (NIR) radiation and perform over the 
range of 320 – 2500nm. For lower wavelengths, a deuterium lamp is used (200 – 400nm). The 
source changes between deuterium and tungsten at 306nm, this is because the source with the 
highest intensity is always used (Harris, 2003). Once the light passes through the sample it is 
measured by a detector (phototube), which when struck by photons produces an electronic signal 
(Harris, 2003). 
For the application of substandard and falsified medicines, UV analysis is often used as a 
confirmatory technique through comparison of an observed spectrum and a reference spectrum. 
In 2015, Figueroa et al., exclusively used UV spectroscopy to detect substandard and falsified 
medicines. The group analysed adulterated samples of acetaminophen and Tylenol to establish if 
UV spectroscopy could identify the concentration of API in different adulterants. Results showed 
that at a specific wavelength the amount of change alongside characteristic shifts enabled UV to 
be used in the detection of substandard and falsified medicines. The absorbance of standard 
solutions were compared and any differences observed showed substandard nature. Shifts in the 
λ max would indicate different species present in the solution but not identify what (Figueroa et al., 
2015).  
Other research groups have used UV analysis in a confirmatory capacity; it has been applied to 
both branded and generic formulations. Baratta et al., (2012) analysed 221 samples of various 





inflammatories, antimalarials and antihypertensive, were assayed, and analysed using UV 
spectroscopy. (Baratta et al., 2012). Vredenbregt et al., (2006) used UV as a reference test to 
identify and quantify the API when analysing suspect Viagra samples by NIR (Vredenbregt et al., 
2006). Again, using UV as a reference test Tipke et al., (2008) analysed antimalarial drugs in 
Burkina Faso, using a minilab. Samples that failed this test were sent to Germany for 
quantification of the API by UV according to EP specifications, further analysis revealed samples 
to be substandard (Tipke et al., 2008). 
 
 Infrared	Spectroscopy	
The measurement of absorption of infrared radiation brought about by changes in molecular 
vibrations within molecules, gives rise to infrared spectroscopy.  Depending on the wavelength 
of this radiation, fingerprint spectra of molecular structures can be obtained. This data provides 
information on the structure of the molecule and in particular the nature of the functional groups 
present in the sample. Raman spectroscopy provides data on similar functional groups within the 
molecule, the data provided is in the form of emissions at specific wavelengths. Both sets of 
information are produced between 4000cm-1 an 400cm-1. The relationship of the different forms 
of IR analysis technique to the rest of the Electromagnetic (EM) spectrum are shown in Figure 
3.2. 
 
Figure 3.2: Electromagnetic spectrum and Infrared region (Chromacademy, undated) 
The three different types of infrared spectroscopy have been involved in the study of SF 







In the past decade, Near Infrared (NIR) Spectroscopy has gained wide acceptance within the 
pharmaceutical industry (Reich, 2005) for various applications, including raw material testing, 
product quality control and process monitoring (Reich, 2005). It was once the method of choice 
for analysing counterfeit medicines (Lopes and Wolff, 2009). 
NIR is a form of molecular spectroscopy, covering the transition from the visible spectral range 
to the mid infrared region.  Samples are illuminated with a broad spectrum of NIR light, which 
can be absorbed, transmitted, reflected or scattered by the sample (Thermofisher, undated)( Figure 
3.3). NIR uses overtone and recombination bands in the range of 12,000cm-1 to 4000cm-1 to 
determine the structure of the sample (Marks and Campbell, 2008). The most prominent 
absorption is related to the overtones and combinations of fundamental vibrations of –CH, –NH 
and –OH functional groups (Reich, 2005). The particular combinations detected are dependent 
on the nature of the primary light source.  
 
Figure 3.3: Schematic of a Near Infrared spectrometer (Buchi, 2017) 
NIR provides rapid, quantitative analysis of tablets with little or no sample preparation required 
(Marks and Campbell, 2008; Laasonen et al., 2004; Baer et al., 2007 and Roggo et al., 2007). The 
technique is non-destructive, allowing samples to be subsequently analysed by other techniques 
(Roggo et al., 2007 and Charvill, 2005). The data produced provides molecular information not 
only of the API, but also of other excipients present from a single measurement (Marks and 
Campbell, 2008; Laasonen et al., 2004 and Baer et al., 2007). Furthermore, the cost per test for 
NIR is often much lower than for other analytical methods, especially when large numbers of 





well controlled production conditions where the direct insertion of the NIR probe into the sample 
is a simple QC procedure rather than analytical test of the unknown. 
There are some disadvantages with NIR, only broad bands are observed and the spectra can be 
difficult to interpret (Roggo et al., 2007). The observed absorbance bands are the result of 
overtones from different functional groups within the sample analysed. Molecules with a similar 
chemical structure will therefore be difficult to distinguish using NIR. Mixture analysis will also 
therefore present spectra with superimposed absorptions and compounds might only be 
recognised if they have a unique functional group (Baer et al., 2007). Careful calibration and 
acquisition of standard spectra of active ingredients and excipients is required in order to ensure 
accurate quantitative identification. This is relatively easy for the pharmaceutical industry 
expecting repeat batches of standard production raw materials and may be possible for repeat 
batches of tablets. NIR spectra are sensitive to samples that absorb water from the atmosphere, it 
has been implied that storage conditions of samples such be considered when using NIR (de 
Peinder et al., 2008 and Moffat et al., 2010). Whilst NIR can be considered a rapid technique to 
obtain spectral data, the lack of data in a NIR spectrum combined with the complexity of the 
signal means that very often specialist software is required to perform the complex calculations 
to determine sample composition (Marks and Campbell, 2008), which can be time consuming. It 
may also require concentrations of each analyte to be measured by another technique (Marks and 
Campbell, 2008). 
NIR has been used to check batch homogeneity and is able to distinguish counterfeits and 
imitations from authentic Viagra (de Veij et al., 2008). Forensically, it has been applied to identify 
and quantify the amount of 3,4-Methylenedioxymethamphetamine (MDMA) in ecstasy tablets, 
by comparing NIR spectra (Baer et al., 2007). 
 
 	Attenuated	 Total	 Reflectance	 Fourier	 Transform	 Infrared	 (ATR	 FTIR)	
Spectroscopy	(4000	–	400cm‐1)	
Fourier Transform Infrared (FTIR) Spectroscopy is a sophisticated tool in the spectral analysis of 
organic compounds (Cheng et al., 2010). FTIR is used to obtain structural information about a 
compound and has many advantages as an analytical technique. This is because all active 
pharmaceutical ingredients give an Infrared (IR) spectrum; the fingerprint region of the spectrum 
is unique and can be used for identification (Cheng et al., 2010). The fingerprint region is between 
2000cm-1 and 400cm-1, the vibrational frequencies and individual molecular motions observed in 
this range are unique to a particular molecule. Therefore, the likelihood of misidentification using 






Traditional FTIR analysis of pharmaceutical samples, rely on sample extraction, solvent 
extraction/drying and subsequent Potassium Bromide (KBr) disc analysis. This can be difficult, 
as making a KBr disc is time consuming and ensuring the correct ratio of sample and KBr to 
provide good radiation transmission through the sample can be hard to achieve. This sample 
preparation approach can be replaced by modern Attenuated Total Reflectance (ATR) techniques 
and the increased sensitivity of FTIR spectrometers make ATR a simple and routine test (Cheng 
et al., 2010, Ortiz et al., 2013). ATR has the ability to measure a wide variety of solid and liquid 
samples without the need for complex sample preparation. ATR is achieved by IR light being 
totally internally reflected at the interface between the sample and the ATR crystal (Chan et al., 
2003).  
 
Figure 3.4 illustrates the principle of ATR.  The penetration depth depends on the wavelength, 
the refractive indices of the ATR crystal and the sample and the angle of the beam. This typically 
can be between 0.5μm and 5μm (Anon, 2005). The light penetrating the sample is attenuated by 
interaction with characteristic molecular vibrations to produce a conventional IR spectrum (Chan 
et al., 2003). It is therefore necessary to ensure maximum surface contact between the sample and 
the ATR crystal. This necessity is a limiting factor of the ATR technique. 
 
 
Figure 3.4: ATR principle (Tanna et al, 2013) 
ATR FTIR is a powerful technique which has successfully been used to analyse a wide range of 
samples, including the polymorphic content of bulk pharmaceuticals (Salari and Young, 1998), 
pharmaceutical formulations (Chan et al., 2003), powder mixture (Planinšek et al., 2006) 
dentifrice adulteration (López-Sánchez et al., 2008), presence of Sildenafil and Tadalafil as 
adulterants in dietary ingredients (Champagne and Emmel, 2011), Chinese herbal and animal 
medicines (Cheng et al., 2010), and the origin of wines (Tarantilis et al., 2008). It is a fast and 
straightforward technique with the need for little or no sample preparation (Cheng et al., 2010 





interference from Potassium Bromide or Nujol signals (Cheng et al., 2010).  This technique can 
be classed as a rapid technique for the surface analysis of powders. 
The use of ATR FTIR to quantify API’s in tablet formulations in order to identify substandard or 
falsified medicines is relatively new. Although conventional FTIR has been applied to quantifying 
anti-diabetic medicines for quality control and the possible detection of counterfeits (Farouk et 
al., 2011). Lawson et al., (2014a) used an ATR FTIR technique to quantify the amount of 
paracetamol in tablets and this data was then compared to an establish BP UV methodology.  
One limitation to ATR FTIR is that it does not sample the bulk of a sample; this is because IR 
radiation only penetrates a few microns into the sample, meaning ATR FTIR is classed as a 
surface technique (Bugay, 2001 and Planinšek et al., 2006). This may lead to misleading analysis 
of the whole tablets especially those that are coated. Previous analyses of some tablets have shown 
that whilst the stated dosage is correct the distribution of the API throughout the tablet is not 
uniform (Lawson et al., 2014b). Homogenisation of the samples especially for quantitative 
analysis is therefore recommended. It has been used for both medical products and medicines; in 
2008, López-Sánchez used this technique to establish if toothpaste samples had been adulterated. 
The study was able to quantify diethylene glycol in dentifrices by using Partial Least Squares 
(PLS) method (López-Sánchez et al., 2008). 
With regards to counterfeit/ substandard medicines, Been et al., (2011) used FTIR in combination 
with NIR and Raman to identify a range of medicines manufactured by F. Hoffmann and La 
Roche Limited and characterise the chemical composition. The study used FTIR microscopy to 
aid the identification and found the results to be complementary to those obtained by NIR and 
Raman (Been et al., 2011). Other studies have identified counterfeit Cialis and Viagra from 
uncoated milled tablets (Ortiz et al., 2013) and artesunate and other antimalarials (Ricci et al., 
2007). 
Salari and Young (1998) attempted to use peak height to quantify mixtures of polymorphs and 
found that there were limiting factors affecting the results. The most important factor was mixing 
efficiency; the study found that a perfect mixture was ‘virtually unattainable with powders’, 
though it was possible to achieve a mixture with a maximum degree of randomness. They also 
cited concerns that interfacial properties of the original material could be replaced when mixed 
with a lubricant, which was able to coat the powder surface (Salari and Young, 1998). SEM was 
used to observe the organisation of the mixture and to see if a perfect mixture could be attained. 






Much of the work reported above is qualitative in nature and as all spectroscopic signals depend 
on the concentration of the analyte in the sample, the original weight of any tablet must be 
determined before quantitative procedure can be carried out. 
 
 Raman	Spectroscopy	
Until the late 1990’s, Raman spectroscopy was not widely applied in the pharmaceutical industry; 
this was due to the industry being less sure of the quality of its raw materials and therefore the 
need to be able to perform rapid QC checks on the materials. Smaller detectors that are more 
efficient coupled with small efficient lasers, as the radiation source have led to the development 
of portable handheld Raman instruments. (Webster and Baldwin, 2005).  
The use of lasers, particularly in handheld systems introduces the problems of radiation safety 
protection. This is of importance where direct sampling of tablets is concerned. In this situation, 
the radiation extends beyond the body of the instrumentation. Several approaches to protecting 
the individual have been used: 
a) Enclosed tablet sample holder, which attaches onto the instrument. 
b) Sample proximity devices limiting the use of the laser. 
c) Specially constructed surround shields. 
This concern produced a delay in ~18 months in accessing and the availability of equipment at 
DMU. 
Similar to other IR absorption techniques, Raman spectroscopy is a form of vibrational 
spectroscopy (Webster and Baldwin, 2005) and is closely related to near- and mid- IR absorption 
spectroscopy (Bugay, 2001).  It has been described as a complementary technique to IR (Pivonka 
et al., 2007; Bumbrah and Sharma, 2016). Whilst some molecular vibrations may be observed in 
both Raman and IR spectra, often vibrations observed using one technique would be extremely 
weak or absent in the other (Webster and Baldwin, 2005). For example, water has strong IR 
absorptions, but is a weak Raman scatterer; therefore, enabling aqueous solutions to be studied 
using Raman, as the signal of the sample is not swamped by that of the solvent (Banwell and 
McCash, 1994).  
When a beam of monochromatic (laser) radiation passes into a sample (Figure 3.5), it will interact 
with the molecules within the sample; the radiation may be reflected, absorbed or scattered 
(Horiba, 2017). The frequency of the scattered radiation will consist of both incident radiation 





Anti-Stokes Raman scattering). Only a small fraction of the scattered light constitutes of Raman 
scattering (~1 x 10-7) (Horiba, 2017).  
 
Figure 3.5: Schematic of a Raman spectrometer (Andor, 2017) 
Rayleigh scattering occurs when there is no change in the frequency of the scattering process. If 
a change in frequency is observed then this process is Raman scattering, this process can 
determine structural and chemical information (Horiba, 2017). Depending on the vibrational state 
of the molecule, Raman shifted protons can be either lower (Stokes) or higher energy (Anti-
Stokes).  
Stokes scattering is the stronger of the two processes and occurs when a photon is scattered at 
lower energy, it is stronger as, principally at room temperature molecules are in their ground 
vibrational state (Horiba, 2017). The weaker Anti-Stokes Raman scattering occurs when the 
scattered photon can be scattered at a higher energy. This happens when a molecule is at a higher 







Figure 3.6: Jablonski Diagram (Horiba, 2017) 
Raman spectroscopy enables the molecular structure of a sample to be characterised, as the 
interaction of the incident photon with the molecule and the energy change of the proton is 
characteristic of the bond (vibration) present. It is important to note that not all vibrations are 
observable with Raman spectroscopy (Horiba, 2017). 
An essential requirement of obtaining a Raman spectrum of a sample is that a change in 
polarisation during molecular vibration must be observed. A typical Raman spectrum plots 
intensity versus wavelength shift and is measured over a range of 4000-100cm-1 (Bumbrah and 
Sharma, 2016). Features in Raman spectrum corresponding to the various vibrational modes of a 
molecule are generally sharp and well resolved for many API’s (Webster and Baldwin, 2005). 
Raman also shares many of the advantages of NIR spectroscopy, in that it is a form of non-
destructive analysis and can analyse both tablets though outer coatings (de Veij et al., 2008) and 
samples through glass (Bugay, 2001). Both techniques have been proposed as a fast-reliable 
analytical method, as there is minimal or no sample preparation. 
Uncertainty about reproducible penetration depth and subsequent emissions for comparable 
samples has led to the need to use Principal Component Analysis (PCA) techniques for 
identification of the major API in tablets by the manufacturers of some handheld instruments. 
The primary advantage of Raman over NIR, is that Raman spectra show highly specific spectral 
fingerprints (Marks and Campbell, 2008) and can be used for polymorph identification (de Veij 
et al., 2008). Figure 3.7 and Figure 3.8 show the differences between the two spectra for both an 





when a sample fluoresces, Raman spectra yield a more detailed fingerprint than that of a NIR 
spectrum.  
 
Figure 3.7: Analysis of TiO2 anatase, a) NIR Spectroscopy; b) Raman Spectroscopy (Shimadzu, 
2016) 
 
Figure 3.8: Analysis of lactose monohydrate, a) NIR Spectroscopy; b) Raman Spectroscopy 
(Shimadzu, 2016) 
A limitation to this technique relates in particular to coloured samples, it has been found that heat 
generated by the focused laser beam can cause decomposition of the sample. Another significant 
limitation is sample fluorescence (Figure 3.6), which results from excitation to a higher electronic 
state and subsequent return to the ground state. Samples of an ‘organic and biological’ nature 
often fluoresce, the amount and type of fluorescence is dependent on the material analysed and 
laser wavelength (Renishaw, 2015). For example, exciting this type of samples with a laser with 
the wavelength of 532nm, could promote fluorescence therefore swamping any underlying 
Raman spectrum and masking the signal (Horiba, 2017). If a laser with a longer wavelength, 
particularly one in the NIR region (785nm), the effect of fluorescence is often reduced, as the 
electronic transition is not promoted, allowing the Raman signal to be easier to detect. However, 
by increasing the wavelength, the scattering efficiency decreases, therefore requiring a higher 
laser power or longer integration times (Horiba, 2017). 
Raman spectroscopy is widely used in the pharmaceutical industry, for monitoring and studying 
API’s, quantitative studies and real-time release testing (Farcaş et al., 2016 and Esmonde-White 







benchtop and handheld instruments, Raman spectroscopy has been used to identify both lifestyle 
(Viagra) (de Veij et al., 2008) and live saving medicines (antimalarials) (Bate and Hess, 2010; 
Kwok and Taylor, 2012 and de Veij et al., 2007)). It has also been used for the authentication of 
counterfeit branded and generic medicines (Assi, 2016 and Kwok and Taylor, 2012) and the in-
situ identification of drugs of abuse in an airport environment (Hargreaves et al., 2008). Due to 
occurrences of falsified and substandard medicines rising significantly, the need for rapid 
identification of these medicines is critical (Dégardin et al., 2017). The quality of medicines 
reaching the patient in some countries can vary enormously, with substandard products changing 
to respond to better detection capabilities (Bate and Hess, 2010). This insidious risk can have an 
impact on the patient, and are likely not to cure the condition and put the individual at risk (Bate 
and Hess, 2010 and Dégardin et al., 2017).   
The advent of the handheld Raman spectrometer, has enabled the lab to be brought to the samples, 
numerous studies have analysed counterfeit medicines using handheld spectrometers. Ricci et al., 
(2008) analysed counterfeit artesunate tablets, they observed the effects of fluorescence when 
using a handheld spectrometer, but used this to their advantage as the API (artesunic acid) 
fluoresced; tablets that did not fluoresce confirmed the absence of the API (Ricci et al., 2008). 
Bate and Hess (2010) compared the handheld Raman spectrometer to the Minilab system that was 
already used in the field. The study analysed antimalarials and found that Raman spectroscopy 
could generate a unique fingerprint signal that reflected the content of the whole sample. Concerns 
over counterfeiters adapting their actions to fool the more basic minilab API assay, whilst failing 
to produce a quality product were discussed (Bate and Hess, 2010). Assi, (2015a) analysed a range 
of antierectile dysfunction samples using a dual wavelength handheld spectrometer to identify the 
presence of various API’s. It was found by using another wavelength (1064nm), the effect of 
fluorescence could be mitigated and Assi was able to identify API’s in the concentration of 5 to 
15% of the tablet (Assi, 2015a). Identification of tablets through packaging has been successfully 
demonstrated (Eliasson and Matousek, 2007) and is becoming commonplace for equipment 
equipped with PCA analysis. Quantitative investigations in this mode can be widely erroneous if 




The Global Pharma Health Fund (GPHF) developed the GPHF-Minilab, as a basic drug testing 





 Physical inspection – enables early rejection of crude counterfeits, 
 Disintegration test – verification of label claims on modified release and enteric-
coated formulations, 
 TLC – to check API content against labelled claims (GPHF, undated). 
The visual inspection of physical attributes of the tablet is performed first in order to reject crude 
falsified samples. The tablet, labelling and packaging are compared with a genuine sample to 
establish if a sample is fake (Sherma, 2007). Samples that pass this test are then investigated by 
ensuring that the samples disintegrate within 30 minutes, unless the sample is modified release or 
enteric-coated. The final test is TLC and the Rf values for the sample are compared to a reference 
(Sherma, 2007). The minilab contains secondary standards for 85 different API’s and has been 
used to identify counterfeit antimalarials, antituberculosis and antiretrovirals (GPHF, undated). 
The minilab has been used in various countries, studies in Malawi by Khuluza et al., (2016) 
analysed the antimalarial sulphadoxine/ pyrimethamine. Out of the 28 samples analysed, 10 
samples were identified as requiring further analysis. Out of these ten samples, one sample was 
identified as being falsified by the minilab which was confirmed by HPLC analysis and a further 
two were identified as substandard by HPLC analysis (Khuluza et al., 2016). It is important to 
note that the Minilab will not identify or quantify other components in the tablet, other than the 
target API (Sherma, 2007). 
 
3.3 Mass	Spectrometry	
Mass spectrometer (MS) instrumentation is changing dramatically with most modern instruments 
being benchtop and there are several examples of portable MS instruments. The large magnetic 
sector analysers have been replaced by small quadrupole based systems, which rely on path 
stability criterion to give mass (m/z) analysis. One of the more significant developments has been 
the change from electron impact (EI) ionisation to the much less energetic proton transfer 
methodologies. Electron impact ionisation is conducted under vacuum conditions inside the MS 
system, whereas proton transfer occurs at atmospheric pressure outside the vacuum system. 
The species detected in each system will therefore be different: electron impact would yield 
molecular and fragment ions, proton transfer would yield ions at m/z value of the molecular 
weight plus a proton, for example (M+H)+. Nonetheless, each technique provides its own 
reproducible fingerprint spectrum of a particular compound. The combination of the stated API 








In the Direct Insertion Probe (DIP) MS system the sample, in a small vial on the end of a probe, 
is introduced directly into the ion source of the MS under vacuum conditions as shown in Figure 
3.9. The sample is rapidly heated under controlled conditions (up to 500⁰C), species released from 
the powder sample are ionised in the electron beam (20 - 70eV), and the ions are directed into the 
MS for analysis. Due to the high ionisation energy, some fragmentation of the molecular ion may 
be observed.  
This technique has been used in a range of applications, such as polymer science (Hacaloglu, 
2012), investigation of low-level pollutants in water (Bauer and Cooks, 1993), for the 
determination of organic compounds in aqueous samples (Bier et al., 1990) and to investigate 
conductive and non-conductive materials. Modern DIP MS technology has yet to be applied to 
the investigation of counterfeit medicines. 
 
 
Figure 3.9: Schematic of a DIP system 
DIP MS is a rapid and cost-effective technique, as it needs little sample preparation and 





2012). Depending on the conditions used, this process can be repeated once every few minutes, 
allowing for a high throughput of samples. 
The use of direct insertion probe MS analysis of API’s in fully formulated tablet forms to identify 
substandard and falsified medicines is novel. 
 
  Atmospheric Solid Analysis Probe (ASAP) Mass Spectrometry (MS) 		 	
The use of the Atmospheric Solid Analysis Probe (ASAP) MS system involves a glass capillary, 
containing the powdered sample, being inserted into a heated stream of nitrogen gas (100-500⁰C), 
which vaporises the sample (Twohig et al., 2010). The vaporised sample is ionised by a corona 
discharge and ions are then focussed directly into the mass spectrometer (Lawson et al., 2016). 
Figure 3.10 shows the schematic of ASAP MS systems. The sample is not introduced into the 
vacuum regions. 
 
Figure 3.10: Schematic of an ASAP system 
The resulting spectra are very simple, as the low energy of the corona discharge (12.6eV) 
produces little fragmentation (Lawson et al., 2016). 
The overall analysis time of the samples is significantly reduced when compared to other MS 





major advantage to this technique is that since the sample preparation requires only crushing and 
the spectra generated are simple, thus limiting the need for specialist operators. 
ASAP MS has been used to identify counterfeit synthetic phosphodiesterase type 5 inhibitors. 
The study by Twohig et al., (2010) effectively used this technique to rapidly detect unknown 
compounds (Twohig et al., 2010). ASAP MS is a rapid technique that can be used to identify 
counterfeit medicines (Twohig et al., 2010). This technique can be used to analyse both volatile 
and semi volatile solid or liquid samples (Twohig et al., 2010). 
Lawson et al., (2016) have also reported the use of ASAP MS to identify falsified and substandard 
products. Their research focused on antimalarials, atenolol, aspirin, caffeine and paracetamol and 
compared ASAP MS to another MS technique. The study found that API’s could be readily 
identified due to the simplicity of the spectra. 
3.4 		Electron	Microscopy	
 Scanning	Electron	Microscopy	(SEM)	
Scanning Electron Microscopy (SEM) has been widely used in both the pharmaceutical and 
forensic industries for the characterisation of API’s, excipients and formulated products (Nichols, 
2012). This technique can be coupled to an Energy Dispersive X-ray Spectroscopy (EDX) 
detector, which enables elemental analysis to be performed. 
The ability to use SEM/EDX to visualise rapidly the spatial distribution of particles in a solid 
dosage form is a desirable as a method to support development and manufacture of medicinal 
products (Nichols, 2012). However, there is a limitation to using EDX mapping, if the elements 
occurring in the sample are lighter than beryllium, then the drug may not be distinguishable from 
the excipients. Lithium used for the treatment of bipolar disorders is an example of this situation. 
When the species being sought contains ‘heavy atoms’, then mapping its distribution can be 
achieved by EDX (Kotula et al., 2003). It is important to note that SEM/EDX is a surface 
technique. 
SEM utilises the analysis of different emissions when a high-energy (1kV – 30kV) beam of 
electrons impacts on the surface of the sample. Figure 3.11 identifies the most frequently studied 
emissions from the surface: 
 Secondary Electron (SE) – information relating to surface structure (topographical) 
 Backscatter (BSE) – information relating to composition and topography 
 X-ray – information relating to elemental analysis 






Figure 3.11: Schematic diagram showing some of the signals that are generated when a primary 
electron beam interacts with a specimen in the Scanning Electron Microscope (Nichols, 2012) 
These methods only provide molecular information, whereas Cathodoluminescence (CL) can 
provide chemical information. This technique has recently been exploited for the analysis of 
organic compounds and pharmaceutical materials (Nichols, 2012). 
CL is most commonly used in geological studies (Götze et al., 2001; Seyedolali et al., 1997) and 
material sciences (Kwon and Boggs, 2002; Rosner and Girolami, 1999). However, it is now being 
applied to pharmaceutical materials (Nichols, 2012). CL is defined as the production of 
electromagnetic radiation (Ultra Violet, Visible and Near Infrared), as a result of an internal 
chemical reaction (Mestre et al., 2001). The emission of light resulting from this reaction is when 
one product returns to its ground state from its excited state (Mestre et al., 2001). Spectral analysis 
of the emitted CL radiation reveals characteristic spectra for pharmaceutical active ingredient 
compounds. Panchromatic CL information can be generated using a VPSE detector with the 
collector bias set to 0.  
SEM has been used extensively for morphological and characterisation studies. Hendrick et al., 
(2010) used SEM to determine if nanoparticles had been incorporated into a matrix and to 
determine if electrospun fabrics had consistent morphology (Hendrick et al., 2010). The technique 
has also been applied to the investigation of the interactions between chitosan and ibuprofen and 
to assess the morphology of the nanocomplex formed (Abioye et al., 2016). SEM/ EDX has been 





products, and focused on confirming the presence of a fumarate salt (Berridge, 1995). Sousa et 
al. (2008) used SEM/ EDX to analyse the formation of an apatite layer of Calcium Phosphate 
with an API (atenolol). Forensically Vogt and Neilly (2010) employed SEM/ EDX to characterise 
two tablet formulations; it was found that one tablet contained particles of stainless steel and the 
other was organic with inorganic formulations. SEM was used to confirm the logo dimensions, 
whilst EDX determined the elemental composition, which was compared to the chemical 
composition identified by FTIR (Vogt and Neilly, 2010). 
There is an absence of published literature for this technique when applied to the detection of SF 
medicines. Microscopy has been applied to the area of counterfeits, in particular Raman and FTIR 
microscopy. Adar et al. (2014) compared both tablet forms and packaging to identify counterfeits 
using Raman microscopy (Adar et al., 2014). A study by Lanzarotta et al. (2011), identified 
counterfeit tablet cores using FTIR microscopy, the study was part of the FDA’s multidisciplinary 
approach, this includes physical, chromatographic and mass spectromic, elemental and molecular 
information being utilised (Lanzarotta et al., 2011). The group considered the effect of excipients 
and the excipient profile on the efficacy of the API. It has been previously found that the presence 
of incorrect excipients and/ or the absence of correct excipients can create issues with the API. 
This can ultimately result in the potential for more frequent adverse patient reactions; this is 
mainly due to higher impurity levels and faster API degradation (Lanzorotta et al., 2011). 
Whilst vibrational spectroscopy continues to expand for the investigation of counterfeits 
(Lanzarotta et al., 2011), very few studies have investigated the elemental composition. There is 
also an absence of studies investigating molecular information, using CL to analyse 
pharmaceutical materials (Nichols, 2012).  
This current research focuses on the EDX mapping and quantification of cross-sectioned tablets 
and investigates its potential for the detection of SF medicines and looks at deconstructing the 
formulation of the tablet. 
 
3.5 Comparison	of	Techniques	
The application of the identification of falsified and substandard medicines applicable to LMIC 
requires consideration of more than just the capabilities of the instruments. Limited infrastructure 
in rural areas or portability requirements may define which instruments are suitable. Cost of the 






Whilst all the instruments discussed here can be applied in a ‘portable’ format, it is probably 
correct to say that only Raman systems can be described as giving handheld analyses. 
Table 3.2 compares some of the parameters of the techniques used in this work. 
 
 General	reliability	of	methods	
The general reliability of the analytical techniques used in this research are discussed below, the 
robustness of these methods will be discussed in section 7.5. 
 UV	Spectroscopy	
Non-specific quantification technique, which when used in conjunction with other separating 
techniques has been demonstrated to produce validated quantification data for API’s, as evidenced 
by the British Pharmacopeia (British Pharmacopeia 2017b). 
 Infrared	Spectroscopy	
Specificity with respect to the identification of individual compounds, which is comparable to a 
fingerprint and is another basic tool cited by the British Pharmacopeia. 
 Raman	Spectroscopy	
Like Infrared, Raman demonstrates specificity with respect to the identification of individual 
formulations, which is comparable to a fingerprint for a tablet formulation. 
 ASAP	Mass	Spectrometry	
Atmospheric ionisation that produces ions of a charge to mass ratio (m/z) values characteristic of 
the target API. 
 DIP	Mass	Spectrometry	
Conventional Mass Spectrometry produces fragmentation of the target molecule, which is 
accepted globally as an identification method via the National Institute of Standards and 
Technology (NIST) database. 
 EDX	Spectroscopy	
When a high-energy electron beam interacts with the surface of a sample excess energy is released 
in the form of electromagnetic radiation, in this case X-rays. The energy of radiation (X-rays) 




Table 3.2: Comparison of various analytical techniques 
 
Technique Sample Technique Sampling Depth Limit of Detection Analysis Time Sampling Probe/ 
eV 
UV Identification      UV/  
2 - 5 Quantification Extract API Fixed 
Wavelength 
Bulk <0.1% of tablet weight >30 minutes 
ATR 
FTIR 
Identification Tablet/ Powder Fingerprint Surface  ~2 minutes IR/  
0.1 – 0.8 Quantification Powder Peak Area Surface 5% of tablet weight < 5 minutes 
Raman Identification Tablet/ Powder Fingerprint Sample dependent  ~2 minutes Laser/ 
1.9 or 1.6 Quantification Powder Peak Area Sample dependent 3% of tablet weight < 5 minutes 
DIP MS Identification Powder m/z value Bulk  10 – 15 minutes Volatilisation and 
Electron Beam/ 
20 – 70  
Quantification Powder m/z value Bulk 1% of tablet weight 10 – 15 minutes 
ASAP MS Identification Powder m/z value Bulk  ~ 5 minutes Volatilisation and 
Proton Transfer/ 
<16  
Quantification Powder m/z value Bulk 1% of tablet weight ~ 5 minutes 
SEM/EDX Identification Tablet/ Powder  Surface  ~15 minutes Electron Beam/ 








This chapter presents details of the instruments and methods used to identify potential rapid 
screening methodologies to identify SF medicines. 
The instrumental methods used in this study to identify the API were: 
 ATR FTIR Spectroscopy,  
 Raman Spectroscopy,  
 Direct insertion probe (DIP) Mass Spectrometry 
 Atmospheric sampling probe (ASAP) Mass Spectrometry.  
The instrumental methods used in this study to quantify the levels of the API were: 
 UV Spectroscopy, 
  ATR FTIR Spectroscopy,  
 EDX Spectroscopy  
Chapter 5 discusses the results obtained from the experimental work for the identification of the 
API in both a whole and crushed tablet sample. 
 
4.1 Instrumentation	
The instruments used for this research are detailed below: 
 UV Spectroscopy  
o A Helios Gamma UV-Vis spectrometer (Thermo Electron Corporation, UK), 
was used to measure the absorbance of the samples at a fixed wavelength 
measurement at 275nm (atenolol) and 232nm (metformin hydrochloride). 
 ATR FTIR Spectroscopy  
o An Alpha with ATR accessory FTIR spectrometer, (Bruker, Coventry, UK), was 
used to acquire data at a spectral resolution of 2cm-1 over a scan range of 
4000cm-1 to 400cm-1. Spectral data was acquired with OPUS software, version 
7.5 (Bruker, Coventry, UK).  
 Raman Spectroscopy 
o A Bravo handheld Raman spectrometer, (Bruker, Coventry, UK) fitted with a 
bag tip holder was used to acquire data at a spectral resolution of 12cm-1 over a 
scan range of 3200cm-1 to 300cm-1, using laser excitation of 785nm and 1084nm. 






o A MIRA-3 handheld Raman spectrometer, (Metrohm, Runcorn, UK) fitted with 
a curvette sample holder was used to acquire data at a spectral resolution of 14 - 
16cm-1 over a scan range of 2300cm-1 to 400cm-1, using laser excitation of 
785nm. Spectral data was acquired with MiraCal, version 3.0.1 software 
(Metrohm, Runcorn, UK).  
o A FORAM-2 benchtop Raman spectrometer, (Foster and Freeman, Evesham, 
UK) was used to acquire data at a spectral resolution of 6cm-1 over a scan range 
of 3200cm-1 to 200cm-1, using laser excitation of 785nm. Spectral data was 
acquired with FORAM 3 software (Metrohm, Runcorn, UK).  
 DIP Mass Spectrometry 
o A 300 single quadrupole mass spectrometer, (Bruker, Coventry, UK) equipped 
with a Direct Insertion Probe (DIP) was used to acquire data at a resolution of 
0.5m/z over a scan range of m/z 100 to m/z 300 (atenolol) and m/z 300 to m/z 
550 (antimalarials). Spectral data was acquired with Workstation software, 
version 7 (Bruker, Coventry, UK).  
 ASAP Mass Spectrometry 
o An Advion expression compact mass spectrometer (CMS), (Advion Ltd, UK) 
equipped with an Atmospheric Solids Analysis Probe (ASAP) was used to 
acquire data at a resolution of 0.5m/z over a scan range of m/z 100 to m/z 550. 
Spectral data was acquired with Advion integrated software.  
 SEM/EDX Electron Microscopy 
o An EVO LS 15 Scanning Electron Microscope (Carl Zeiss Ltd, Cambridge, UK) 
was used as a source of primary electrons for Secondary Electron (SE), 
Backscatter (BSE) and EDX Spectroscopy. Images were acquired using Smart 
SEM version 5.7 software (Carl Zeiss Ltd, Cambridge, UK). An Oxford Xmax 
80 mm2 EDX detector (Oxford Instruments, High Wycombe, UK) was used for 
elemental analysis. Elemental data was processed using INCA software (Oxford 




Excipient samples were selected upon the most commonly used excipients in the manufacture of 
tablets, as detailed in Chapter 2.2. The excipients were purchased from a variety of suppliers and 





a) the conventional analytically pure materials, b) formulated tablets as supplied to healthcare 
providers. The reference standards purchased for this study are detailed in Table 4.2. The solvents 
used for UV analysis are listed in Table 4.3. 
Table 4.1: Manufacturer and batch numbers of excipients used 
Excipient Manufacturer Batch Number 
Calcium carbonate Acros Organics 
(Loughborough, UK) 
A0327003 
Calcium phosphate Pfizer (UK) 98EXC03 
Carnauba wax Baer Locher (France) 185598 
Citric acid JM Loveridge (Southampton, 
UK) 
K645 
Croscarmellose sodium Sigma Aldrich (Gillingham, 
UK) 
015K0176 
Colloidal silicon dioxide Evonik (Manchester, UK) 155070314 
HPMC Colorcon (Kent, UK) P180F44003 
Iron Oxide Acros Organics 
(Loughborough, UK) 
 
Lactose monohydrate Blackburn Distribution 
(Nelson, UK) 
15058 
Lactose anhydrous Fluka (Gillingham, UK) BCBM7015V 
Lactose (Tablettose) Meggle (Germany) 0248 
Magnesium stearate JM Brown (UK) 231106 
MCC (Avicel PH101) Fluka (Gillingham, UK) BCBN7864V 
PEG Fisher Scientific 
(Loughborough, UK) 
0304382 
Povidone Acros Organics 
(Loughborough, UK) 
A0336639 
SLS Fisher Scientific 
(Loughborough, UK) 
1484584 
Sodium starch glycolate JRS Pharma LP (USA) E0173 
Starch – maize Fisher Scientific 
(Loughborough, UK) 
 
Starch - potato  JM Loveridge (Southampton, 
UK) 
K714 
Stearic acid Acros Organics 
(Loughborough, UK) 
A0327293 
Talc VWR International 
(Lutterworth, UK) 
160180006 
Tartaric acid Sigma Aldrich (Gillingham, 
UK) 
STBC1798V 








Table 4.2: Manufacturer and batch numbers of analytical reference APIs used 
API Manufacturer Batch Number 
Atenolol Sigma Aldrich (Gillingham, 
UK) 
BCBL0559V 
Metformin hydrochloride Sigma Aldrich (Gillingham, 
UK) 
LRAA8975 
Chloroquine diphosphate salt Sigma Aldrich (Gillingham, 
UK) 
BCBM9716V 
Quinine 99% anhydrous Acros Organics 
(Loughborough, UK) 
A0316466 
Quinine monohydrochloride Sigma Aldrich (Gillingham, 
UK) 
STBD7305W 
Quinine sulphate Fissons (UK) 39673025 
 
Table 4.3: Manufacturer and batch numbers of solvents used 
Solvent Manufacturer Batch Number 
Methanol (HPLC grade) VWR International 
(Lutterworth, UK) 
161284013 
Water (HPLC grade) Fisher Scientific 
(Loughborough, UK) 
1367414 





Patients can source medicines by various methods. Traditionally, patients in the UK would 
purchase medicines over the counter (OTC) directly from a pharmacy/ supermarket, or if they 
required a prescription only medicine (POM), this would be prescribed by a doctor and dispensed 
by a pharmacist. However, with the advent of the internet, medicines can be directly purchased 
online. In other countries both POM and OTC medicines, can be purchased from pharmacies, the 
internet and from ‘non-pharmacy’ vendors, as is the case in Kenya and most LIC. Medicines can 
also be purchased without a prescription for POM’s in other countries, as a personal supply to an 
individual. The atenolol, metformin hydrochloride and antimalarial tablets studied in this research 
were supplied by individuals who obtained the medicine as a personal supply from pharmacies. 
An antimalarial sample was obtained from an unlicensed vendor ‘tuck shop’. The UK tablets were 
supplied by a pharmacy for research purposes.  
The atenolol tablets that were investigated were obtained from five countries; these were the UK, 
India, Pakistan, Saudi Arabia, and Nepal. The tablets analysed are summarised in Table 4.4 and 





The metformin hydrochloride tablets that were investigated were obtained from three countries; 
these were the UK, India and Saudi Arabia. The tablets analysed are summarised in Table 4.5 and 
have been anonymised. 
The antimalarial tablets that were investigated were obtained from five countries; these were the 
UK, Ghana, Zimbabwe, Nigeria and Nepal. The tablets analysed and their API’s are summarised 
























Table 4.4: Atenolol tablet samples analysed 






At/UK/1 25mg UK 28 Leicester 
At/UK/2 50mg UK 28 Leicester 
At/UK/3 100mg UK 28 Leicester 
At/UK/4 25mg UK 28 Leicester 
At/UK/5 50mg UK 28 Leicester 
At/UK/6 100mg UK 28 Leicester 
At/UK/7 50mg UK 28 Leicester 
At/IND/1 25mg India 14 Gauribidnur 
At/IND/2 25mg India 14 Gauribidnur 
At/IND/3 25mg India 2 Mumbai 
At/IND/4 25mg India 2 Mumbai 
At/IND/5 50mg India 14 Darjeeling 
At/IND/6 50mg India 14 Darjeeling 
At/IND/7 50mg India 14 Gauribidnur 
At/IND/8 50mg India 14 Pondicherry 
At/IND/9 50mg India 14 Gauribidnur 
At/IND/10 50mg India 14 Gauribidnur 
At/IND/11 25mg India 14 Gauribidnur 
At/IND/12 50mg India 14 Pondicherry 
At/IND/13 50mg India 14 Gauribidnur 
At/IND/14 50mg India 14 Darjeeling 
At/IND/15 50mg India 14 Gauribidnur 
At/IND/16 50mg India 14 Pondicherry 
At/IND/17 25mg India 2 Goa 
At/IND/18 50mg India 14 Pondicherry 
At/PAK/1 50mg Pakistan 20 Lahore 
At/PAK/2 100mg Pakistan 20 Lahore 
At/SA/1 50mg Saudi Arabia 28 Mecca 
At/SA/2 50mg Saudi Arabia 28 Mecca 
At/SA/3 100mg Saudi Arabia 14 Medina 
At/SA/4 100mg Saudi Arabia 14 Medina 
At/SA/5 100mg Saudi Arabia 14 Medina 
At/NEP/1 50mg Nepal 14 Pokhara 
At/NEP/2 50mg Nepal 14 Pokhara 









Table 4.5: Metformin Hydrochloride tablet samples analysed 








Met/UK/1 500mg  UK 56 Leicester 
Met/UK/2 850mg  UK 56 Leicester 
Met/IND/1 250mg  India 10 Gauribidnur 
Met/IND/2 500mg  India 10 Gauribidnur 
Met/IND/3 850mg  India 10 Gauribidnur 
Met/IND/4 * 500mg  India 20 Gauribidnur 
Met/IND/5 * 850mg  India 10 Gauribidnur 
Met/IND/6 * 500mg Yes India 15 Gauribidnur 
Met/IND/7 500mg Yes India 10 Gauribidnur 
Met/IND/8 500mg Yes India 10 Gauribidnur 
Met/IND/9 500mg  India 10 Gauribidnur 
Met/IND/10 * 500mg  India 15 Gauribidnur 
Met/IND/11 400mg Yes India 10 Gauribidnur 
Met/IND/12 400mg Yes India 10 Gauribidnur 
Met/IND/13 500mg Yes India 10 Gauribidnur 
Met/IND/14 500mg Yes India 10 Gauribidnur 
Met/IND/15 * 1000mg  India 10 Gauribidnur 
Met/IND/16 500mg  India 20 Gauribidnur 
Met/SA/1 500mg  Saudi Arabia 50 Medina 
* Sustained Release Formulations 
 
Table 4.6: Antimalarial tablet samples analysed 
Name of 
Tablet 





AM/UK/1 250mg Chloroquine Phosphate UK 20 
AM/GHA/1 500mg/25mg Sulphadoxine + 
Pyrimethamine 
Ghana 6 
AM/NEP/1 250mg Chloroquine Phosphate Nepal 30 
AM/NIG/1 80mg/480mg Artemether + Lumefantrine Nigeria 6 
AM/NIG/2 80mg/480mg Artemether + Lumefantrine Nigeria 6 
AM/NIG/3 400mg Chloroquine Sulphate Nigeria 5 
AM/ZIM/1 20mg/120mg Artemether + Lumefantrine Zimbabwe 12 
AM/ZIM/2 20mg/480mg Artemether + Lumefantrine Zimbabwe 12 
AM/ZIM/3 500mg/25mg Sulphadoxine + 
Pyrimethamine 
Zimbabwe 5 






This section details the preparation of calibration mixtures of API’s and selected excipients in dry 
form for the qualitative and quantitative analysis of tablet samples. Details of the techniques 




Calibration standard mixtures of atenolol and microcrystalline cellulose (MCC) were prepared as 
shown in Table 4.7. Calibration standard mixtures of metformin hydrochloride and maize starch 
were prepared as shown in Table 4.8. The calibration standards were mixed and ground for 2 
minutes using an agate pestle and mortar.  The differences in calibration standards for the two 
API’s are due to the amount of API in the tablet; atenolol tablets typically contain ~25% API w/w 
and metformin hydrochloride 70-90% API w/w. 





Weight of Atenolol 
(mg) 
Weight of MCC 
(mg) 
0 0 0 100 
5 4.9 4.9 94.5 
10 9.4 9.5 91.2 
20 20.4 20.8 81.3 
25 24.7 24.9 76.1 
30 30.2 30.7 70.9 
40 41.1 42.0 60.3 
50 49.9 50.8 51.1 
60 60.4 60.2 39.5 
75 73.6 75.5 27.1 




















Weight of Maize 
Starch (mg) 
0 0 0 100 
10 7.7 7.3 87.7 
20 18.4 18.4 81.4 
30 31.8 33.2 71.1 
40 39.4 59.9 39.1 
50 49.8 50.3 49.9 
60 59.2 59.7 41.2 
70 69.4 70.2 31.0 
80 78.8 79.7 21.5 
90 88.5 89.8 11.7 
100 100 100 0 
 
 Raman	Spectroscopy	
For the purpose of Raman spectroscopy, a different set of calibration standard mixtures were 
analysed, this was due to the effect of fluorescence with the excipient MCC. Calibration standard 
mixtures of atenolol and lactose were prepared as shown in Table 4.9. Calibration standard 
mixtures of paracetamol and maize starch were prepared as shown in Table 4.10. The calibration 

















Weight of Atenolol 
(mg) 
Weight of Lactose 
(mg) 
0 0 0 100 
10 9.9 9.7 88.3 
20 19.2 18.8 79.8 
30 30.5 31.2 71.0 
40 40.7 41.0 60.2 
50 49.3 49.3 50.7 
60 59.8 59.7 40.1 
70 70.4 70.2 29.5 
80 78.8 80.8 21.7 
90 90.7 85.4 8.8 
100 100 100 0 
 










Weight of Maize 
Starch (mg) 
0 0 0 100 
10 11.1 10.9 87.6 
20 20.3 20.5 80.6 
30 30.4 30.5 69.9 
40 39.4 40.8 62.7 
50 50.9 52.1 50.3 
60 61.3 63.2 39.9 
70 70.1 70.1 29.9 
80 79.4 80.1 20.8 
90 86.8 90.4 13.8 







The sample preparation for the UV determination of atenolol in tablet dosage forms was adapted 
and modified from the British Pharmacopoeia 2017 assay method for atenolol tablets (British 
Pharmacopeia 2017b). A single tablet was crushed using an agate pestle and mortar and the 
powder transferred to a 50ml volumetric flask using 30ml of HPLC grade methanol. The resulting 
suspension was heated to 60ºC and shaken for 15 minutes in a shaking water bath. The solutions 
were then cooled and diluted to volume (50ml) with HPLC grade methanol; this was then filtered 
using Whatman GF/C glass microfibre filter paper. A suitable volume of filtrate was then diluted 
with methanol to produce a solution containing 0.01% w/v of atenolol. The absorbance of the 
resulting solution was measured. 
 
 Metformin	Hydrochloride	
The sample preparation for the UV determination of metformin hydrochloride in tablet dosage 
forms was adapted and modified from the British Pharmacopoeia 2017 assay method for 
metformin hydrochloride tablets (British Pharmacopeia 2017c). Samples were weighed and 
crushed using an agate pestle and mortar. A quantity of powder containing 0.1g of metformin 
hydrochloride was shaken with 70ml of HPLC grade water for 15 minutes. The solutions were 
then diluted to volume (100ml) with HPLC grade water; this was then filtered using Whatman 
Grade 1 cellulose filter paper. The first 20mls of filtrate was discarded; 10ml of the subsequent 
filtrate was then diluted to 100ml with HPLC grade water. A further dilution of the resulting 
solution (10ml) to 100ml with HPLC grade water was performed. The absorbance of the resulting 
solution was measured. 
 
 ATR	FTIR	Specimen	Preparation	and	Analysis	
Both the tablet and excipient samples for ATR FTIR Spectroscopy were crushed and ground into 
a fine powder for a minimum of two minutes using an agate pestle and mortar and directly 
analysed using ATR FTIR. 
The reference and tablet samples were analysed using the ATR accessory with a background 
correction. Samples were analysed in absorbance mode, measurements were taken on a small 
amount of sample deposited on the crystal. Each sample was analysed 5 times, with identical 





was analysed the crystal was cleaned with isopropanol and allowed to dry in ambient air. A 
background of 30 scans was performed after each sample group had been analysed.  
Each spectrum was baseline corrected before processing for quantification. 
 Reproducibility	of	Data	
To ensure the reproducibility of the data, five replicates of each sample were analysed. Figure 4.1 
shows the reproducibility for an analytical standard (atenolol). The spectra are in good agreement 
with one another. To prevent repetition in the thesis, spectra shown in Chapter 5 and 6 will only 
show a single spectrum for each sample rather than the five replicates. 
 
Figure 4.1: ATR FTIR Spectra of atenolol analytical reference, 1 (Blue), 2 (Red), 3 (Green), 4 
(Purple) and 5 (Cyan) 
 
 Analysis	of	calibration	mixtures	
In order to generate a calibration plot for the calibration standard data, four peak areas 
characteristic to atenolol were integrated using the OPUS software. These were:  Area 1) 3009 – 






Figure 4.2: ATR FTIR spectrum of atenolol with integration areas highlighted 
The areas used for metformin hydrochloride were:  Area 1) 1678 – 1605cm-1, 2) 1605 – 1501cm-
1, 3) 1501 – 1432cm-1 and 4) 1432 – 1341cm-1 (Figure 4.3). 
 
Figure 4.3: ATR FTIR spectrum of metformin hydrochloride with integration areas highlighted 
The peak areas were integrated using three different methods (Figure 4.4): 
 Method A – The area between the band, abscissa and the frequency limits defined is 
integrated, 
 Method B – The area above the line drawn between the peaks of the two defined 
frequency limits is integrated, 






Figure 4.4: Different Integration Methods, a) Method A, b) Method B and c) Method K 
Calibration plots were plotted in Microsoft Excel using the mean integrated peak areas, for all 
four areas and integration methods.  
 Raman	Sample	Preparation	and	Analysis	
Samples for Raman spectroscopy can be either the whole tablet or a finely ground powder. For 
the purpose of this study, both types of sample preparation were analysed. For tablets that were 
either film coated or had a coloured coating, the effects of the tablet coating on the spectra were 
studied by comparing a surface spectrum with that from a crushed sample. To obtain the latter the 
coating was removed and the remaining tablet crushed and ground into a fine powder using an 
agate pestle and mortar and directly analysed. For some samples the coating was also crushed into 
the main body of the sample and the total powder analysed. 
 
 	Handheld	Raman	Spectrometers	
Two different handheld spectrometers were used for this research; these were a Bruker BRAVO 
and Metrohm MIRA-3 spectrometers. 
A BRAVO Raman spectrometer was used to analyse the atenolol samples. The samples were 
analysed in absorbance mode, measurements were taken on either a whole or a crushed tablet 
deposited over the bag tip.  
A MIRA-3 Raman spectrometer was used to analyse the atenolol and metformin hydrochloride 
samples. Measurements were taken on a crushed tablet placed in a glass curvette using the 







A FORAM 2 Raman spectrometer was used to analyse the atenolol, metformin hydrochloride and 
antimalarial samples. Measurements were taken on whole tablets placed under the objective lens 
and focused using the XYZ translation stage. The results were compared with powdered samples 
analysed by the FORAM-2. 
 Reproducibility	of	Data	
To ensure the reproducibility of the data, five replicates of each sample were analysed. To prevent 
repetition in the thesis, spectra shown in Chapter 5 will only show a single spectrum for each 
sample rather than the five replicates. 
 
 	DIP	Sample	Preparation	and	Analysis	
The tablet samples analysed by DIP needed to be a fine powder. Samples were crushed into a fine 
powder using an agate pestle and mortar. A small amount of sample was then transferred to a 
flared vial (Bruker, Coventry, UK) using a Platinum wire adhered to a glass capillary tube. 
 
An empty flared sample vial was inserted into the heated tip of the probe and inserted into the MS 
through the vacuum interlock and ran as a blank three times. The sample was then transferred to 
the blank flared sample vial using a platinum wire adhered to a glass capillary tube and analysed.  
The atenolol samples were heated over a temperature range of 30ºC to 250ºC, with a 30ºC a 
minute ramp. The source temperature was set at 300ºC; with the ionising electron energy set at 
70eV and the run time was set to 10 minutes. The antimalarial samples were heated over a 
temperature range of 40ºC to 350ºC, with a 30ºC a minute ramp. The source temperature was set 
at 250ºC; with the ionising electron energy set at 70eV and the run time was set to 10.3 minutes. 
These were collated to produce the thermal ionic fingerprint of the analytes. 
 Reproducibility	of	Data	
To ensure the reproducibility of the data, three replicates of each sample were analysed. To 
prevent repetition in the thesis, spectra shown in Chapter 5 will only show a single spectrum for 







The tablet samples analysed by ASAP needed to be a fine powder. Samples were crushed into a 
fine powder using an agate pestle and mortar. A small amount of sample was then transferred to 
the closed end of a melting point tube. Excess powder was removed before the probe was inserted 
 directly into the ionisation region and the flow of heated nitrogen (300ºC) volatises the API/’s. 
Ionisation occurs by protonation in the cornea discharge field. Ions are focussed into the Advion 
Compact MS for analysis. 
 
 SEM/EDX	Specimen	Preparation	and	Analysis	
Materials selected for SEM/ EDX must be compatible (non-volatile) with the vacuum in the SEM 
specimen chamber and stable when irradiated with a beam of high energy electrons (Nichols, 
2012).  
Cross-sections of the tablets were prepared by cutting the tablets with a tablet cutter (Safe and 
Sound Health, Hampshire, UK). The cross-sections were then mounted onto 12.5 mm aluminium 
stubs (Agar Scientific, Stansted, UK), using Leit-C carbon cement (Agar Scientific, Stansted, 
UK). The samples were then sputtered coated with 15nm of gold using a Q150RS sputter coater 
(Quorum Technologies, Sussex, UK); this was to make the samples conductive. 
The samples were analysed under high vacuum, as the samples were gold coated and therefore 
conductive. The samples were analysed with a beam accelerating voltage of 20kV, 20µm beam 
aperture, a probe current of 100pA and a working distance of 8.5mm. It has been observed by 
some research groups and from experience that images for samples analysed under high vacuum 
are of a better quality and higher resolution than of those analysed under variable pressure 
(Nichols, 2012 and Stokes 2008). Images were recorded using both a SE and BSE detectors, SE 
images are more three-dimensional and give topographical information, whilst BSE images can 
appear flatter due to the mounting of the detector, but will give compositional information. 
For EDX the same conditions were used, with the exception of the probe current, which was set 
at 1000pA; this was to facilitate the optimum collection of X-rays. When analysing non-
conductive samples by EDX, it is known that carbon coating is better than gold, this is due to the 
gold peaks interfering with some elements. For the purpose of this research, it was decided that 
as most tablets are organic the carbon peaks would be of interest and that the gold peaks did not 
interfere with any of the elements being analysed. Elemental data was acquired using INCA 
software (Oxford Instruments, High Wycombe, UK); mapping and quantitative data were 





This chapter is devoted to the identifying the API’s based on results obtained from the 
experimental work detailed in the previous chapter. Results are presented according to 
identification of an API in a whole tablet and a crushed tablet sample. Within these two sections, 
results are grouped together by technique. 
It has been stated by previous studies, in particular by Bugay and Brush (2010), that in the 
development of a chemical identification assay, obtaining a pure reference spectrum under the 
same conditions is the most important step (Bugay and Brush, 2010). Without an authentic 
reference spectrum, the validity of the chemical identification assay is susceptible (Bugay and 
Brush, 2010). For applications such as the study of substandard and falsified medicines ‘in the 
field’, the appropriate reference material is in fact the formulated tablet. Furthermore, these 




Reference spectra was obtained for the most common tablet excipients as discussed in Chapter 2 
and for analytical grade atenolol, metformin hydrochloride, chloroquine phosphate and quinine 
sulphate references using ATR FTIR and Raman spectroscopy. The reference material for both 
API and excipients was crushed and ground into a fine powder. 
 
 ATR	FTIR	Spectroscopy	
Figure 5.1 shows the ATR FTIR spectra for common excipients in atenolol tablets, Figure 5.2 
shows the ATR FTIR spectra for common excipients in metformin hydrochloride tablets and 






Figure 5.1: ATR FTIR spectra for common excipients in atenolol tablets, A) calcium carbonate, B) dicalcium phosphate, C) lactose monohydrate, D) 






Figure 5.2: ATR FTIR spectra for common excipients in metformin hydrochloride tablets, A) hypromellose, B) magnesium stearate, C) maize starch, D) 






Figure 5.3: ATR FTIR spectra for common excipients in antimalarial tablets, A) croscarmellose sodium, B) hypromellose, C) lactose monohydrate, D) 






Figure 5.4: ATR FTIR spectrum of atenolol (analytical standard) 
The ATR FTIR spectrum for the atenolol analytical standard (Figure 5.4) exhibited characteristic 
peaks for atenolol at 3159 – 3347cm-1 (hydroxyl and amine) (El-Leithy et al., 2012), 2866 – 
2966cm-1 (CH, aliphatic) (El-Leithy et al., 2012), 1633cm-1 (C=O carbonyl) (Jalindar et al., 2001), 
1514cm-1 (aromatic ring) and 1412cm-1 (nitro compound) (Edukondalu et al., 2011). 
 
Figure 5.5: ATR FTIR spectrum of metformin hydrochloride (analytical standard) 
The ATR FTIR spectrum for the metformin hydrochloride analytical reference standard (Figure 
5.5) exhibited characteristic peaks for metformin hydrochloride at 3148 – 3368cm-1 (Primary 
Amine) (Roselet and Premakumari, 2015), 1417 – 1622cm-1 (NH) (Roselet and Premakumari, 
2015 and Sheela et al., 2010) 1062 – 1166cm-1 (CN Amine) (Sheela et al., 2010) and 420 – 582cm-





Using the excipient spectra and comparing it to the analytical grade atenolol standard spectrum, 
we can summarise which excipients mask characteristic atenolol peaks. This is summarised in 
Table 5.1. 
Table 5.1: Summary of excipients and their differentiation with characteristic atenolol peaks 
 Atenolol Reference Peaks (cm-1) 
Excipient 3347 3159 2966 2923 1633 1515 1412 1235 
Calcium carbonate         
Calcium phosphate         
Carnauba wax         
Citric acid         
Croscarmellose sodium         
Colloidal silicon dioxide         
HPMC         
Iron Oxide         
Lactose *         
Magnesium stearate         
MCC         
PEG         
Povidone         
SLS         
Sodium starch glycolate         
Starch #         
Stearic acid         
Talc         
Tartaric acid         
Titanium dioxide         
 
 - Atenolol peaks can be observed fully/partially  - Atenolol peaks inhibited 
* Lactose including lactose monohydrate 80M, Grannulac 200, lactose EP granular, Refined 
lactose and Tablettose. 
# Starch including corn, maize and potato. 
 
Using the excipient spectra and comparing it to the analytical grade metformin hydrochloride 
standard spectrum, we can summarise which excipients mask characteristic metformin 






Table 5.2: Summary of excipients and their differentiation with characteristic metformin 
hydrochloride peaks 
 Metformin hydrochloride Reference Peaks (cm-1) 
Excipient 3368 3148 1623 1418 1166 1063 937 583 420 
Calcium carbonate          
Calcium phosphate          
Carnauba wax          
Citric acid          
Croscarmellose sodium          
Colloidal silicon dioxide          
HPMC          
Iron Oxide          
Lactose *          
Magnesium stearate          
MCC          
PEG          
Povidone          
SLS          
Sodium starch glycolate          
Starch #          
Stearic acid          
Talc          
Tartaric acid          
Titanium dioxide          
 
 - Metformin hydrochloride peaks can be observed fully/partially  
 - Metformin hydrochloride peaks inhibited 
* Lactose including lactose monohydrate 80M, Grannulac 200, lactose EP granular, Refined 
lactose and Tablettose. 







Figure 5.6: ATR FTIR spectrum of chloroquine phosphate (analytical standard) 
The ATR FTIR spectrum for the chloroquine phosphate analytical standard (Figure 5.6) exhibited 
characteristic peaks for chloroquine phosphate at 2971cm-1, 1612cm-1, 1459cm-1 and 1212cm-1 
(Kozicki et al., 2015). 
 
Figure 5.7: ATR FTIR spectrum of quinine sulphate (analytical standard) 
The ATR FTIR spectrum for the quinine sulphate analytical standard (Figure 5.7) exhibited 
characteristic peaks for quinine sulphate at 3191cm-1, 1619cm-1, 1509cm-1, 1243cm-1 and 1026cm-





Using the excipient spectra and comparing it to the analytical grade chloroquine phosphate 
standard spectrum, we can summarise which excipients mask characteristic chloroquine 
phosphate peaks. This is summarised in Table 5.3. 
Table 5.3: Summary of excipients and their differentiation with characteristic chloroquine 
phosphate peaks 
 Chloroquine Phosphate Reference Peaks (cm-1) 
Excipient 2971 1612 1459 1212 
Calcium carbonate     
Calcium phosphate     
Carnauba wax     
Citric acid     
Croscarmellose sodium     
Colloidal silicon dioxide     
HPMC     
Iron Oxide     
Lactose *     
Magnesium stearate     
MCC     
PEG     
Povidone     
SLS     
Sodium starch glycolate     
Starch #     
Stearic acid     
Talc     
Tartaric acid     
Titanium dioxide     
 
 - Chloroquine phosphate peaks can be observed fully/ partially 
 - Chloroquine phosphate peaks masked 
* Lactose including lactose monohydrate 80M, Grannulac 200, lactose EP granular, Refined 
lactose and Tablettose. 







Using the excipient spectra and comparing it to the analytical grade quinine sulphate standard 
spectrum, we can summarise which excipients mask characteristic quinine sulphate peaks. This 
is summarised in Table 5.4. 
Table 5.4: Summary of excipients and their differentiation with characteristic quinine sulphate 
peaks 
 Quinine Sulphate Reference Peaks (cm-1) 
Excipient 3191 1619 1509 1243 1026 
Calcium carbonate      
Calcium phosphate      
Carnauba wax      
Citric acid      
Croscarmellose sodium      
Colloidal silicon dioxide      
HPMC      
Iron Oxide      
Lactose *      
Magnesium stearate      
MCC      
PEG      
Povidone      
SLS      
Sodium starch glycolate      
Starch #      
Stearic acid      
Talc      
Tartaric acid      
Titanium dioxide      
 - Quinine sulphate peaks can be observed fully/partially 
 - Quinine sulphate peaks inhibited 
* Lactose including lactose monohydrate 80M, Grannulac 200, lactose EP granular, Refined 
lactose and Tablettose. # Starch including corn, maize and potato. 
 
 Raman	Spectroscopy	
Raman spectra were obtained for tablet excipients and for analytical grade atenolol, metformin 
hydrochloride, chloroquine phosphate and quinine sulphate references.  Figure 5.8 shows the 
Raman spectra for common excipients tablets. The reference material for both API and excipients 






Figure 5.8: Raman spectra for common excipients, A) calcium carbonate, B) croscarmellose sodium, C) dicalcium phosphate, D) lactose monohydrate, 








Figure 5.9: Raman spectra of atenolol (analytical standard) using BRAVO handheld spectrometer 
(Red), FORAM-2 spectrometer (Blue) and MIRA handheld spectrometer (Green) 
The Raman spectrum for the atenolol analytical standard (Figure 5.9) exhibited characteristic 
peaks for atenolol at 368cm-1, 637cm-1, 828cm-1, 1187cm-1, 1209cm-1, 1301cm-1, 1423cm-1, 
1451cm-1, 1615cm-1,1680cm-1 (Farças et al., 2016), 2916cm-1 and 3072cm-1 (Cozar et al., 2010). 
Variation within the spectra can be observed for the different spectrometers, with the FORAM-2 
spectrum displaying additional peaks. Table 5.5 summarises the peaks attributed to atenolol for 


































Table 5.5: Characteristic Raman peaks of atenolol and their assignments 
Peak Position (cm-1)  











368 368   366 368 NH rocking 
638 638 638  636 637 In plane ring 
deformation 
723 722 725   732  
828 828 
 
829 828 825 828 Out of plane 
bending (CH) + ring 
861 863 861   859 Ring breathing 
1142 1144 1141  1140 1143 In plane bending 
chain + ring 
1185 1188 1185 1198  1183 Chain stretching 
1206 1209 1207  1205 1205 Chain stretching 
 1245   1244 1243 In plane bending 
chain 
1302 1302 1301 1295 1301 1301 In plane bending 
CH2 
 1424 1422  1424 1423 In plane bending 
chain 
1456 1451 1453 1444 1454 1448 In plane bending 
CH3 
1585 1586 1586 1585  1584 Ring stretching 
1614 1616 1613 1609 1614 1612 Ring stretching 
2916 2922   2899  Symmetric 
stretching CH2 











Figure 5.10: Raman spectrum of metformin hydrochloride (analytical standard) using MIRA-3 
handheld spectrometer 
 
The Raman spectra for the metformin hydrochloride reference standard (Figure 5.10) exhibits 
peaks that are characteristic for metformin hydrochloride at 426cm-1, 518cm-1 and 565cm-1, 
attributable to C-N-C deformation (Renganayaki and Srinvasan, 2011). Vibrations occurring at 
628cm-1, 737cm-1, 800cm-1 and 937cm-1 are assigned respectively as NH2 rocking and N-H out of 
plane bending and NH2 vibration modes (Sheela et al, 2010, Renganayaki and Srinvasan, 2011). 
Peaks at 1039cm-1, 1081cm-1, 1168cm-1 are attributable to C-N stretching, whereas the peak at 
1645cm-1 is attributable to C=N stretching (Renganayaki and Srinvasan, 2011). Vibrations 
occurring at 1420cm-1 and 1645cm-1 can be assigned to CH3 asymmetric deformation 
(Renganayaki and Srinvasan, 2011). 
Table 5.6 summarises the peaks attributed to metformin hydrochloride for the different 







































Table 5.6: Characteristic Raman peaks of metformin hydrochloride and their assignment 
Peak Position (cm-1)  
 
Assignment  
Experimental Literature Values 





 426 432 432 C-N-C deformation 
518 518 524  C-N-C deformation 
562 565 569 569 C-N-C deformation 
 628 634  NH2 rocking 
740 737 744 744 N-H out of plane bending 
796 800 806 806 N-H wagging 
 937 943 943 N-H wagging 
1036 1039 1043 1043 C-N stretching 
 1081 1087 1087 C-N stretching 
 1168 1169 1169 C-N stretching 
1426 1420  1427 CH3 asymmetric deformation 
1456 1465 1472 1472 CH3 asymmetric deformation 
  1571 1571 C=N stretching 
1646 1645 1653 1653 C=N stretching 
 
 


































The Raman spectra for the chloroquine phosphate reference standard (Figure 5.11) exhibits peaks 
that are characteristic for chloroquine phosphate at 396cm-1, attributable to C-N-C deformation. 
Vibrations occurring at 788cm-1 and 830cm-1 are assigned respectively as NH2 rocking and N-H 
out of plane bending (Cîntǎ‐Pînzaru et al., 2006). Peaks at 1362cm-1 and 1430cm-1 are attributable 
to C-C stretching and CH3 asymmetric deformation (Cîntǎ‐Pînzaru  et al., 2006). Vibrations 
occurring at 2952cm-1 and 3094cm-1 can be assigned to CH3 asymmetric stretching and N-H 
symmetric stretching (Cîntǎ‐Pînzaru et al., 2006). 
 
 
Figure 5.12:  Raman spectrum of quinine sulphate (analytical standard) using FORAM-2 
benchtop spectrometer 
The Raman spectra for the quinine sulphate reference standard (Figure 5.12) exhibits peaks that 
are characteristic for quinine sulphate. The peak at 434cm-1 attributable to C-N-C, vibrations 
occurring at 760cm-1, 804cm-1 and 966cm-1 are assigned respectively as NH2 rocking and N-H out 
of plane bending and NH2 vibration modes. Peaks at 1366cm-1 and 1432cm-1 are attributable to 
C-C stretching and CH3 asymmetric deformation. Vibrations occurring at 2960cm-1 and 3094cm-
1 can be assigned to CH3 asymmetric stretching and N-H symmetric stretching. 
 
 Discussion	
Using the spectra obtained for reference APIs and excipients libraries can be created in order to 
determine the content of a tablet. From looking at the ATR FTIR and Raman spectra, there are 



































From analysing the ATR FTIR spectra, distinct peaks for atenolol and metformin hydrochloride 
with little or no interference from excipients can be observed. These peaks can potentially be used 
to quantify the amount of API in a tablet; this will be discussed further in the next chapter. 
 
 Whole	Tablet	Studies	
The most common oral dosage form is a tablet; because of this, it is important to be able to identify 
an API within the physical dosage form. This capability will speed up the analysis, which would 
be invaluable in assessing tablet consignments. 
 
 ATR	FTIR	Spectroscopy	
Whole atenolol tablets were analysed in order to see if ATR FTIR analysis produced meaningful 





















Figure 5.13: A) ATR FTIR Spectra of At/UK/3 edge (Blue) and At/UK/3 centre (Green), B) ATR 
FTIR Spectra of At/UK/3 centre (Green) and atenolol analytical reference (Red) 
Figure 5.13 show differences between face and edge sampling for coated and non-coated tablets. 
The At/UK/3 sample is representative of atenolol tablets that are colour coated (orange). The 
spectra for the whole tablet of At/UK/3 (Figure 5.13A) shows differences between the centre and 
the edge of the tablet, this is due to the interaction of the tablet surface on the sampling area. The 
surface area of the tablet in contact with the sampling area is greater for the centre than when the 
edge is in contact, due to the shape of the tablet; this can be observed by the difference in intensity 




reference, there are no characteristic peaks for atenolol visible and those that are present could be 
related to coating. 
 
Figure 5.14: A) ATR FTIR Spectra of At/IND/6 edge (Blue) and At/IND/6 centre (Green), B) 
ATR FTIR Spectra of At/IND/6 centre (Green) and atenolol analytical reference (Red) 
The At/IND/6 sample is representative of atenolol tablets that are non-coated and flat in shape. 
The spectra for the whole tablet of At/IND/6 (Figure 5.14A) shows little differences between the 
centre and the edge of the tablet, this is due to the shape of the tablet; as the tablet is flat all areas 
are in contact with the sampling area equally. Figure 5.14B compares the whole tablet spectra to 
that of the atenolol analytical reference, there are no clear characteristic peaks for atenolol, as the 





Figure 5.15: A) ATR FTIR Spectra of At/SA/1 edge (Blue) and At/SA/1 centre (Green), B) ATR 
FTIR Spectra of At/SA/1 centre (Green) and atenolol analytical reference (Red) 
The spectra for the film coated atenolol sample (At/SA/1), showed similarities to the non-coated 
sample spectra, however there is some limited additional information from the surface of the film-
coated sample but with insufficient signal intensity. 
The spectra for the whole tablet of At/SA/1 (Figure 5.15A) shows differences between the centre 
and the edge of the tablet, this is due to the interaction of the tablet surface on the sampling area. 
Differences in peak intensity and resolution can be observed. Figure 5.15B compares the whole 
tablet spectra to that of the atenolol analytical reference, no characteristic peaks for atenolol are 






Figure 5.16: ATR FTIR Spectra of Met/UK/1 (Blue) and metformin hydrochloride analytical 
reference (Red) 
The Met/UK/1 sample is representative of metformin hydrochloride tablets that is film coated and 
flat in shape. Figure 5.16 compares the whole tablet spectra to that of the metformin hydrochloride 
analytical reference, there are no clear characteristic peaks for metformin hydrochloride and any 





Figure 5.17: A) ATR FTIR Spectra of Met/IND/2 (Blue) and metformin hydrochloride analytical 
reference (Red), B) ATR FTIR Spectra of Met/IND/4 (Blue) and metformin hydrochloride 
analytical reference (Red) 
Figure 5.17 compares the spectra of standard (Met/IND/2) and sustained/ extended release 
(Met/IND/4) tablets of the same dose (500mg) and the same manufacturer to that of the metformin 
hydrochloride analytical reference. There are no clear characteristic peaks for metformin 
hydrochloride observed for either sample and any peaks observed are likely to be the coating, as 
ATR FTIR is primarily a surface technique. The spectrum for Met/IND/2 (Figure 5.17A) showed 
few poorly resolved peaks at a low intensity, whereas for the spectrum for Met/IND/4 (Figure 





Figure 5.18: ATR FTIR Spectra of Met/IND/11 (Blue) and metformin hydrochloride analytical 
reference (Red) 
The Met/IND/11 sample is representative of metformin hydrochloride tablets that contain another 
API. Figure 5.18 compares the whole tablet spectra to that of the metformin hydrochloride 
analytical reference, there are no clear characteristic peaks for metformin hydrochloride and any 




Figure 5.19: ATR FTIR Spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple) 
and tablet 4 (Yellow) 
Results shown in Figure 5.19 are from one antimalarial AM/ZIM/4 sample, the API was identified 




tablets obtained from a hospital in Zimbabwe. The overlaid spectra for the four whole tablets of 
AM/ZIM/4 (Figure 5.19) shows differences between peak intensity and peak shape.  
 
Figure 5.20: ATR FTIR Spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple), 
tablet 4 (Yellow) and quinine sulphate reference (Red) 
 
Figure 5.20 compares the whole tablet spectra to that of the quinine sulphate reference, there are 
some characteristic peak shapes for quinine sulphate though these are hard to distinguish. There 
is certainly evidence of intensity variation due to either differences in the API concentration or 











Figure 5.21: Raman Spectra of At/UK/3, BRAVO (Green) and atenolol analytical reference, 
BRAVO (Red) 
The spectrum for the whole tablet of At/UK/3 (Figure 5.21) exhibited characteristic peaks for 
atenolol at 368cm-1, 637cm-1, 828cm-1, 1187cm-1, 1209cm-1, 1301cm-1, 1423cm-1, 1451cm-1, 
1615cm-1, 1680cm-1, 2916cm-1 and 3072cm-1. The spectrum also shows similarities with the 
atenolol analytical reference, however additional peaks at 480cm-1, 520cm-1 and 1122cm-1 are 
present. These additional peaks could be excipient related, using the excipient library created for 
this work, it is possible to infer that croscarmellose sodium is present in this formulation. The 
Raman spectrum for At/UK/3 was able to confirm the presence of the API unlike the ATR FTIR 
























Figure 5.22: Raman spectra for At/UK/2 using BRAVO (Red) and MIRA-3 (Green) handheld 
spectrometers 
Spectra for AT/UK/1-3 and At/UK/4-6 confirmed the presence of atenolol, as the spectra showed 
characteristic peaks for atenolol. The spectrum obtained using the MIRA-3 was heavily affected 
by fluorescence. Figure 5.22 compares the spectra obtained using the two different spectrometers 
(BRAVO and MIRA-3), with the MIRA-3 spectrum showing signs of fluorescence and poorly 
resolved peaks. Pharmaceutical samples often fluoresce, the amount and type of fluorescence is 
dependent on the material analysed and laser wavelength (Renishaw, 2015), this type of sample 
could promote fluorescence therefore swamping any underlying Raman spectrum and masking 
the signal (Horiba, 2017), as seen with the MIRA-3 spectrum. The spectrum for the FORAM-2 is 



























Figure 5.23: Raman spectra for At/UK/1 (Green), At/UK/2 (Blue) and At/UK/3 (Red) using the 
BRAVO spectrometer 
The spectra for the different dosage levels (25mg, 50mg and 100mg) for both manufacturers 
showed good correlation of peak position, but little change in peak intensity in relation to the 
four-fold change in dosage (Figure 5.23).  
5.1.2.2.1.2 Indian	Tablets	
All of the tablets that were analysed from India (At/IND/1 - 2, At/IND/4 – 16 and At/IND/18) 
confirmed the presence of atenolol using the BRAVO and FORAM spectrometers.  
 
Figure 5.24: Raman Spectra of At/IND/1 25mg (Green) and At/IND/5 50mg (Blue) tablets using 













































The spectra showed good agreement when comparing the different 25mg tablets together and the 
various 50mg tablets. This could indicate that the 25mg tablets were all manufactured using the 
same formulation and any variation in signal intensity could be attributed to matrix effects. These 
matrix effects are most likely caused by excipients within the sample, or the particle size of the 
API. Differences between the 25mg and 50mg formulations for At/IND/1 and At/IND/5 (Figure 
5.24), indicates the presence of a different excipient used in the formulation of the 25mg tablet. 
The 25mg spectra all contained a peak at 988cm-1, using the excipient library developed for this 
work; this peak can be attributed to dicalcium phosphate. This peak (988cm-1) is absent in the UK 
25mg formulations. 
The spectra for the 50mg tablets analysed from different batches and manufacturers are in good 
agreement, suggesting that they were manufactured using the same formulation, with differing 
signal intensities attributed to matrix effects. 
 
Figure 5.25: Raman Spectra of At/IND/6, BRAVO (Green) and atenolol analytical reference, 
BRAVO (Red) 
The spectrum for the whole tablet of At/IND/6 (Figure 5.25) exhibited characteristic peaks for 
atenolol, however additional peaks at 476cm-1 and 1094cm-1 are present, and the peak at 2910cm-
1 is a different shape and intensity to the reference. These additional peaks could be excipient 
related using the excipient library created for this work, it is possible to infer that MCC is present 
in this formulation, as MCC exhibits peaks at 1094cm-1 and 2894cm-1. The Raman spectrum for 



























Figure 5.26: Raman Spectra of At/PAK/1 (Green) and At/PAK/2 (Blue) using the BRAVO 
spectrometer 
The spectra for tablets At/PAK/1 and At/PAK/2 confirmed the presence of atenolol. There are 
some similarities between the spectra (Figure 5.26), but there are some clear differences indicating 
the use of different excipients in the formulation process. In particular peaks at 940cm-1 and 
479cm-1 for the At/PAK/2 tablet. This could indicate the presence of starch or sodium starch 





































Figure 5.27: Raman Spectra of At/SA/1, BRAVO (Green) and atenolol analytical reference, 
BRAVO (Red) 
The spectra for the two different manufacturers for the Saudi Arabian tablets (At/SA/1 & 2 and 
At/SA/3-5) confirmed the presence of atenolol.  
The spectrum for the whole tablet of At/SA/1 (Figure 5.27) exhibited characteristic peaks for 
atenolol, however additional peaks at 396cm-1, 516cm-1, 638cm-1 and 1460cm-1 are present, and 
the peak at 1118cm-1 is a different shape to the reference. These additional peaks (396cm-1, 516cm-
1 , 638cm-1 and 1460cm-1) could be excipient related, using the excipient library created for this 
work, it is possible to infer that titanium dioxide is present in this formulation, most likely in the 
coating, as well as starch. The spectrum for At/SA/2 is not shown, as it is identical to the one 






























Figure 5.28:  Raman Spectra of AT/NEP/1 (Green) and At/NEP/2 (Blue) tablets using the 
BRAVO spectrometer 
All three samples analysed from Nepal indicate that atenolol was present in the tablet samples. 
The spectra for At/NEP/2 and At/NEP/3 are from the same manufacturer and are in good 
agreement, with a slight difference in peak intensity (~2911cm-1); this difference may be 
attributed to matrix effects. The At/NEP/1 spectrum is different to the AT/NEP/2 and At/NEP/3 
spectra, suggesting that they are a different formulation (Figure 5.28). The more intense peak for 
At/NEP/1 at 1120cm-1 could indicate the presence of starch, as listed in the patient information 
leaflet. The excipients for At/NEP/2 and At/NEP/3 were unavailable, further work is required to 
determine if the inclusion of different excipients is the sole reason for the difference between 


























Figure 5.29: Raman Spectra of At/SA/1 (Green) and At/NEP/1 (Purple) using the BRAVO 
spectrometer  
However, when the At/NEP/1 sample is compared to that of the same manufacturer from Saudi 
Arabia (At/SA/1) (Figure 5.29), the spectra are not in good agreement. The Nepalese sample 
spectrum shows similar peaks to those in the Saudi Arabian samples, but at different intensities. 
The Nepalese sample also shows some peaks at different positions (368cm-1 and 480cm-1) and the 
addition of a peak at 576cm-1, indicating the possibility of titanium dioxide in the coating.  
 
5.1.2.2.2 Metformin	Hydrochloride	




The Raman spectra using the FORAM-2 spectrometer confirmed the presence of metformin 
hydrochloride in the 500mg and 850mg formulations, as characteristic peaks were observed in 
























Figure 5.30: Raman Spectra of Met/UK/1 (Green) and Met/UK/2 (Blue) using the FORAM-2 
spectrometer  
The spectra showed good agreement for the different dosages tablets (Figure 5.30), with the only 
differences in signal intensity; this may be due to the different levels of API in the tablet. There 
are no extra peaks observed from excipients when compared to the reference standard spectrum; 
this may be due to the metformin hydrochloride tablets containing a high percentage concentration 
of API in relation to the tablet weight (~85%). 
 
5.1.2.2.2.2 Indian	Tablets	
All the tablets from India confirmed the presence of metformin hydrochloride, there was generally 
good agreement between the spectra. Using the FORAM-2 spectrometer all the peaks were clearly 


























Figure 5.31: Raman Spectra for Met/IND/6 (Blue) and Met/IND/11 (Red) tablets using the 
FORAM-2 spectrometer 
Some of the tablet samples analysed were stated to contain another API (Met/IND/6, - 8, 
Met/IND/11 – 14). No significant differences between the sample and analytical reference 
standard were observed between the spectra (Figure 5.31), as metformin hydrochloride is present 
at a high concentration compared to the other API’s. This suggests that there may be a lower 
detection limit for mixtures of several APIs. This is investigated in the following chapter. 
No differences were observed between the spectra for standard release and extended/sustained 
release, suggesting either little or no difference in the formulation of the tablets or the differences 
























Figure 5.32: Raman Spectra of Met/IND/6 (Blue), score line (Red) using FORAM-2 
spectrometer 
Tablet formulations are usually assumed to be uniform within any coating material, but in some 
instances the appearance of the tablet indicates two apparently different material layers to be 
present. This situation occurs for some multiple API diabetes tablets and also some antimalarial 
tablets. In this study the sample Met/IND/6 is an example of this, there are clear differences in 
the spectra (Figure 5.32) for the two sides, with the non-score line face exhibiting characteristic 
peaks for metformin hydrochloride. 
 
5.1.2.2.2.3 Saudi	Arabian	Tablets	
The spectrum for the sample from Saudi Arabia confirmed the presence of metformin 
hydrochloride, as characteristic metformin hydrochloride peaks could be identified. 
 
5.1.2.2.3 Antimalarial	Tablets	from	Zimbabwe	
Whole antimalarial tablets were analysed as per 5.1.2.1.2 using the benchtop system (FORAM-






















Figure 5.33: A) Raman spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple), 
tablet 4 (Yellow) and tablet 5 (Red) 
 
 
Figure 5.34: Raman spectra of AM/ZIM/4 tablet 1 (Green), and tablet 5 (Red) 
The spectra for the whole tablet of AM/ZIM/4 (Figure 5.33) shows differences between peak 
intensity and peak shape. Figure 5.34 compares tablet 1 and 5, there are differences between peak 
intensity and ratio of peaks for the two spectra. The peaks at 392cm-1, 512cm-1 and 636cm-1, are 
indicative of titanium dioxide and the peak at 1366cm-1 is characteristic of quinine sulphate. The 
spectrum for tablet 1 indicates a higher concentration of titanium dioxide than quinine sulphate, 
whereas the spectrum for tablet 5 shows a higher concentration of quinine sulphate, with different 




































of the tablets. These differences may be due to surface coatings and the distribution of API and 
excipients within the tablet or could possibly indicate a difference in level of API within the tablet. 
 
 Discussion 
It is clear from the data obtained that only Raman analyses can provide consistently meaningful 
data from the investigation of whole tablets. ATR FTIR can in some circumstances, provide 
information but this is dependent on adequate surface contact between the sample and the 
sampling region. In short, it is sample/tablet shape dependent and is therefore unsuitable for a 
rapid identification system for whole tablets. 
The Raman spectra for supposedly the same tablets from a range of different sources have shown, 
in general the same peaks to be present, indicative of the API or so called ‘good Raman absorbers’ 
within the excipients. Furthermore, this work presents evidence of the significant changes the 
Raman Effect can produce when looking at tablets from the same batch. The AM/ZIM/4 series of 
results are particularly informative and one explanation may be poor QC on the titanium dioxide 




Whole tablets were powdered to give homogenous samples that would provide sufficient contact 







Figure 5.35: ATR FTIR Spectra of At/UK/2 (pre-2016) (50mg) (Blue) and At/UK/3 (pre-2016) 
(100mg) (Green) and atenolol analytical reference (Red) 
The powdered samples analysed produce much better spectra as expected and the spectrum for 
the At/UK/2 50mg and At/UK/3 100mg (pre-2016) samples (Figure 5.35) exhibited the 
characteristic peaks for atenolol. The first thing to note is that the peak intensities for the two 
tablet samples are virtually identical, despite a factor of 2 in dosage level. This suggests that the 
size of the tablet increases with dose and the relative concentrations within the tablet remains the 
same. The peak shape for the aliphatic CH (2954cm-1 & 2922cm-1) and carbonyl (1634cm-1) are 
not identical to those of the atenolol reference spectra. Other excipients could exhibit peaks in the 
same regions, therefore slightly altering the peak shape. The aromatic peak at 1514cm-1 is not 
masked by any excipients present in this tablet formulation and is clearly identifiable, as is the 
peak at 1236cm-1.  
From looking at the spectra excipients can be identified within the sample, using the excipient 
reference spectra obtained. Maize starch exhibits a hump in the range of 3500– 2500cm-1, which 
could account for the hydroxyl and amine peaks being raised in the spectra; maize starch also 
exhibits peaks at 1200 – 1000cm-1 and the peak shape of the CH aliphatic group differing from 
the atenolol reference spectra. This is also consistent with the patient information leaflet contained 
within the packaging. 
Overall none of the excipients used in the At/UK/2 sample (pre-2016) formulation exhibit peaks 
at 1514cm-1 and 1236cm-1; clear sharp peaks can be observed and are not masked nor is the peak 




detect the hydroxyl, amine and aliphatic CH peaks, the peak shape is slightly different and a range 
of excipients exhibit peaks in these regions.  Thus, enabling the aromatic ring and amide peaks to 
be used as a marker to detect atenolol in the tablet and could be used to quantify the amount of 
atenolol present. 
 
Figure 5.36: ATR FTIR Spectra of At/UK/1 (25 mg) (Green) overlaid with atenolol analytical 
reference (Red) 
The spectrum for the At/UK/1 25mg sample (Figure 5.36) exhibited the characteristic peaks for 
atenolol, however when the spectra is compared; the aromatic ring (1514cm-1), carbonyl (1634cm-
1) and nitro compound (1412cm-1) are not identical to those of the atenolol reference spectra. 
Other excipients could exhibit peaks in the same regions, therefore slightly altering the peak 
shape. The aromatic ring peak at 1514cm-1 is masked by magnesium carbonate; no other 
excipients produce a peak at this wavenumber. The amide peak (1236cm-1) is not masked by any 
excipients and a clear sharp peak can be observed. Excipients can be identified within the sample 
using the excipient reference spectra obtained, with at least one excipient falling in the range of 





Figure 5.37: ATR FTIR spectra of At/UK/2 pre-2016 (Green) and At/UK/2 post-2016 (Blue) 
The formulation for atenolol tablets At/UK/1, At/UK/2 and At/UK/3 appears to have changed 
post 2016. Figure 5.37 shows At/UK/2 pre-2016 overlaid with At/UK/2 post-2016 formulation. 
This is important to note when analysing spectra to identify SF tablets that formulations for the 
same manufacturer may change without notice. The once visible aromatic ring peak (1514cm-1) 
is now masked by magnesium carbonate within the formulation; this change can be confirmed by 
analysing the spectra using the excipient library. 
 
Figure 5.38: ATR FTIR Spectra of At/UK/4 (25 mg) (Green) overlaid with atenolol analytical 
reference (Red) 
The spectra for the AT/UK/4 (Figure 5.38) exhibited the characteristic peaks for atenolol; 




not identical to those of the atenolol analytical reference. Other excipients could exhibit peaks in 
the same regions, therefore slightly altering the peak shape. The aromatic ring peak at 1514cm-1 
is masked by magnesium carbonate, all other excipients in this tablet are absent at this 
wavenumber. The amide peak (1236cm-1) is not masked by any excipients and a clear sharp peak 
can be observed. Excipients can be identified within the sample using the excipient reference 
spectra obtained. Magnesium carbonate exhibits a peak in the range of 1550–1000cm-1, which 
masks the aromatic ring peak. A clear sharp peak can be identified at 1236cm-1, enabling this peak 
to be used as a marker to detect atenolol in the tablet and possibly to quantify the amount of 
atenolol present. 
The spectra for the At/UK/4, At/UK/5, At/UK/6 and At/UK/7 tablets are identical and the same 
points can be considered. It is worth noting that the samples for At/UK/1 – 3; At/UK/4 - 6 and 




Figure 5.39: ATR FTIR Spectra of At/IND/1 (Green) and At/IND/2 (Blue) (25 mg) overlaid with 
atenolol analytical reference (Red) 
 
The spectra for the At/IND/1 and At/IND/2 25mg tablets (Figure 5.39) are identical to one another 
and exhibited the characteristic peaks for atenolol; however, the hydroxyl, amine (3350cm-1 and 
3152cm-1) and aliphatic CH (2954cm-1 and 2922cm-1) peaks are not identical to those of the 




The excipient list for this tablet was unavailable, however using the excipient reference spectra; 
excipients can be identified within the sample. Maize starch exhibits a hump in the range of 3500– 
2500cm-1, which could account for the hydroxyl and amine peaks being raised in the spectra. 
MCC can be identified from the spectra, with peaks at 1150 – 1000cm-1. Overall none of the 
excipients used in the At/IND/1 and At/IND/2 tablet formulation exhibit some peaks at 1514cm-
1 and 1236cm-1. Clear sharp peaks can be observed and are not masked or the peak shape altered 
by other excipients, unlike other characteristic atenolol peaks.  
 
Figure 5.40: ATR FTIR spectrum of At/IND/5 (50mg) 
The spectra for the At/IND/5 50mg tablet (Figure 5.40) exhibited the characteristic peaks for 
atenolol; however, the hydroxyl, amine (3350cm-1 and 3152cm-1) and aliphatic CH (2954cm-1 and 
2922cm-1) peaks are not identical to those of the atenolol reference spectra. Other excipients could 
exhibit peaks in the same regions, therefore slightly altering the peak shape. The aromatic peak 
at 1515cm-1 and the amide peak at 1236cm-1 are not masked by any excipients present in this tablet 
formulation and are clearly identifiable. 
Excipients can be identified within the sample using the excipient reference spectra obtained. 
Maize starch exhibits a hump in the range of 3500 – 2500cm-1, which could account for the 
hydroxyl and amine peaks being raised in the spectra. MCC can be identified from the spectra, 
with peaks exhibited at 1150 – 1000 cm-1. Comparing this spectrum with that of tablets from the 
same manufacturer, the spectra are identical. As the At/IND/5 – At/IND/10 tablets all confirm the 
presence of atenolol and appear to be the same formulation the spectra are included as an overlay 





Figure 5.41: ATR FTIR spectra of At/IND/5 (Blue), At/IND/6 (Green), At/IND/7 (Purple), 
At/IND/8 (Yellow), At/IND/9 (Red) and At/IND/10 (Pink) Atenolol (50 mg) 
The close agreement of these spectra demonstrate both the reproducibility of the analytical 
process and the good QC applied to the production of these tablets from different sources 
throughout India. 
The analyses showed that all the Indian samples were represented by the data shown in either 
Figure 5.39 or Figure 5.40 and are as follows: 
 Figure 5.39 – At/IND/1 – 4, At/IND/11 and At/IND/12 










Figure 5.42: ATR FTIR Spectra of At/IND/17 (Green) and atenolol analytical reference (Red) 
The spectrum for the At/IND/17 (Figure 5.42) exhibited characteristic peaks for atenolol, but was 
significantly different to the two characteristic tablet spectra (Figure 5.39 and Figure 5.40) 
recorded earlier. Differences were observed in the following spectral regions 3500cm-1, 1000cm-
1 and 800 – 600cm-1. The aromatic peak at 1514cm-1 is not masked by any excipient s present in 
this tablet formulation and is clearly identifiable. 
The excipient list for this tablet was unavailable, however using the excipient reference spectra 
and performing a library search it is possible to infer that lactose, maize starch, silicon dioxide 
and MCC are present in the tablet. Further work is needed to confirm this.  
Overall none of the excipients used in the At/IND/17 tablet formulation exhibit a peak at 1514cm-
1 and a clear sharp peak can be observed and is not masked or peak shape altered by other 
excipients, unlike other characteristic atenolol peaks. Whilst we can still detect the hydroxyl, 
amine and aliphatic CH peaks, the peak shape is slightly different and a range of excipients exhibit 
peaks in these regions.  Thus, enabling the aromatic ring peak to be used as a marker to detect 










Figure 5.43: ATR FTIR Spectra of At/PAK/1 (Green) and atenolol analytical reference (Red) 
The spectra for the At/PAK/1 50mg tablet (Figure 5.43) exhibited characteristic peaks for 
atenolol. The aromatic peak at 1514cm-1 and amide peak at 1236cm-1 are not masked by any 
excipients present in the tablet formulation and are clearly identifiable. 
The excipient list for this tablet was unavailable, however using the excipient reference spectra 
and performing a library search, it is possible to infer that silicon dioxide and starch are present 
in the tablet. Further work is needed to confirm this.  
Overall none of the excipients used in the At/PAK/1 tablet formulation exhibit peaks at 1514 cm-
1 and 1236cm-1; clear sharp peaks can be observed and are not masked or peak shape altered by 
other excipients, unlike other characteristic atenolol peaks. Whilst we can still detect the hydroxyl, 
amine and aliphatic CH peaks, the peak shape is slightly different and a range of excipients exhibit 
peaks in these regions.  Thus, enabling the aromatic ring and amide peaks to be used as markers 







Figure 5.44: ATR FTIR Spectra of At/PAK/2 (Green) and atenolol analytical reference (Red) 
The spectra for the At/PAK/2 100mg tablet (Figure 5.44) differs from At/PAK/1 in the spectral 
region below 1200cm-1. 
The excipient list for this tablet was unavailable, however using the excipient reference spectra 
and performing a library search it is possible to infer that povidone, crosscarmellose sodium, 









The spectra for the At/SA/1 and At/SA/2 are identical (Figure 5.45) and exhibited characteristic 
peaks for atenolol. However, the hydroxyl, amine (3350cm-1 and 3152cm-1) and aliphatic CH 
(2954cm-1 and 2922cm-1) and nitro compound (1412cm-1) are not identical to those of the atenolol 
analytical reference. The aromatic ring peak at 1514cm-1 is masked by magnesium carbonate, all 
other excipients in this tablet are absent at this wavenumber. The amide peak at 1236cm-1 can be 
observed as a clear sharp peak, enabling this to be used as a marker for atenolol and used to 
quantify the API. 
 
Figure 5.46: ATR FTIR Spectra of At/SA/3 (Green) and atenolol analytical reference (Red) 
The spectra for the At/SA/3 100mg tablet (Figure 5.46) exhibited characteristic peaks for atenolol. 
From looking at the spectra, excipients can be identified within the sample using the excipient 
reference spectra obtained. Maize starch exhibits a hump in the range of 3500 – 2500cm-1, which 
could account for the hydroxyl and amine peaks being raised in the spectra. MCC can be identified 
from the spectra, with peaks exhibited at 1150 – 1000cm-1. Comparing this spectra with other 
tablets from the same manufacturer (At/SA/4 and At/SA/5), the spectra are identical and the same 
points can be inferred. 
Overall, none of the excipients used in the At/SA/3, At/SA/4 and At/SA/5 tablet formulations 
exhibit peaks at 1514cm-1 and 1236cm-1 and clear sharp peaks can be observed and are not masked 








Figure 5.47: ATR FTIR Spectra of At/NEP/1 (Green) and atenolol analytical reference (Red) 
The spectrum for the At/NEP/1 sample (Figure 5.47) exhibited characteristic peaks for atenolol. 
The aromatic ring peak at 1514cm-1 is masked by magnesium carbonate, all other excipients in 
this tablet are absent at this wavenumber. The amide peak at 1236cm-1 can be observed as a clear 
sharp peak, enabling this to be used as a marker for atenolol.  
 
Figure 5.48: ATR FTIR Spectra of At/NEP/2 (Green) and atenolol analytical reference (Red) 
 
The spectrum for AT/NEP/2 50mg tablets (Figure 5.48) exhibited characteristic peaks for 




excipients present in the tablet formulation and can be clearly identified. The spectra for the two 
samples (At/NEP/2 and At/NEP/3) are identical and are the same observations can be made. 
 
Figure 5.49: ATR FTIR Spectra of At/SA/1 (Green), At/SA/2 (Blue), At/UK/7 (Purple) and 
At/NEP/1 (Yellow) 
The spectrum for At/NEP/1 is very similar to At/UK/7; At/SA/1 and At/SA/2 (Figure 5.49), the 
formulation of these four tablets should be identical as they are from the same manufacturer. The 
patient information leaflet for the UK sample indicates the use of the following excipients: gelatin, 
magnesium carbonate, magnesium stearate, hypromellose, SLS, maize starch and titanium 
dioxide. The carbonate peak at ~1393cm-1 can be observed, as this masks the aromatic peak for 














Figure 5.50:  ATR FTIR Spectra of Met/UK/1 (Green), Met/UK/2 (Blue) and metformin 
hydrochloride analytical reference (Red) 
The ATR FTIR spectra for the Met/UK/1 and Met/UK/2 tablets are identical (Figure 5.50); 
therefore, the same observations can be made. The samples exhibited characteristic peaks for 
metformin hydrochloride at 3368cm-1, 3152cm-1, 1622cm-1, 1418cm-1, 1166cm-1, 1062cm-1, 
582cm-1 and 421cm-1. 
The spectra for the Met/UK/1 and Met/UK/2 tablets matches that of the metformin hydrochloride 
analytical reference, suggesting that any excipients in the tablet are present in a low concentration 
and/ or masked by the intense metformin hydrochloride peaks. 
 
5.1.3.1.2.1 Indian	Metformin	Hydrochloride	Tablets	
The spectra for the Met/IND/1, Met/IND/2 and Met/IND/3 tablets are identical to the spectra for 
the UK tablets (Figure 5.50). 
Although the samples Met/IND/1, Met/IND/2 and Met/IND/3 are of different dosages, the spectra 







Figure 5.51:  ATR FTIR Spectra of Met/IND/4 (Green), Met/IND/5 (Blue) and metformin 
hydrochloride analytical reference (Red) 
The spectra for the Met/IND/4 and Met/IND/5 tablets extended/sustained release samples are 
identical (Figure 5.51); therefore, the same observations can be made. The samples exhibited 
characteristic peaks for metformin hydrochloride. 
The spectra for the Met/IND/4 and Met/IND/5 tablets resembles that of the metformin 
hydrochloride analytical reference, however there is the addition of the CH aliphatic peaks 
(2915cm-1 and 2848cm-1) and another peak at 1698cm-1, this could due to the metformin 
hydrochloride tablet being formulated differently for sustained release. The CH aliphatic peaks 
are characteristic of metformin hydrochloride (Roselet and Premakumari, 2015), however these 
peaks may be excipient related, and further work is needed to confirm this. There is also the 






Figure 5.52: ATR FTIR Spectra of Met/IND/6 (Green) and metformin hydrochloride analytical 
reference (Red) 
The spectrum for the Met/IND/6 (Figure 5.52) exhibited characteristic peaks for metformin 
hydrochloride at 3368cm-1, 3152cm-1, 1622cm-1, 1418cm-1, 1166cm-1, 1062cm-1, 582cm-1 and 
421cm-1. 
The spectrum for the Met/IND/6 tablet matches that of the metformin hydrochloride analytical 
reference, however, there is a difference at 801cm-1, and this may be due to the addition of another 
API. Glimepiride is present in a low concentration (1mg) compared to metformin hydrochloride 
(500mg) and may not be able to be detected, further work is needed to confirm this. 
The spectra for the Met/IND/7 and Met/IND/8 were identical to the data shown in Figure 5.50. 
This demonstrates the comparability of generic formulations and the reproducibility of ATR FTIR 













Figure 5.53: ATR FTIR Spectra of Met/SA/1 (Green) and metformin hydrochloride analytical 
reference (Red) 
The spectrum for the Met/SA/1 (Figure 5.53) is identical to the metformin hydrochloride 
analytical reference, suggesting that any excipients in the tablet are present in a low concentration 
and/ or masked by the intense metformin hydrochloride peaks. This situation was replicated for 
all the metformin hydrochloride samples analysed with the exception of the sustained/extended 













Figure 5.54: ATR FTIR Spectra of AM/UK/1 (Green) and chloroquine phosphate analytical 
reference (Red) 
The spectrum for the AM/UK/1 250mg tablet sample (Figure 5.54) exhibited characteristic peaks 
for chloroquine phosphate at 3368cm-1, 3152cm-1, 1622cm-1, 1418cm-1, 1166cm-1, 1062cm-1, 
582cm-1 and 421cm-1. The spectrum for AM/UK/1 is similar to the chloroquine phosphate 
analytical reference, suggesting that any excipients in the tablet are present in a low concentration 
and/ or masked by the intense chloroquine phosphate peaks. 
 
Figure 5.55: ATR FTIR Spectra of AM/ZIM/4 (Green) and quinine sulphate reference (Red) 
The spectrum for the AM/ZIM/4 (Figure 5.55) exhibited characteristic peaks for quinine sulphate 




The spectrum for AM/ZIM/4 is similar to the quinine sulphate reference; however, there are 
additional peaks at 3200cm-1, 2917cm-1, 2850cm-1 and 1630cm-1, suggesting these may be 
excipient related. Further work is required to determine this. The peaks at 2917cm-1, 2850cm-1 
and 1620cm-1 are similar to those observed for the powered sustained/extended release metformin 
hydrochloride samples. 
Reference spectra for titanium dioxide showed very broad peaks in the IR centred on 3200cm-1 
and 820cm-1, with a sharper peak at 1628cm-1. The presence of these peaks in this sample 
correlates well with the more clearly observed peaks in the Raman spectra for the whole tablet 
samples for AM/ZIM/4. 
 
Figure 5.56: ATR FTIR Spectra of AM/NEP/1 (Green) and chloroquine phosphate analytical 
reference (Red) 
The spectrum for the AM/NEP/1 (Figure 5.56) exhibited characteristic peaks for chloroquine 
phosphate at 2971cm-1, 1612cm-1, 1459cm-1 and 1212cm-1. The spectrum for AM/NEP/1 is similar 
to the chloroquine phosphate analytical reference, suggesting that any excipients in the tablet are 
present in a low concentration and/ or masked by the intense chloroquine phosphate peaks. 
The spectrum for the AM/NIG/3 exhibited characteristic peaks for chloroquine sulphate at 







For the majority of tablets there was no significant differences between spectra for the whole 
tablet and powdered tablet samples. Differences were observed for the colour-coated samples 
(At/UK/1-6 and At/SA/3-5). 
 
Figure 5.57:  Raman Spectra of At/SA/3 whole (Green) and powdered (Blue) tablets using the 
BRAVO spectrometer 
Clear differences between the powdered and whole tablets using the BRAVO spectrometer 
(Figure 5.57) were observed for the tablet samples for At/SA/3, At/SA/4 and At/SA/5. The spectra 
for the whole tablet were at a weaker peak intensity and showed some peaks at a slightly different 
wavenumber and others absent. The peaks at 394cm-1, 518cm-1 and 638cm-1 for the whole tablet 
can be attributed to titanium dioxide; this may be due to the coating of the tablet. The peaks at 
826cm-1, 1298cm-1 and 1460cm-1 for the powdered tablet are characteristic of atenolol. There was 
good agreement for the spectra for At/SA/3, At/SA/4 and At/SA/5, results for At/SA/4 and 
At/SA/5 are not shown as a result of this. 
5.1.3.2.2 Metformin	Hydrochloride	
The metformin hydrochloride samples analysed using the MIRA-3 handheld spectrometer were 
































Figure 5.58: Raman Spectra of Met/IND/6 (Blue) and score line (Red) whole tablet using the 
FORAM-2 and crushed (Green) tablet using the MIRA-3 spectrometer 
There were no significant differences between the samples analysed except for Met/IND/6 (Figure 
5.58). Differences in the spectra were observed between the benchtop and the handheld systems, 
with the MIRA-3 spectra less clearly resolved.  
Figure 5.59: Raman Spectra for Met/IND/2 tablets using the MIRA-3 (Green) and FORAM-2 
(Blue) spectrometers 
However, the spectra of some of the tablets analysed by the MIRA-3 spectrometer showed the 
API characteristic peaks at a weaker intensity, and appeared to suffer from the effect of 
fluorescence (Figure 5.59). The same tablets were then analysed whole using the FORAM 









































Figure 5.60: Raman Spectra for AM/ZIM/4 whole tablet (Blue) and powdered (Red) using the 
FORAM-2 spectrometer 
Clear differences between the powdered and whole tablets using the FORAM-2 spectrometer 
(Figure 5.60) were observed for the tablet samples for AM/ZIM/4. The spectra for the whole tablet 
were at a stronger peak intensity and showed some peaks at a slightly different wavenumber and 
others absent. The peaks at 394cm-1, 518cm-1 and 638cm-1 for the whole tablet can be attributed 
to titanium dioxide; this may be due to the coating of the tablet. The peaks at 1362cm-1 and 
1430cm-1 for the whole and powdered tablets are characteristic of quinine sulphate.  
 
 Discussion	
The powdered samples analysed by ATR FTIR gave much more detailed spectra than those for 
the whole tablets. Significant differences between the two sample types could be observed; well-
resolved peaks for the powdered samples enabled the identification of the target APIs when 
compared to reference spectra. In general, the atenolol ATR FTIR spectra gave similar spectra to 
one and another, with the exception of excipient interactions. Samples from the same 
manufacturers showed good agreement and reproducibility of the data. The ATR FTIR spectra 
for metformin hydrochloride showed good agreement amongst the samples, with the exception of 
Met/IND/4 and Met/IND/5, the sustained release samples; further work is required to investigate 
the formulation of these tablets. 
Overall, there was no significant differences observed between the whole and powdered tablet 




















suggesting that the sampling penetration depth of Raman did not pass through the coating of these 
samples. The metformin hydrochloride samples showed no differences in the Raman spectra for 
whole and powdered tablets, with the exception of Met/IND/6 which contained another API and 
had two different faces for the whole tablet. The antimalarial sample of AM/ZIM/4 showed 
differences in the Raman spectra for whole and powdered samples, suggesting that the coating 
was observed for the whole tablet, as characteristic peaks for titanium dioxide were identified. 
 
5.2 DIP	Mass	Spectrometry	
The samples were analysed in fine powder form as detailed in Chapter 4.3.5. 
 
 Reference	Spectra	
Analytical reference samples for atenolol and quinine sulphate and chloroquine phosphate were 
analysed using DIP Mass Spectrometry. Total ion chromatogram (TIC) and spectra were recorded 
and compared. MS data obtained was validated and compared to the National Institute of Science 
and Technology (NIST) database. (NIST, 2017) 
 
Figure 5.61: DIP MS spectra for atenolol analytical reference 
The TIC for atenolol showed a large peak at 65ºC, the mass spectra (Figure 5.61) was then 
extracted from the TIC data, the presence of ions at m/z 222 (100%), m/z 107 (28%), m/z 251 
(23%), m/z 223 (18%), m/z 116 (10%), m/z 149 (8%) and m/z 267 (5%) were detected. The 
prominent fragment ions at m/z 222, m/z 251 and m/z 223 are characteristic of atenolol, which 




On comparison of this work with Carlsen and Aase (1994), who performed similar experiments 
with deuterated atenolol, identified the production of similar major ions by electron impact DIP 
process at m/z 223 and m/z 251. 
  
Figure 5.62: DIP MS spectra for chloroquine phosphate analytical reference 
The TIC for chloroquine phosphate showed a large peak at 232ºC, the mass spectra (Figure 5.62), 
was then extracted from the TIC data, the presence of ions at m/z 319 (100%), m/z 321 (30%) 
and m/z 304 (18%) were detected. The prominent fragment ions at m/z 304, m/z 319 and m/z 321 
are characteristic of chloroquine. The NIST database reports that the most intense m/z peak for 
chloroquine to be m/z 86, some 10 times more intense than the m/z 319 peak. The m/z 319 peak 
is more characteristic of chloroquine. In this work, the selected mass range excluded the detection 








Figure 5.63: DIP MS spectra for quinine sulphate analytical reference 
The TIC for quinine sulphate showed a large peak at 130ºC, the mass spectra (Figure 5.63)  was 
then extracted from the TIC and the presence of ions at m/z 324 (100%), m/z 325 (30%), m/z 309 
(23%), m/z 326 (15%) and m/z 306 (8%) were detected. The prominent fragment ions at m/z 306, 
m/z 324 and m/z 325 are characteristic of quinine sulphate. The molecular weight of quinine 









The TIC for At/UK/5 showed a large peak at 80ºC, the mass spectra (Figure 5.64) was then 
extracted from the TIC data and the presence of ions at m/z 222 (100%), m/z 223 (15%), m/z 251 
(13%) and m/z 102 (8%) were observed, which are characteristic of atenolol (Carlsen and Aase, 
1994). 
This data was characteristic of the UK atenolol samples. 
 
 
Figure 5.65: DIP MS spectra for At/IND/5 
The TIC for At/IND/5 showed a large peak at 150ºC, the mass spectra (Figure 5.65) was then 
extracted from the TIC data and the presence of ions at m/z 222 (100%), m/z 223 (20%), m/z 251 
(15%) and m/z 102 (5%) were observed, which are characteristic of atenolol (Carlsen and Aase, 
1994). This data was characteristic of the Indian atenolol samples. 
 
 Metformin	Hydrochloride	
Due to lack of availability of equipment, no DIP data was obtained for metformin hydrochloride. 
Literature data for the EI mass spectra of metformin hydrochloride in a non-derivatised form is 







Samples were taken from various countries in Africa, with a range of different API’s anticipated 
to be present. These were chloroquine phosphate, chloroquine sulphate, quinine sulphate, 
artemether, lumefantrine, sulphadoxine and pyrimethamine. Reference samples for several of 
these antimalarials were not available due to the cost and literature data was used to provide 
reference m/z values. 
  
Figure 5.66: DIP MS spectra for AM/UK/1 
The TIC for AM/UK/1 showed a large peak at 258ºC, the mass spectra (Figure 5.66) was then 
extracted from the TIC data and the presence of ions at m/z 319 (100%), m/z 321(33%), m/z 320 
(28%), m/z 322 (10%) and m/z 304 (8%) were detected. The prominent fragment ions at m/z 304, 
m/z 319 and m/z 321 are characteristic of chloroquine phosphate and match those in the 








Figure 5.67: DIP MS spectra for AM/GHA/1 
The TIC for AM/GHA/1 showed a large peak at 195ºC, the mass spectra (Figure 5.67) was then 
extracted from the TIC data and the presence of ions at m/z 311 (100%), m/z 312 (18%) and m/z 
313 (8%) were detected. This data lacks information on the presence of pyrimethamine m/z 248 
and m/z 250 due to the selected scan range m/z 300 – 500. Furthermore, the data for sulphadoxine 
(m/z 311 and m/z 312) is 1 m/z value higher than expected suggesting poor calibration of the 
mass range or a high proton affinity for this molecule leading to the formation of the M + H+ 
species at m/z 311 (Figure 5.76). 
  
Figure 5.68: DIP MS spectra for AM/NEP/1 
The TIC for AM/NEP/1 showed a large peak at 195ºC, the mass spectra (Figure 5.68) was then 




322 (10%) were detected. The prominent fragment ions at m/z 319 and m/z 321 are characteristic 
of chloroquine phosphate and match those in the chloroquine phosphate analytical standard. 
  
Figure 5.69: DIP MS spectra for AM/NIG/1 
The TIC for AM/NIG/1 showed a large peak at 220ºC, the mass spectra (Figure 5.69) was then 
extracted from the TIC data. The presence of ions at m/z 322 (100%), m/z 324 (60%), m/z 320 
(30%), m/z 384 (28%), m/z 385 (15%), m/z 325 (15%), m/z 346 (13%), m/z 484 (8%) and m/z 
369 (8%) were detected. The prominent fragment ions at m/z 321, m/z 346, m/z 384 and m/z 484 
are characteristic of lumefantrine (NIST 2017).  
  







The TIC for AM/NIG/2 showed a large peak at 235ºC, the mass spectra (Figure 5.70) was then 
extracted from the TIC data. The presence of ions at m/z 322 (100%), m/z 324 (28%), m/z 323 
(28%), m/z 346 (18%), m/z 325 (15%), m/z 386 (13%), m/z 369 (10%) and m/z 484 (8%) were 
detected. The prominent fragment ions at m/z 322, m/z 346, m/z 386 and m/z 484 are 
characteristic of lumefantrine.  
 
  
Figure 5.71: DIP MS spectra for AM/NIG/3 
The TIC for AM/NIG/3 showed a large peak at 215ºC, the mass spectra (Figure 5.71) was then 
extracted from the TIC data. The presence of ions at m/z 319 (100%), m/z 321 (33%), m/z 304 
(10%) and m/z 322 (8%) were detected. The prominent fragment ions at m/z 304, m/z 319 and 






Figure 5.72: Representative DIP MS spectra for AM/ZIM/1 and AM/ZIM/2 
The TIC for AM/ZIM/1 exhibited a large peak 230ºC, the mass spectra (Figure 5.72) was then 
extracted from the TIC data. The presence of ions at m/z 322 (100%), m/z 324 (58%), m/z 323 
(28%), m/z 325 (15%), m/z 386 (13%), m/z 346 (10%), m/z 369 (8%) and m/z 484 (5%) were 
detected. The prominent fragment ions at m/z 322, m/z 346, m/z 386 and m/z 484 are 
characteristic of lumefantrine (NIST, 2017).  
The data for AM/ZIM/2 is comparable to that of AM/ZIM/1 and is not shown. 
  
Figure 5.73: DIP MS spectra for AM/ZIM/3 
The TIC for AM/ZIM/3 exhibited large peaks at 225ºC, the mass spectra (Figure 5.73) was then 




313 (8%) were detected. This data is identical to that obtained for AM/GHA/1 and the comments 
made for that sample can be applied here. These tablets merit further investigation (Figure 5.76) 
 
  
Figure 5.74: DIP MS spectra for AM/ZIM/4 
The TIC for AM/ZIM/4 exhibited a large peak at 230ºC, the mass spectra (Figure 5.74) was then 
extracted from the TIC data and the presence of ions at m/z 324 (100%), m/z 325 (28%), m/z 309 
(23%), m/z 323 (8%) and m/z 306 (5%) were detected. The prominent fragment ions at m/z 306, 
m/z 324 and m/z 325 are characteristic of quinine sulphate. 
 
 Discussion	
The DIP mass spectra for the tablet samples containing atenolol, chloroquine phosphate and 
quinine sulphate all confirmed the presence of the API, by reference to the spectra of the analytical 
standards. The APIs present in the antimalarial samples were sulphadoxine, pyrimethamine, 
lumefantrine and artemether and no reference samples were available and so a standard scan range 
was selected. This m/z range was only partially successful as fragmentation led to smaller ions 
outside of the specified range. However, characteristic data was obtained for these compounds. 
Further work is needed to repeat these samples for the scan range to include the following values; 
m/z 221 for artemether, m/z 529 lumefantrine and m/z 153 and 155 for sulphadoxine (Mr 310) 




Conventionally new spectrometric identifications are based on the characteristic positive ion 
fragmentation patterns produced by high-energy electron impact (EI) ionisation processes used in 
the mass spectrometer (NIST, 2017). This can be summarised as: 
M + e-(H) = [M+] + 2e-(L) = m1+ + m2+ 
Where e-(H) is high-energy electron and e-(L) is low energy electron 
In many instances, the intensity of the molecular ion (M+) is significantly reduced. It is also 
possible for the sample molecule to be ionised by a low energy electron to produce a negatively 
charged molecular ion, which is unlikely to fragment. The results obtained by this process are 
compared to data obtained from the new atmospheric pressure or ambient ionisation techniques. 
In these techniques, the ionisation process can be represented as: 
M + H+ = (M + H) +  (this is the pseudo-molecular ion) 
Atmospheric pressure or ambient ionisation techniques offer two technical differences to the EI-
MS process. In atmospheric pressure systems ions are created outside the MS vacuum system, 
usually by the addition of a proton rather than the removal of an electron, and under these 
conditions the energy transferred to the target molecule is low and little fragmentation is observed. 
Under these conditions, the target signal is the anticipated molecular weight plus 1 mass unit. 
 
Figure 5.75: ASAP MS spectra for atenolol analytical reference 
The ASAP MS spectra shown in Figure 5.75 is much comparable to that obtained for DIP MS, 






Figure 5.76: ASAP MS spectra for a sulphadoxine/ pyrimethamine tablet from Zimbabwe 
Figure 5.76 shows example spectra for antimalarial tablets and again it can be observed that the 
ASAP spectra shows less fragmentation that the DIP spectra. There is clear evidence of the 
protonated molecular ion at m/z 311 (for sulphadoxine) and virtually no fragmentation ions. The 
ions at m/z 248 and 249 are the molecular species for pyrimethamine (M+ and M + H+). The data 
for sulphadoxine from this analysis is comparable to the DIP analysis of the same tablets (Figure 
5.73) and comparable samples in Figure 5.67. Whilst the data for sulphadoxine was consistent 
between the samples (all stated to contain this API), the DIP results were unable to confirm the 
presence of pyrimethamine. 
 
5.3 Summary	
The results for the identification of an API within either a whole or crushed tablet were discussed. 
Raman Spectroscopy was the only analytical method that could identify the API in a whole tablet 
successfully. The other methods (ATR FTIR, DIP MS and ASAP MS) required the sample to be 
crushed. There was no significant differences in the wavelengths of the observed absorption bands 
between the whole tablet and the powdered sample Raman spectra for atenolol and metformin 
hydrochloride. Tablet samples produced enhanced Raman absorption signals versus the powdered 
samples. Differences were observed for colour-coated samples, suggesting that the sampling 
penetration depth of Raman did not pass through the coating. The spectra for the antimalarial 
sample AM/ZIM/4 showed differences in the Raman spectra for several different whole samples, 
suggesting that the coating, titanium dioxide, was poorly dispersed on the surface.   
The DIP mass spectra for the samples containing atenolol, chloroquine phosphate and quinine 
sulphate all confirmed the presence of the API. the other antimalarials (sulphadoixine, 
pyrimethamine, lumefantrine and artemether) analysed were unable to confirm the presence of 




identified. ASAP spectra showed less fragmentation that the DIP spectra and could be used to 
identify atenolol, sulphadoxine and pyrimethamine.  
Once the target API was identified within a sample, it was possible to quantify the amount of API 
present. Chapter 6 discusses the quantification of the API within a sample and the results are 






This chapter presents and discusses the API quantification results obtained from tablet samples 
using a selection of analytical techniques as discussed in Chapter 3.  
Unlike most analytical projects, the target reference material in this study was the ‘innovator 
tablet’. In the countries under study for this work, generic medicine formulations are common 
and therefore appropriate FDA and EMA guidelines with respect to generic formulations have 
been used. These guidelines suggest that generic medicines should contain between 80 – 125% 
(FDA) (van Gelder, 2017 and Vinks, 2017) or 90 – 110% (EMA) (van Gelder, 2017 and Vinks, 
2017) of the dose of the innovator drugs API. 





Figure 6.1: Percentage of stated dosage of UK atenolol tablets as calculated by UV with EMA 
(90-110%) (--) and FDA (80-125%) (--) limits 
Figure 6.1 summarises the quantification results for the UK atenolol tablets using UV. The results 
are mixed with variation between dosage and manufacturer being observed. The At/UK/1, 
























The tablets that fell out of this range generally fell above this threshold. The At/UK/2, At/UK/4 
and At/UK/7 samples were slightly higher but fell within the FDA range (80 – 125%). 
 
Figure 6.2: Percentage of stated dosage of At/IND/1-18 tablets as calculated by UV with EMA 
(90-110%) (--) and FDA (80-125%) (--) limits 
Figure 6.2 summarises the quantification results for the At/IND/1& 2 and 5 - 18 tablets using UV. 
The results for Indian atenolol samples all fell within the EMA (90 – 110%) acceptable range, 
with At/IND/5, At/IND/10 and At/IND/14 just falling short of the acceptable limit, but well within 






























Figure 6.3: Percentage of stated dosage of Pakistani, Saudi Arabian and Nepalese atenolol tablets 
as calculated by UV EMA (90-110%) (--) and FDA (80-125%) (--) limits 
Figure 6.3 summarises the quantification results for the Pakistani, Saudi Arabian and Nepalese 
atenolol samples. The At/PAK/2 sample fell within the acceptable range, whilst the At/PAK/1 
sample was significantly low and considerably outside both the EMA and FDA acceptable limits. 
This could indicate the possibility of poor quality control or that the sample is counterfeit/ 
substandard.  
The tablets from Saudi Arabia (At/SA/1, At/SA/2, At/SA/3, At/SA/4 and At/SA/5), all fell within 
the acceptable range for atenolol as outlined by the BP 2017. The tablets from Nepal (At/NEP/1 
and AT/NEP/3), all fell within the EMA acceptable range for atenolol except for At/NEP/2. The 
At/NEP/2 sample appears to contain a higher concentration (115%) of atenolol than expected, but 




























Figure 6.4: Percentage of stated dosage of UK metformin hydrochloride tablets as calculated by 
UV with EMA (90-110%) (--) and FDA (80-125%) (--) limits 
Figure 6.4 summarises the quantification results for the UK metformin hydrochloride tablets 
using UV. The results are mixed, with variation between dosage and manufacturer being 
observed. The percentage of stated dose for the Met/UK/2 sample is lower than expected and falls 
below the acceptable EMA range (90 -110%), but within the FDA limits (80 – 125%).  
 
Figure 6.5: Percentage of stated dosage of Indian and Saudi Arabian metformin hydrochloride 
tablets as calculated by UV with EMA (90-110%) (--) and FDA (80-125%) (--) limits 
Figure 6.5 summarises the quantification results for the Indian metformin hydrochloride tablets 












































hydrochloride. Met/IND/2 and Met/IND/12 are just outside the EMA limits, but within the FDA 
limits. The Met/IND/13 samples indicate a lower than anticipated level of metformin 
hydrochloride. The Met/IND/7 is significantly high and considerably outside the both the EMA 
and FDA acceptable limits. This could indicate the possibility of poor quality control or that the 
sample is counterfeit/ substandard. This may be related to the overall quality of the tablet, on 
receipt of the tablets, several of them were broken and appeared to be of poor quality in the blister 
packaging (Figure 6.6); this may account for the difference in values for the two Met/IND/7 and 
Met/IND/8 samples, which are from the same manufacturer. 
 





Calibration mixtures for the quantification of atenolol in a single tablet were prepared as detailed 





Figure 6.7: ATR FTIR Spectra of standard calibration mixtures, A) 5% atenolol, B) 25% atenolol, 
C) 50% atenolol and D) 75% atenolol 
Figure 6.7 shows selected spectra for the different calibration mixes and the change in key peaks 
for atenolol and MCC, as the concentration varied. 
 
Table 6.1 summarises the characteristic peaks for atenolol and MCC and the presence of them in 















Table 6.1: Summary of characteristic atenolol and MCC peaks in calibration mixtures 
Calibration 
Mixture 
Characteristic Peaks (cm-1) 
Atenolol MCC 
3347 3159 2966 2866 1633 1515 1412 3328 1104 897 
100% Atenolol: 
0% MCC 
          
75% Atenolol: 
25% MCC 
       ~ ~  
60% Atenolol: 
40% MCC 
       ~ ~  
50% Atenolol: 
50% MCC 
       ~ ~  
40% Atenolol: 
60% MCC 
       ~ ~  
30% Atenolol: 
70% MCC 
          
25% Atenolol: 
75% MCC 
          
20% Atenolol: 
80% MCC 
          
10% Atenolol: 
90% MCC 
          
5% Atenolol: 
95% MCC 
~          
0% Atenolol: 
100% MCC 
          
 
From the table, it can be shown that it is possible to detect atenolol at 10% within an excipient 






Figure 6.8: ATR FTIR spectrum of atenolol with integration areas highlighted 
A total of 12 different calibration plots were calculated from the mean integrated peak areas 
(Figure 6.8) over the ranges of 1) 3009 – 2893cm-1, 2) 1530 – 1490cm-1, 3) 1272 – 1193cm-1 and 
4) 858 – 758cm-1, using the different integration methods. 
The calibration plots for the various methods and peak areas gave the following equations of a 
line and R2 values. 
 Method A: 
o Area 1)  0.0715 4.5616  R2 = 0.8359 
o Area 2)  0.0432 0.5586  R2 = 0.9242 
o Area 3)  13.59 1.9101  R2 = 0.9479 
o Area 4)  0.1195 0.2017 R2 = 0.9709 
 
 Method B: 
o Area 1)  0.0414 0.2586 R2 = 0.9026 
o Area 2)  0.0336 0.4782  R2 = 0.9080 
o Area 3)  11.075 1.3348 R2 = 0.9261 
o Area 4)  0.0775 0.6067 R2 = 0.9327 
 
 Method K: 
o Area 1)  0.0008 0.0270  R2 = 0.9283 
o Area 2)  0.0031 0.0432 R2 = 0.9102 
o Area 3)  0.4629 	0.056  R2 = 0.9256 
o Area 4)  0.0020 0.0191 R2 = 0.9323 






Table 6.2: Integration methods ranked according to R2 values for atenolol 
Integration Method and  
Peak Area 
R2 Value Rank 
A1 0.8359 12 
A2 0.9242 8 
A3 0.9479 2 
A4 0.9709 1 
B1 0.9026 11 
B2 0.9080 10 
B3 0.9261 6 
B4 0.9327 3 
K1 0.9283 5 
K2 0.9102 9 
K3 0.9258 7 
K4 0.9323 4 
Analysing the R2 values in Table 6.2, integration method A and peak area 4 (Figure 6.9) yielded 
the best results, the R2 value is the closest to one.  
 



























Rearranging the equation of the line (Figure 6.9) for integration method A, peak area 4 it is 
possible to calculate the concentration of atenolol in a tablet. 
The equation of the line is: y= 0.1194803x + 0.2017352  
Rearrange to give x, x = (y - 0.2017352) / 0.1194803 
Where x is the concentration of atenolol and y is the mean integral. 
 
 Quantification	of	API	within	a	tablet	
Table 6.3 summarises the quantification results for the UK atenolol tablets using ATR FTIR and 
are shown graphically in Figure 6.10. Overall most tablets are in the range as outlined by the 
EMA (90 – 110%). The tablets At/UK/1, At/UK/2 and At/UK/3 generally all fall below this 
threshold, suggesting that the methodology does not work for this formulation. Further work is 
needed to determine if formulation of tablets affects the quantification. At/UK/7 also is outside 
the EMA range, but within the FDA range (80 – 125%) for a higher calculated amount of API. 
 
Table 6.3: Quantification results for UK atenolol tablets calculated by ATR FTIR 













At/UK/1 UK 25mg 3.4674 0.1057 16.37 17.30 
At/UK/2 UK 50mg 3.676 0.2167 17.42 37.74 
At/UK/3 UK 100mg 3.6548 0.4231 17.31 73.24 
At/UK/4 UK 25mg 4.491 0.1097 21.50 23.59 
At/UK/5 UK 50mg 4.4708 0.2189 21.40 46.85 
At/UK/6 UK 100mg 4.6472 0.4286 22.29 95.51 






Figure 6.10: Percentage of stated dosage of UK atenolol Tablets as calculated by UV (X) and 
ATR FTIR (X) with EMA (90-110%) (--) and FDA (80-125%) (--) limits 
The quantification results for the Indian, Pakistani, Saudi Arabian and Nepalese atenolol tablets 
using ATR FTIR are summarised in Table 6.4 and are shown graphically in Figure 6.11 for the 
Indian tablets and Figure 6.12 for the Pakistani, Saudi Arabian and Nepalese tablets. Overall most 
tablets are outside range as outlined by the EMA (90 – 110%), this is quite concerning as it may 
mean most of these tablets are substandard. Further work is needed to determine if these tablets 


































Table 6.4: Quantification Results for Indian Atenolol Tablets as calculated by ATR FTIR 













At/IND/1 India 25mg 3.0774 0.1883 14.42 27.14 
At/IND/2 India 25mg 2.4758 0.1856 11.40 21.16 
At/IND/5 India 50mg 2.7508 0.1827 12.78 23.35 
At/IND/6 India 50mg 3.4662 0.1839 16.36 30.09 
At/IND/7 India 50mg 3.2022 0.1837 15.04 27.63 
At/IND/8 India 50mg 3.5206 0.1878 16.64 31.25 
At/IND/9 India 50mg 3.5492 0.1877 16.78 31.50 
At/IND/10 India 50mg 3.5966 0.1828 17.02 31.11 
At/IND/11 India 25mg 2.605 0.1865 12.05 22.47 
At/IND/12 India 50mg 3.2008 0.1843 15.03 27.71 
At/IND/13 India 50mg 3.3318 0.1878 15.69 29.47 
At/IND/14 India 50mg 2.1786 0.1943 9.91 19.26 
At/IND/15 India 50mg 3.9304 0.1903 18.69 35.57 
At/IND/16 India 50mg 3.7428 0.1899 17.75 33.71 
At/IND/17 India 25mg 4.5005 0.1097 21.55 23.64 
At/IND/18 India 50mg 3.7692 0.1936 17.88 34.62 
At/PAK/1 Pakistan 50mg 4.3556 0.1524 20.82 31.73 
AT/PAK/2 Pakistan 100mg 3.4882 0.2925 16.48 48.19 
At/SA/1 Saudi 
Arabia 
50mg 5.888 0.2041 28.51 58.18 
At/SA/2 Saudi 
Arabia 
50mg 5.4638 0.2114 26.38 55.76 
At/SA/3 Saudi 
Arabia 
100mg 1.7088 0.4141 7.55 31.29 
At/SA/4 Saudi 
Arabia 
100mg 1.5238 0.3994 6.63 26.47 
At/SA/5 Saudi 
Arabia 
100mg 1.8138 0.4111 8.08 33.22 
At/NEP/1 Nepal 50mg 4.7278 0.2017 22.69 45.76 
At/NEP/2 Nepal 50mg 2.4236 0.1884 11.14 20.98 







Figure 6.11: Percentage of stated dosage of Indian atenolol tablets as calculated by UV (X) and 
ATR FTIR (X) with EMA (90-110%) (--) and FDA (80-125%) (--) limits 
In general, the trend is to underestimate the level of atenolol within the tablet, it is interesting to 
note that the ATR FTIR results for the four Indian samples (At/IND/1, AT/IND/2, At/IND/11 and 
At/IND/17) do not fit this trend. On closer inspection of the tablet weights and dosage level of the 
API, these four tablets are stated to contain 25mg of the API, but have a similar tablet weight to 
the 50mg tablets. This suggests that the API is present in a lower ratio to excipients for 25mg than 
the 50mg tablets. This ‘dilution’ of the API within the tablet may prevent agglomeration of the 
API; this will be discussed further in this chapter. The results for the Indian 25mg are not 
replicated for the UK tablets, as the tablet weight varies according to dose. 
 
Figure 6.12: Percentage of stated dosage of Pakistani, Saudi Arabian and Nepalese atenolol 










































Overall, the results for quantification are low for the majority of tablets from the different 
countries; this may be due to excipients interacting with the chosen peak range to quantify from 
or it may stem from poor mixing (not quite achieving a maximum degree of randomness) and 
potential issues with agglomeration of particles. Salari and Young (1998) discussed that not 
attaining a ‘perfect mixture’ or as close to would affect quantification of powders. It is possible 
that atenolol agglomerates and therefore did not achieve a ‘perfect mixture’ or one, which had a 
high degree of randomness.  
 
Figure 6.13: SEM Images for atenolol A) raw and B) ground. 
The analytical reference standard for atenolol was analysed by SEM (Figure 6.13) in both its raw 
and ground format. From the images, it is clear that once the atenolol is ground using a pestle and 
mortar it sticks together and agglomerates. This physical attribute may have influenced the 
calibration plot and may/ may not affect the quantification of the API in a tablet form. 
Quantification data was calculated using the equation of the line for other peak areas and the 




Calibration mixtures for the quantification of metformin hydrochloride in a single tablet were 
prepared as detailed in Chapter 4.3.1. Calibration mixtures of metformin hydrochloride and maize 
starch were analysed. Characteristic peaks for metformin hydrochloride were observed for the 






Table 6.5: Summary of characteristic metformin and maize starch peaks in calibration mixtures 
Calibration 
Mixture 
Characteristic Peaks (cm-1) 
Metformin hydrochloride Maize 
starch (MS) 








































     ~ ~    
0% Metformin: 
100% MS 
          
 
From the table, it can be shown that it is possible to detect metformin hydrochloride at 
concentrations >10% within an excipient mix.  
Four peak areas characteristic to metformin hydrochloride were integrated using the Opus 
software. These were Area 1) 1648 –1605cm-1, Area 2) 1605 – 1501cm-1, Area 3) 1501 – 1432cm-






Figure 6.14: ATR FTIR spectrum of metformin hydrochloride with integration areas highlighted 
The 12 calibration plots for the various integration methods and peak ranges gave the following 
equations of a line and R2 values. 
 Method A: 
o Area 1)  0.0489 0.2156  R2 = 0.8610 
o Area 2)  0.1995 1.691   R2 = 0.8682 
o Area 3)  0.1034 0.6414  R2 = 0.8050 
o Area 4)  0.0427 0.2455  R2 = 0.6791 
 
 Method B: 
o Area 1)  0.0147 0.0744  R2 = 0.8740 
o Area 2)  0.0823 0.9235  R2 = 0.8785 
o Area 3)  0.0298 0.2660  R2 = 0.8529 
o Area 4)  0.0076 0.1088 R2 = 0.8587 
 
 Method K: 
o Area 1)  0.0009 0.0066  R2 = 0.8805 
o Area 2)  0.0015 0.0115  R2 = 0.8915 
o Area 3)  0.0007 0.0060  R2 = 0.8452 









Table 6.6: Integration methods ranked accorded to R2 values for metformin hydrochloride 
Integration Method and 
Peak Area 
R2 Value Rank 
A1 0.8610 7 
A2 0.8682 6 
A3 0.8050 11 
A4 0.6791 12 
B1 0.8740 5 
B2 0.8785 3 
B3 0.8529 9 
B4 0.8587 8 
K1 0.8805 2 
K2 0.8915 1 
K3 0.8452 10 
K4 0.8762 4 
 
Table 6.6 ranks the R2 values according to their value, those that are closest to one are ranked 
highest. Analysing the R2 values integration method K and peak area 2 yielded the best results, 
with the R2 value is the closest to one.   
Rearranging the equation of the line for integration method K, peak area 2 it is possible to 
calculate the concentration of metformin hydrochloride in a tablet. 
 
The equation of the line is: 0.0015 0.0115 
Rearrange to give x, x = (y + 0.0115) / 0.0015) 
Where x is the concentration of metformin hydrochloride and y is the mean integral. 
 
 Quantification	of	API	within	a	tablet	
Table 6.7 summarises the quantification results for the UK metformin hydrochloride tablets using 




outlined by the FDA (80 – 125%), this could indicate substandard medicines, or there may be an 
issue with the calibration method, as the R2 value for the calibration plot showed poor linearity. 
Table 6.7: Quantification results for UK metformin hydrochloride tablets as calculated by ATR 
FTIR 













Met/UK/1 UK 500  0.1574 0.5899 112.60 664.23 
Met/UK/2 UK 850 0.149 0.9928 107.00 1062.30 
 
 
Figure 6.15: Percentage of stated dosage of UK metformin hydrochloride tablets as calculated 
by UV (X) and ATR FTIR (X) with EMA (90-110%) (--) and FDA (80-125%) (--) limits 
Table 6.8 summarises the quantification results for the Indian and Saudi Arabian metformin 
hydrochloride tablets using ATR FTIR and are shown graphically in Figure 6.16. Overall, the 
tablets are outside range as outlined by the EMA (90 – 110 %), this could indicate substandard 
medicines. There may be an issue with the calibration method, as the R2 value for the calibration 
plot showed poor linearity, or the equation chosen, but the results for a range of UV analyses were 



























Table 6.8: Quantification results for Indian and Saudi Arabian metformin hydrochloride tablets 
as calculated by ATR FTIR 














Met/IND/1 India 250 0.0846 0.2946 64.07 188.74 
Met/IND/2 India 500 0.1154 0.5984 84.60 506.25 
Met/IND/3 India 500 0.1654 0.7085 117.93 835.56 
Met/IND/4 India 850 0.1356 1.0161 98.07 996.46 
Met/IND/5 India 850 0.1674 1.1285 119.27 1345.92 
Met/IND/6 India 500 0.1104 1.0132 81.27 823.39 
Met/IND/8 India 500 0.1174 0.6765 85.93 581.34 
Met/IND/9 India 500 0.1352 0.6731 97.80 658.29 
Met/IND/10 India 500 0.1434 0.5842 103.27 603.28 
Met/IND/11 India 500 0.1464 0.7417 105.27 780.76 
Met/IND/12 India 400 0.082 0.5883 62.33 366.71 
Met/IND/13 India 400 0.1526 0.5396 109.40 590.32 
Met/IND/14 India 500 0.1284 0.6389 93.27 595.88 
Met/IND/15 India 500 0.1524 0.6448 109.27 704.55 
Met/IND/16 India 1000 0.139 1.3401 100.33 1344.57 
Met/IND/17 India 500 0.1584 0.5233 113.27 592.72 
Met/SA/1 Saudi 
Arabia 







Figure 6.16: Percentage of stated dosage of Indian and Saudi Arabian metformin hydrochloride 
tablets as calculated by UV (X) and ATR FTIR (X) EMA (90-110%) (--) and FDA (80-125%) (-
-) limits 
Overall, the results for quantification are high for the majority of tablets from the different 
countries; this may be due to excipients interacting with the chosen peak to quantify from or it 
may stem from poor mixing and/or issues with agglomeration of particles. Salari and Young 
(1998) discussed that not attaining a ‘perfect mixture’ or as close to would affect quantification 
of powders. It is possible that either the API or excipient agglomerates and therefore did not 
achieve a ‘perfect mixture’. Using the equation of a line for other integration methods and peak 
areas, the quantification results for metformin hydrochloride still tended to be on the high side of 
the acceptable limits. Further work is required to investigate the choice of peak area for 
quantification. 
 





















The reference standard for metformin hydrochloride was analysed by SEM (Figure 6.17) in both 
its raw and ground format. From the images, it can be inferred that metformin hydrochloride is a 
crystalline material and once ground using a pestle and mortar it is a free-flowing powder. It is 
therefore important to analyse the excipient (maize starch) (Figure 6.18) and a mixture of API 
and excipient (Figure 6.19). 
 
Figure 6.18: SEM images for maize starch A) raw and B) ground 
The images in Figure 6.18 show that maize starch is a free flowing powder both when it is raw 
and ground format. The particle size is not uniform, even after grinding which could indicate 
potential reasons for the poor quantification ATR FTIR results. 
 
Figure 6.19: SEM images for 50:50 metformin hydrochloride: maize starch. 
The image for the 50:50 calibration mix shows a good distribution of maize starch (the large 




as it is not distributed evenly with the excipient. This may account for the poor linearity of the 




Calibration mixtures of atenolol and lactose were prepared over the range of 0 – 100% at 10% 
intervals. The calibration mixes were different to those used for ATR FTIR, as MCC is known to 
fluoresce and for this reason, lactose was selected. A calibration plot was calculated from the peak 
heights of 366cm-1. The peaks that were not masked by the excipient were severely limited and 
resulting in just one peak being selected for quantification. 
The calibration plot gave a significantly low R2 value (0.0203), suggesting that the data for 
atenolol and lactose was poor. Further work is required to investigate other excipients with the 
API, in order to determine if quantification of an API using Raman is viable. 
 Paracetamol	
Calibration mixtures of paracetamol and maize starch were prepared over the range of 0 – 100% 
at 10% intervals to see if the poor results for atenolol were API or technique related. Calibration 
plots were calculated from the peak heights of (1) 212cm-1, 2) 650cm-1, 3) 1612cm-1 and 4) 
1650cm-1). 
The calibration plots for the various peaks gave the following equations of a line and R2 values. 
 Peak 1)  0.0190 0.0767  R2 = 0.8620 
 Peak 2)  0.0422 0.1242  R2 = 0.8919 
 Peak 3)  0.0952 0.4739 R2 = 0.8975 
 Peak 4)  0.0759 0.3498 R2 = 0.8937 
The R2 values for the paracetamol calibration are low and suggest poor linearity of the data. 
Further work is needed to investigate this. 
 
6.4 EDX	spectroscopy	
As most of the tablets showed similar morphology to one another using SEM, the cross sections 
of the tablets were mapped and quantified using EDX. Many APIs and excipients contain marker 
elements, for example phosphorous, chlorine, titanium and magnesium, which can be detected by 




From this fingerprint, the nature of some excipients and possibly the API/s can be inferred. Figure 
6.20 shows an overlaid elemental map for a cross section of an ibuprofen tablet, mapping data 
can be overlaid and false coloured to give the spatial distribution of elements. From the composite 
image, several observations can be made; the tablet has a clear distinct coating (blue), suggesting 
the use of titanium dioxide in the formulation, the disintegrant croscarmellose sodium is present 
as indicated by the red areas and the manufacturer uses an iron oxide to print the brand name on 
the tablet (pink).  
 
  
Figure 6.20: Composite image of elemental maps for a cross section of an ibuprofen tablet 
(titanium (blue), magnesium/ silicon (green), carbon (yellow), sodium (red) and iron (pink)) 
For the purpose of this study, the quantification data for carbon and oxygen is reported, but is not 




The EDX data for the samples At/UK/1, At/UK/2 and At/UK/3 can be summarised in Table 6.9. 
From the quantification data, the different dosages of the At/UK/1 -3 tablets are of an identical 
elemental composition, with similarities in the quantification data. The AT/UK/3 tablet 
compromised of a higher nitrogen concentration and lower magnesium and aluminium 
concentration. The formulation for At/UK/4 - 6 samples is similar to that of the At/UK/1 -3 
samples with the exception of the absence of nitrogen and the presence of titanium. One of the 




quantify especially in the presence of titanium, this is because the Kα peaks for nitrogen and 
titanium overlap. 
Table 6.9: Comparison of EDX quantification data for At/UK/1 -3 tablets 
Element Concentration (%) 
At/UK/1 At/UK/2 At/UK/3 
Carbon 49.54 47.79 50.10 
Nitrogen 7.71 7.43 8.20 
Oxygen 39.34 40.98 38.88 
Sodium 0.17 0.19 0.14 
Magnesium 2.62 2.98 2.21 
Aluminium 0.27 0.25 0.11 
Silicon 0.26 0.29 0.26 
Chlorine 0.05 0.06 0.05 
Calcium 0.02 0.03 0.03 
From the mapping data, the possibility of carbon, oxygen and magnesium being present in the 
outer layer of the coating, suggests that opacifiers were not used in the formulation of this brand 









The EDX data for the samples At/UK/4, At/UK/5 and At/UK/6 is summarised in Table 6.10. 
From the quantification data, the different dosages of tablets from the same manufacturer are a 
similar elemental composition. 
Table 6.10: Comparison of EDX quantification data for At/UK/4 -6 tablets 
Element Concentration (%) 
At/UK/4 At/UK/5 At/UK/6 
Carbon 58.26 57.95 56.98 
Oxygen 37.88 39.23 39.26 
Sodium 0.17 0.14 0.19 
Magnesium 2.46 2.36 2.51 
Aluminium 0.82 0.04 0.52 
Silicon 0.27 0.21 0.41 
Chlorine 0.07 0.05 0.07 
Calcium 0.03 0.02 0.03 
Titanium 0.04  0.03 
 
From the mapping data, there is an absence of a clear element present in the coating; the At/UK/6 
map identifies the possibility of carbon and magnesium present in the outer layer of the tablet 
(Figure 6.22).  The presence of titanium in the tablet core is interesting, as titanium (titanium 
dioxide) is normally found on the coating of tablets. The excipient titanium dioxide is more 
commonly used as a whitening agent. The At/UK/4 and At/UK/6 tablets contained a higher level 
of aluminium, which was distributed as distinct regions in the tablet core; the At/UK/6 tablet also 










The EDX data for the At/UK/7 tablet is summarised in Table 6.11. From the quantification data, 
the At/UK/7 tablet consists of fewer elements, suggesting that less excipients are used in the 
formulation. There is a higher concentration of carbon present in the sample, though this may be 
relative as there is an absence of nitrogen in the tablet cross section. The magnesium content 
indicates the presence of magnesium carbonate and magnesium stearate, as indicated by the 
patient information leaflet. 
Table 6.11: EDX quantification data for At/UK/7 tablet 






The mapping data shows a clear layer of titanium in the coating, suggesting that titanium dioxide 
was used as an excipient to ‘whiten’ the coating (Figure 6.23). 
 







The EDX data for At/IND/1 – 2 and At/IND/4 – 10 is summarised in Table 6.12. Elemental composition and quantification data can be inferred from the 
data. Elemental analysis identified the presence of aluminium in only two tablets (At/IND/1 and At/IND/8) and phosphorous in three tablets (At/IND/1, 
At/IND/2 and At/IND/5). 
Table 6.12: Comparison of EDX quantification data for At/IND/1-2 and At/IND/4-10 
Element Concentration (%) 
At/IND/1 At/IND/2 At/IND/4 At/IND/5 At/IND/7 At/IND/8 At/IND/9 At/IND/10 
Carbon 52.30 52.26 53.33 54.21 54.64 54.30 54.39 55.15 
Nitrogen 8.39 8.76 11.93 12.37 11.46 11.5 13.69 11.99 
Oxygen 36.33 36.24 33.30 32.09 32.59 32.53 30.42 31.58 
Sodium 0.23 0.18 0.10 0.10 0.17 0.18 0.22 0.17 
Magnesium 0.33 0.28 0.33 0.22 0.26 0.34 0.285 0.22 
Aluminium 0.03     0.05   
Silicon 0.61 0.58 0.73 0.55 0.57 0.68 0.61 0.52 
Phosphorous 0.83 0.79  0.20     
Chlorine 0.04 0.04 0.04 0.03 0.03 0.03 0.07 0.06 






At/IND/5 is similar to the At/IND/1-2 tablets, in that the results confirmed the presence of 
phosphorus, mapping data showed this to be in the same areas as calcium, indicating the use of 
dicalcium phosphate (Figure 6.24). It is also clear that there is no indication of a coating present 
on the tablet, as the excipients are present throughout the cross section. 
 
Figure 6.24: Elemental maps of Calcium and Phosphorous for At/IND/5 
Maps for the At/IND/4 - 10 tablets indicate distinct regions of calcium, silicon and magnesium in 
the tablet core. 
The EDX data for At/IND/11 – 13 is summarised in Table 6.13. Results indicate that At/IND/11 
is similar in formulation to At/IND/1 - 2. At/IND/12 & 13 are of a similar elemental composition 
and the quantification data is comparable for the two tablets. At/IND/12 & 13 are similar in 
composition to At/IND/11, however like with the samples of At/IND/4, 6 - 10; there is an absence 
of phosphorous on the surface of the cross section. 
Table 6.13: Comparison of EDX quantification data for At/IND/11 – 13 tablets 
Element Concentration (%) 
At/IND/11 At/IND/12 AT/IND/13 
Carbon 52.21 53.90 53.53 
Nitrogen 7.86 13.71 12.42 
Oxygen 37.39 31.49 32.71 
Sodium 0.13  0.08 
Magnesium 0.33 0.13 0.27 
Aluminium  0.04  
Silicon 0.59 0.35 0.61 
Phosphorous 0.74   
Chlorine 0.04 0.03 0.03 
Calcium 0.73 0.35 0.35 
 
Mapping data for AT/IND/11 confirms the presence of the excipient dicalcium phosphate, as the 
elemental maps for calcium and phosphorous show identical distribution. Calcium and 





The EDX results for the AT/IND/14 - 16, show the same elemental composition (Table 6.14); 
however, there is variation within the quantification data. There are differences in the elemental 
composition for these samples compared to other Indian atenolol tablets, interestingly calcium, 
phosphorous and chlorine are absent. 
Table 6.14: Comparison of Quantification data At/IND/14 – 16 tablets. 
Element Concentration (%) 
At/IND/14 At/IND/15 At/IND/16 
Carbon 58.80 62.08 62.30 
Nitrogen 4.68 5.80 6.73 
Oxygen 35.03 31.78 30.08 
Sodium 0.11 0.11 0.13 
Magnesium 0.25 0.08 0.11 
Silicon 1.13 0.15 0.64 
 
The data shows variation in the concentration of all elements identified except for sodium. 
Elemental mapping shows that sodium is more evenly distributed in At/IND/14 and At/IND/15, 
than that of At/IND/16 (Figure 6.25).  
 





Similar applies for silicon and magnesium, At/IND/14 has a higher concentration present and is 
distributed across the tablet; this is also the same for At/IND/16, however At/IND/15 contains a 
small distinct region. 
The EDX results for At/IND/18 indicates similar ratio of carbon, nitrogen and oxygen to other 
atenolol formulations from the same region. Mapping indicates the presence of magnesium and 
silicon in the same positions. 
 
 Pakistani	Tablets	
The elemental composition of the At/PAK/1 tablet contains carbon, nitrogen and oxygen at 
similar ratios to other atenolol tablets. There is an absence of calcium, though this is probably due 
to formulation differences. The quantification data is summarised in Table 6.15 and compared to 
another tablet (At/PAK/2) from Pakistan. Mapping data indicates that magnesium and silicon are 
widely distributed and are in identical positions. There is a clear region of sodium, indicating the 
possible use of sodium croscarmellose, as it is a single large particle. The At/PAK/2 tablet is 
similar in formulation to At/PAK/1, in that carbon, nitrogen and oxygen are present in similar 
quantities. The formulation differs in the absence of sodium and silicon. Mapping indicates that 
magnesium is concentrated on one side of the tablet. This may be due to the homogeneity of the 
sample, or limitation of the technique. However, it is unlikely to be technique related as the rest 
of the sample was mapped successfully. 
Table 6.15: Comparison of EDX quantification data for At/PAK1 and At/PAK/2 tablets 
Element Concentration (%) 
At/PAK/1 At/PAK/2 
Carbon 60.27 63.28 
Nitrogen 8.63 7.01 
Oxygen 29.77 29.67 
Sodium 0.24  
Magnesium 0.34 0.03 
Silicon 0.56  
Chlorine 0.19 0.02 
 
 Saudi	Arabian	Tablets	







Table 6.16: Comparison of EDX quantification data for Saudi Arabian tablets 
Element Concentration (%) 
At/SA/1 At/SA/2 At/SA/3 At/SA/4 At/SA/5 
Carbon 61.81 59.33 62.62 62.96 58.22 
Oxygen 35.97 38.28 36.53 36.57 37.47 
Sodium 0.08 0.07 0.44 0.23 0.28 
Magnesium 2.10 2.28 0.08  1.19 
Aluminium   0.03  0.46 
Silicon   0.19 0.15 1.53 
Chlorine   0.08 0.09 0.15 
Titanium 0.04 0.04 0.03  0.69 
 
The EDX results for the At/SA/1 and At/SA/2 are comparable, as they contain the same elemental 
composition and at similar concentrations. The elemental composition is similar to that of the UK 
tablet (At/UK/7) from the same manufacturer, however the Saudi Arabian tablets contain sodium 
and the quantification results indicate a variation in the atomic percentage. Mapping data indicates 
that these tablets are coated with titanium dioxide. 
The EDX results for At/SA/3, At/SA/4 and At/SA/5 indicate a difference in elemental 
composition, At/SA/3 and At/SA/5 are identical in the elemental composition identified, and 
however these are not at similar concentrations. The elemental composition of At/SA/4 shows the 
absence of magnesium, aluminium and titanium, this may be due to formulation differences or 
the area examined.  





Mapping indicates that there is no distinct coating present in these tablets. The map for At/SA/5 
shows magnesium and silicon present in the same positions; however, they are concentrated closer 
to the edge of the tablet unlike in any other formulation (Figure 6.26). The level of titanium is 
significantly higher in the At/SA/5 sample; mapping data indicates that the titanium is present in 
the coating. 
 Nepalese	Tablets	
 The EDX data for the Nepalese samples is summarised in Table 6.17.  
Table 6.17: Comparison of EDX quantification data for the Nepalese samples 
Element Concentration (%) 
At/NEP/1 At/NEP/2 At/NEP/3 
Carbon 48.47 61.34 61.75 
Nitrogen 4.09 7.23 7.49 
Oxygen 43.45 30.79 30.20 
Sodium 0.10 0.12 0.10 
Magnesium 3.89 0.19 0.18 
Silicon  0.28 0.23 
Chlorine  0.06 0.04 
 
The EDX results for At/NEP/2 and At/NEP/3, show identical elemental composition and good 
agreement between the atomic percentage quantification results. Mapping indicates similar 
distribution of elements between the two tablets. 
The results for At/NEP/1 show a similar elemental composition to other samples manufactured 
by the same company (At/UK/7, At/SA/1 and At/SA/2). However, it is not identical, the 
quantification results differ to the other samples, the carbon and oxygen ratio differs, and the 
presence of nitrogen alters this ratio. There is also a higher concentration of magnesium. Mapping 
indicates magnesium is distributed across the tablet; however, there appears to be an absence of 




The EDX data for the different UK metformin hydrochloride tablets summarised in Table 6.18. 
From the quantification data, it can be inferred that the different dosages of metformin 
hydrochloride tablets are of a similar elemental composition, with the exception of calcium in the 
Met/UK/1 tablet. This may be due to differences in formulation. The quantification results show 





Table 6.18: Comparison of Quantification data for UK Metformin Hydrochloride tablets. 
Element Concentration (%) 
Met/UK/1 Met/UK/2 
Carbon 50.08 49.25 
Nitrogen 36.96 37.96 
Oxygen 8.06 7.91 
Sodium 0.08 0.08 
Magnesium 0.07 0.06 
Silicon 0.35 0.24 
Chlorine 4.32 4.44 
Calcium 0.03  
Titanium 0.06 0.06 
 
Mapping indicates a high concentration of chlorine, which is widely distributed across the tablet; 
however, there are some regions with an absence of chlorine (Figure 6.27). Results also indicate 
the presence of titanium in a fine layer in the tablet coating, also there is an amount of magnesium 
present in the coating (Figure 6.28). 
 
Figure 6.27: Elemental map of Chlorine for Met/UK/2 






The EDX data for the Met/IND/1 – 5 tablets can be summarised in Table 6.19.  
Table 6.19: Comparison of EDX quantification data for Met/IND/1 -5 tablets 
Element Concentration (%) 
Met/IND/1 Met/IND/2 Met/IND/3 Met/IND/4 Met/IND/5 
Carbon 44.86 44.87 60.98 50.35 58.20 
Nitrogen 40.31 40.66 24.58 36.71 27.97 
Oxygen 9.86 9.65 10.61 7.90 10.10 
Sodium    0.08  
Magnesium 0.06 0.06 0.06 0.07  
Silicon 0.28 0.25 0.16 0.26 0.14 
Chlorine 4.60 4.47 3.53 4.56 3.53 
Calcium 0.03 0.03    
Titanium   0.09 0.07 0.06 
 
In general, the EDX data indicates similarities in the elemental composition between formulations and dosage for Met/IND/1 – 5 tablets. There is a marked 
difference between the standard and sustained release formulations; the concentration of carbon and oxygen is higher and the nitrogen and chlorine 
concentration is lower in the sustained release tablets. From the mapping data, chlorine is widely distributed throughout the tablet for all of the Met/IND/1 
– 5 formulations. There is a clear layer of titanium coating for the Met/IND/3 – 5 tablets, possibly indicating a difference in formulation to the Met/IND/1 




Table 6.20: Comparison of EDX quantification data for Met/IND/6 - 8 tablets 
Element Concentration (%) 
Met/IND/6 Met/IND/7 Met/IND/8 
Carbon 54.17 46.90 46.87 
Nitrogen 20.96 34.69 34.08 
Oxygen 19.92 14.16 14.70 
Sodium   0.11 
Magnesium  0.09  
Silicon 0.14 0.28 0.37 
Chlorine 11.88 3.87 3.87 
 
The Met/IND/6 sample tablet contained less elements /excipients than the other tablet 
formulations. The chlorine concentration is considerably higher than that of other tablets. 
Mapping shows small distinct areas of silicon and that chlorine is widespread throughout the 
tablet, but again in distinct regions. 
The Met/IND/7 and Met/IND/8 tablets are similar in composition and the quantification data is 
in good agreement, with slight differences in magnesium and silicon concentrations. 
The EDX data for the Met/IND/9 and Met/IND/10 can be summarised in Table 6.21. From the 
quantification data, it can be observed that the different dosages of metformin hydrochloride 
tablets are of a similar elemental composition, with the exception of calcium in the Met/IND/10 
sustained release tablet. This may be due to differences in formulation.  
Table 6.21: Comparison of Quantification data for Met/IND/9 and Met/IND/10 tablets 
Element Concentration (%) 
Met/IND/9 Met/IND/10 
Carbon 44.38 55.45 
Nitrogen 42.17 24.02 
Oxygen 8.84 17.49 
Sodium 0.10 0.20 
Silicon 0.09 0.13 
Chlorine 4.43 2.69 





The quantification results show differences in the atomic percentage of the two tablets, it is clear 
that the sustained release tablet is of a different formulation, whilst being of a similar composition. 
The data for Met/IND/10 is different to the sustained release formulations of another manufacturer 
(Met/IND/4 & 5) suggesting a different formulation. Mapping shows clear distinct regions of 
sodium that relates to large particles, suggesting the use of sodium croscarmellose as a 
disintegrant. 
The EDX data for the Met/IND/11 and Met/IND/14 – 16 can be summarised in Table 6.22. From 
the quantification data, it can be inferred that the different brands of metformin hydrochloride 
tablets are of a similar elemental composition, with the exception of the Met/IND/16 tablet and 
the presence of calcium in the Met/IND/15 tablet. This may be due to differences in formulation; 
however, this is consistent with other sustained release tablets. The Met/IND/16 sample identified 
fewer elements, suggesting that very few if any excipients are included in the tablet, indicating a 
different formulation; SEM images also indicated a difference in morphology for this particular 
tablet. 
Table 6.22: Comparison of EDX quantification data for Met/IND/11. Met/IND/14 – 16 tablets 
Element Concentration (%) 
Met/IND/11 Met/IND/14 Met/IND/15 Met/IND/16 
Carbon 58.32 59.28 57.54 62.76 
Nitrogen 21.56 22.06 22.42 18.82 
Oxygen 17.21 15.23 16.86 14.37 
Silicon 0.09 0.18 0.24  
Chlorine 2.82 3.25 2.91 4.06 
Calcium   0.02  
 
Mapping data indicates that chlorine is widely distributed across the tablets. One noticeable 
difference was observed for the Met/IND/15 tablet. Chlorine is distributed across the tablet; 





Figure 6.29: Elemental maps of Sodium and Chlorine for Met/IND/15 tablet. 
The EDX data for the Met/IND/12 & 13 tablets can be summarised in Table 6.23. From the 
quantification data, the different formulations of Met/IND/12 & 13 tablets are of a similar 
elemental composition. The quantification data differs, suggesting a different formulation. 
 
Table 6.23: Comparison of Quantification data for Met/IND/12 & 13 tablets 
Element Concentration (%) 
Met/IND/12 Met/IND/13 
Carbon 46.46 56.86 
Nitrogen 39.02 21.25 
Oxygen 10.24 18.19 
Sodium 0.10 0.08 
Silicon 0.26 0.66 
Chlorine 3.90 2.97 
Calcium 0.03  
 
Mapping data indicates a clear region of silicon in the Met/IND/13 map. 
 Saudi	Arabian	Tablets	
The quantification data for Met/SA/1 tablet is summarised in Table 6.24. The elemental 
composition is similar to that of the Met/IND/16 tablet from India, although the concentration 
element differs significantly. The EDX data indicates the possible absence of excipients in this 






Table 6.24: Quantification data for Met/SA/1 tablet 







The quantification of the API in single tablets was assessed by UV Spectroscopy and ATR FTIR 
Spectroscopy. The value measured by UV spectroscopy was taken as the analytical reference. 
The majority of the tablets analysed (atenolol and metformin hydrochloride) by UV Spectroscopy 
had API levels within either the EMA (90-110%) or the FDA (80-125%) acceptable ranges of the 
stated dose. The exceptions were the atenolol sample At/PAK/1 and the metformin hydrochloride 
samples Met/IND/7 and Met/IND/13, this could indicate substandard tablets. 
The same samples were analysed by ATR FTIR Spectroscopy, overall the quantification results 
for atenolol was low for the majority of tablets from the different countries. This may be due to 
interactions between the excipients and the chosen peak range used to quantify the atenolol, or it 
may stem from poor mixing and agglomeration issues. However, the metformin hydrochloride 
samples gave high quantification results; again, similar inferences concerning mixing can be 
drawn.  SEM results for atenolol showed signs of agglomeration and non-uniform particle size 
for metformin hydrochloride. 
Raman Spectroscopy was unsuccessful in producing reproducible quantification data for an API 
within a tablet; further work is required to investigate this further. 
Elemental analysis performed by EDX Spectroscopy, showed differences in the inorganic content 
of the tablet. Particular differences were observed for the samples At/UK/7, At/SA/1, At/SA/2 
and At/NEP/1; the blister packaging indicated these samples from the same manufacturer. The 
UK and Saudi Arabian samples were comparable to each other; however, the Nepalese sample 






This chapter is devoted to the discussion and comparison of results presented in the previous two 
chapters. Results for the various techniques will now be compared against one another, whilst 
considering the need to provide a rapid screening method to identify SF medicines in LIC and 
LMIC’s. 
The Raman, ATR FTIR and Mass Spectrometric techniques used in this study were all able to 
detect the target API’s provided the level in the tablet was greater than 1% w/w. 
 
7.1 ATR	FTIR	and	Raman	Spectroscopy	
When comparing the two techniques, Raman spectroscopy offers a non-destructive technique, 
which can analyse whole tablet formulations, whereas ATR FTIR is unable to analyse the whole 
tablet and requires the tablet sample to be crushed. Both techniques are complementary and can 
be used in a tandem, for example some formulations can provide different Raman and IR spectra 
due to some bonds being Raman active and IR inactive and vice versa (Schlűcker et al., 2003). 
The ability of the two techniques to identify different bonds is important if a molecule contains 
polar bonds for example an OH group, which is a strong IR absorber ATR FTIR spectra can 
become swamped by this signal, however as it is a weak Raman scatterer the sample can be 
successfully analysed by Raman.  
One limitation to Raman spectroscopy is the effect of fluorescence on the spectra, the fluorescence 
signal can overload and swamp the relatively weak Raman signal. This means that some coated 
samples and some API’s can give a misleading spectrum.  Sometimes the effect of fluorescence 
can be advantageous; Ricci et al., (2008) used this to distinguish falsified artesunate tablets. The 
API artesunic acid fluoresced, enabling the group to determine that tablets that give this signal, 
the API was absent from the sample. The effect of fluorescence can be mitigated by changing the 
excitation laser wavelength, the closer the wavelength is to the NIR region the lesser the effect 
(Horiba, 2017).  
The principal differences between the ATR FTIR and Raman spectroscopy can be summarised 
as: 
i) Raman is able to identify APIs in a whole tablet formulation whereas ATR FTIR cannot 
gain sufficient surface contact to give good spectra. 
ii) ATR FTIR has a fixed penetration depth, whereas the depth penetration in Raman 





iii) ATR FTIR can more readily provide quantitative data than Raman. 
iv) The Raman spectra generally have fewer peaks than IR. 
v) Raman spectra can be prone to the effect of fluorescence. 
vi) It is difficult to deal with mixtures due to the complex spectra produced. Generally, 
handheld Raman spectrometers failed for mixtures. 
It is also important to consider the ability to quantify the level of API in a single tablet. ATR FTIR 
spectra are easy to quantify using the OPUS software once a calibration plot has been generated. 
The ability to do this within the analysis software allows for rapid quantification of a single tablet. 
However, quantification of an API using Raman spectroscopy is not as simple as the method for 
ATR FTIR. Complex models are computed using multivariant analysis (PLS or PCA), these 
models are generated using large data sets on multiple batches of/and tablet repeats. Often the 
data used for multivariant analysis has been acquired using Surface Enhanced Raman 
spectroscopy (SERS). 
One example of the differences between techniques is for the API atenolol and the tablets 
At/IND/1 - 2 and At/IND/5 - 10. The ATR FTIR spectra suggests that the tablets are not identical 
in formulation, as the spectra are inconsistent with one another (Figure 7.1), with additional 
components between 3500 and 3800cm-1 and around 1000cm-1. 
 
Figure 7.1: ATR FTIR spectra of At/IND/1 (Green) and At/IND/5 (Blue 
This is surprising, as the samples are all from the same manufacturer, the only difference being 






The Raman spectra for the same samples indicates a difference between the 25mg and 50mg 
tablets (Figure 7.2). Using the excipient library created for this research, it is possible to infer that 
the difference in spectra was as a result of the presence of dicalcium phosphate (988cm-1). 
 
Figure 7.2: Raman spectra of At/IND/1 (Green) and At/IND/5 (Blue) 
Figure 7.3A and B compares the ATR FTIR and Raman spectra for At/IND/1 and At/IND/5. For 
the purpose of this comparison, the Raman spectra have been plotted on the same x-axis as the 












Figure 7.3: A) Raman spectra of At/IND/1 (Blue) and ATR FTIR spectra of At/IND/1 (Red), B) 
Raman spectra of At/IND/5 (Blue) and ATR FTIR spectra of At/IND/5 (Red) 
Whilst the pre-normalised Raman spectra were more intense, differences can be observed between 
the two types of spectra for the samples. One of the characteristic peaks for atenolol (1515cm-1, 
aromatic) is present in the ATR FTIR spectrum, but is absent in the Raman spectra. There are 








Figure 7.4: A) ATR FTIR spectra of At/SA/1 (Green), At/SA/2 (Blue), At/UK/7 (Purple) and 
At/NEP/1 (Yellow), B) Raman spectra of At/SA/1 (Green), and At/NEP/1 (Purple)  
 
The spectra obtained for the atenolol sample At/NEP/1 differs for the two techniques when 
compared to other samples from the same manufacturer. Figure 7.4 shows the ATR FTIR and 
Raman spectra for At/NEP/1 compared to comparable samples. The ATR FTIR spectra is 
identical to one another, whereas the Raman spectra show differences between At/NEP/1 and the 
other samples.  
The Raman spectra shows peaks at different positions (368cm-1 and 480cm-1) and an additional 
peak at 576cm-1. This may indicate the possibility of titanium dioxide in the coating or the 























the sample by X-ray Diffraction (XRD) would be able to confirm the presence/ absence of a 
polymorph. Variation in crystal structure may give rise to the additional peak at 576cm-1. This is 
a good example of the benefit of the sharp peaks for titanium dioxide in the Raman spectra, which 
can be clearly observed, versus the broad IR peaks, which can be masked by other excipients. 
Another example of the differences between Raman and ATR FTIR spectra is the antimalarial 
sample AM/ZIM/4.  Whole tablets from the AM/ZIM/4 sample were analysed, multiple tablets 
were analysed with varying success. Both techniques could identify differences in peak intensity 
and shape for the samples, however the peaks were harder to distinguish in the ATR FTIR spectra 
(Figure 7.5A), this is due to ATR FTIR being a surface technique (Bugay and Brush, 2001 and 
Planinšek et al., 2016) and the limited depth of sample penetration. The spectra for the crushed 


















Figure 7.5:  A) ATR FTIR spectra of AM/ZIM/4 tablet 1 (Green), tablet 2 (Blue), tablet 3 (Purple) 
and tablet 4 (Yellow), B) ATR FTIR spectra of AM/ZIM/4 whole (Blue) and crushed (Green) 
 
The Raman spectra for AM/ZIM/4 showed differences between the tablets, particularly tablet 1 
(Green) and 5 (Red) (Figure 7.6). The ratio of peaks for the excipient titanium dioxide and the 






Figure 7.6: Raman spectra of AM/ZIM/4 tablet 1 (Green), and tablet 5 (Red) 
The spectrum for tablet 1 suggests a higher concentration of titanium dioxide, whereas the 
spectrum for tablet 5 infers a higher concentration of API within the tablet. These differences may 
be attributed to the surface coating and distribution of API and excipients within the tablet, or 
may indicate the possibility of a difference in the level of API within the tablet. Further analysis 
by SEM/EDX would enable the amount of titanium in the samples to be quantified. 
 
 
Figure 7.7: Raman Spectra for AM/ZIM/4 whole tablet (Blue) and powdered (Red) using the 
FORAM-2 spectrometer 
Clear differences between the powdered and whole tablets (Figure 7.7) were observed for the 





































showed some peaks at a slightly different wavenumber and others absent. The peaks at 394cm-1, 
518cm-1 and 638cm-1 for the whole tablet can be attributed to titanium dioxide; this may be due 
to the coating of the tablet. The peaks at 1362cm-1 and 1430cm-1 for the whole and powdered 
tablets are characteristic of quinine sulphate.  
This data for the AM/ZIM/4 quinine sulphate tablets are an example of the limitation of Raman 
spectroscopy. The samples are from the same identical batch, yet the Raman spectra (Figure 7.6 
and Figure 7.7) indicate differences in the nature of the sample. Peaks observed in the whole tablet 
spectra indicate the presence of titanium dioxide, the intensity of these peaks vary amongst the 
batch of tablets. This variation indicates a difference in the thickness of the coating layer, 
suggesting poor QC during manufacture. The spectrum for the powdered sample confirms that 
titanium dioxide is contained within the coating layer of the tablet, as the peaks for it are absent. 
The intensity of the quinine sulphate peaks also varies within the batch. Modern Raman 




This research compared the application of handheld and benchtop Raman spectrometers to 
identify a target API within a tablet. This was met with varying levels of success. The three 
different spectrometers used to analyse atenolol, were all able to identify the API using an 
analytical reference standard. However, the MIRA-3 handheld spectrometer struggled to obtain a 
spectrum for the tablet samples, both whole and crushed; this was due to the effect of fluorescence.  
The other handheld spectrometer (BRAVO) was able to compensate this effect due to the dual 
wavelength capability and therefore could generate a meaningful spectrum. A study by Assi, 
(2015a) confirmed the outcomes in this research regarding fluorescence and dual wavelength 
spectrometers. The group were able to mitigate the effect of fluorescence for antimalarials by 
using a dual wavelength spectrometer, as was found in this study by comparing the MIRA-3 and 







Figure 7.8: Raman spectra of atenolol (analytical standard) using BRAVO handheld spectrometer 
(Red) and FORAM-2 spectrometer (Blue) 
 
The spectra obtained for the benchtop system (FORAM-2) showed small differences when 
compared to the handheld spectrometer (BRAVO) (Figure 7.8). Peaks at 2180cm-1, 2744cm-1, 
2890cm-1 and 3106cm-1, could be observed using the FORAM-2 spectrometer but are absent in 
the BRAVO spectrum. The spectra for the handheld and benchtop spectrometers were comparable 
to one another with the FORAM-2 identifying the extra peaks for the API atenolol. Differences 
between handheld and benchtop spectrometers has been observed by other groups (Bugay and 
Brush, 2010), whilst the advent of the handheld spectrometer takes ‘the laboratory to the sample’ 
(Assi et al., 2015b), the handheld spectra can appear noisy as the signal to noise ratio is poor and 



























Figure 7.9: Raman spectra of metformin hydrochloride (analytical standard) using FORAM-2 
spectrometer (Blue) and MIRA-3 handheld spectrometer (Green) 
The API metformin hydrochloride was analysed using two different spectrometers (MIRA-3 and 
FORAM-2). Whilst both spectrometers could identify the API, clear differences could be 
observed between the spectra, notably peak intensity and the effect of fluorescence. As with 
atenolol, the MIRA-3 was prone to this effect when analysing metformin hydrochloride, however 
unlike with atenolol the peaks were well resolved and defined (Figure 7.9). 
 
 
Figure 7.10: Raman spectra of Met/IND/13 (Green) and metformin hydrochloride analytical 







































Tablets that contained multiple API’s, for example Met/IND/13, which contained 5mg of 
glipizide and 500mg metformin hydrochloride, showed no difference between the sample and 
analytical reference. The glibenclamide was unable to be detected by Raman spectroscopy (Figure 
7.10); this is because the API glibenclamide is at a low concentration within the tablet (~2%) as 
opposed to ~80% of the API metformin hydrochloride. As a result of the metformin hydrochloride 
tablets containing a high percentage of API, there are no obvious excipient peaks in the spectrum. 
 
 
Figure 7.11: A) ATR FTIR spectra of Met/IND/2 (Blue) and Met/IND/4 (Green), B) Raman 























Differences in spectra were observed for standard and extended/ sustained release tablets using 
ATR FTR, this is due to differences in formulation (Figure 7.11A). The ATR FTIR spectra 
showed differences between the standard release (Met/IND/2) and the extended/ sustained release 
(Met/IND/4) (Figure 7.11A); extra peaks are due to the additional compound being IR active, 
whereas the Raman spectra (Figure 7.11B) showed little or no difference, suggesting the addition 
of Raman inactive material. 
Both techniques (Raman and ATR FTIR) an are capable of single tablet analysis, which is 
important in this research. 
 
7.2 UV	and	ATR	FTIR	Spectroscopy	
UV analysis of an API is an established methodology that is used by the BP and other 
pharmacopoeias to assay various APIs to ensure quality control specifications are met. Analysis 
by UV often resorts in a large quantity of tablets being used for analysis, for example, the BP 
2017 requires 20 tablets of atenolol for the assay. Whilst in HIC and QC laboratories this does 
not present a problem, in LIC and LMIC the reality is a patient/ healthcare provider does not have 
this volume to analyse. They often only have a small amount and rarely can be spared; the majority 
of tablets obtained from India for this study were sold in ‘fortnightly’ 14-day blister packs.  
Another issue with the UV assay test is that if there were variation within a batch, this would not 
be detected, as the overall result is an average of the 20 tablets. Single tablet analysis allows the 
quantification of the API of a single dose, this is important, as a patient is unable to normalise the 
level of API, as is done by batch quantification. The individual would be susceptible to 
fluctuations in the level of API and may not receive the correct dosage. 
UV analysis requires solvent extraction of the API and can often be time consuming. The 
proposed rapid methodology of quantification of an API by ATR FTIR is a novel technique   for 
the application of atenolol and metformin hydrochloride.  It offers ‘single tablet’ capability and 
analyses both API and excipients, as opposed to just the API as with UV analysis. 
UV analysis responded as expected for all of the tablets analysed for both atenolol and metformin 
hydrochloride. Using and adapting the methodology outlined in the BP 2017, it was possible to 
quantify the level of API in a single tablet for atenolol and metformin hydrochloride. 
The quantification results by UV analysis for atenolol tablets ranged from 74% to 122% of 
percentage API content. The majority of samples fell within the acceptable limits as outlined by 





When comparing the UV quantification results with the ATR FTIR quantification results, several 
observations can be made. The UV measurements were all trended to the upper limit set by the 
BP or above this limit for percentage content of atenolol, whilst there is a general trend of the 
ATR FTIR data towards the lower value of API content. Figure 7.12 compares the quantification 
data obtained for both UV and ATR FTIR analysis. The data for the Indian samples At/IND/1, 
At/IND/2 and At/IND/11, show a concentration effect, as the results analogues to the Beer 
Lambert Law, additional work is required to investigate this further. 
 
 
Figure 7.12: Percentage of stated dosage of Indian atenolol tablets as calculated by UV (X) and 
ATR FTIR (X) with EMA (--) and FDA (--) limits 
Whilst both methods identified substandard tablets, the API content as calculated by ATR FTIR 
was generally lower. One factor that may attribute to these values being lower is a limitation of 
this technique; samples need to be crushed and sufficiently mixed/homogenised, Particle size and 
homogeneity is critical and agglomeration of particles can affect this. Salari and Young (1998) 
reported that not attaining a ‘perfect mixture’ affects the quantification of powders. It is possible 
that the atenolol agglomerated and thus caused issues with the calibration plots, resulting in low 
quantification values. It is important to ensure that the crushed sample is mixed and homogenous 
sufficiently, in order to allow for uniformity of particle size. 
The quantification data for metformin hydrochloride, as analysed by UV analysis ranged from 
78% to 137%, with the bulk of the samples falling within the acceptable limits as outlined by the 
EMA (90% to 110%) and FDA (80% to 125%). Those that fell outside of the range were generally 
lower with the exception of Met/IND/7, which was significantly higher than expected. This may 


























broken and appeared to be of poor quality within the blister packaging.  In contrast to the atenolol 
results, the metformin hydrochloride samples analysed by ATR FTIR trended towards the upper 
limit (105%) and above.  
This again may be due to poor mixing and /or choice of excipient for the calibration mixtures; 
metformin hydrochloride tablets contain a large percentage content of API, in this study the 
percentage content of API ranged from 70% to 95% of the total tablet weight. Metformin 
hydrochloride tablets can be classed as containing a high percentage concentration of API; 
because of this, there are no obvious excipient peaks in the ATR FTIR spectra, as discussed in 
the previous section. Since the percentage API content within the tablet is so high and few 
excipients are used in the formulation, selection of the calibration excipient is important. Maize 
starch was selected for this study as it is present in the highest concentration within a tablet, 
however due to the API concentration being considerably higher, this may have influenced the 
calibration plot particularly at high excipient concentrations, resulting in a low R2 value (0.8915) 
and poor linearity. However, this methodology does have potential as shown by Lawson et al., 
(2014a); it can be applied to the quantification of other API’s, in particular paracetamol, which 
occurs at comparable levels (85%) in tablets. The technique does have the potential for the 
quantification of atenolol and metformin hydrochloride, further work is required to investigate 
optimum mixing and excipient interactions. Whilst ATR FTIR provides a rapid screening 
methodology for quantification and identification of a target API within a tablet, it is important 
to cross-reference any new method against an established one to ensure its viability.  
Identification of atenolol and metformin hydrochloride reference material by ATR FTIR and 
Raman in the presence of excipients was possible at >5% w/w and is viable within 5 minutes, as 
opposed to 30 to 60 minutes for UV analysis. Quantification of the target API can be obtained 
from the same sample within the same analysis time. 
 
7.3 Mass	spectrometry		
Results from DIP MS showed promise and the technique can be used to identify the components 
of mixtures of APIs in a sample. This technique enabled compound specific data to be obtained. 
The target API’s in the antimalarial samples analysed for this study were identified by DIP MS. 
The spectral data was generally quite simple, often with only two or three data points being 
produced per API identified. Further work is required to develop this as a novel technique for the 
application of identifying SF medicines. One significant limitation to this study was the reliability 
of the equipment. A consequence of the DIP, is that it is directly inserted into the MS source; 





availability of parts (in this case the ion volume) and specialist knowledge to remedy any issues 
hindered the throughput of samples and availability of this technique. 
 
7.4 Elemental	Analysis	
Elemental analysis by EDX is limited, as it is only a surface technique and can be time consuming 
to section and mount the tablet samples. A significant limitation is the inability to detect lighter 
elements; though newer, more expensive detectors are able to detect boron and lithium. 
 
 
Figure 7.13: Elemental maps of Calcium and Phosphorous for At/IND/1 
However, this technique is successfully able to deformulate a tablet, by mapping the spatial 
resolution of the elemental composition and quantifying the data. By combining the mapping and 
the quantification data, it is possible to infer the excipient composition of some formulations. An 
example of this is the samples At/IND/1 and At/IND/2. Raman spectroscopy identified the 
presence of the excipient dicalcium phosphate; EDX mapping data was able to confirm the 
presence of this excipient in the sample cross section (Figure 7.13).   
 
Whilst there is an absence in published literature of the application of SEM/EDX to identify SF 
medicines, substantial work is required to validate this novel technique as worthwhile.   Though 
EDX analysis cannot determine the chemical composition and spatial distribution like Raman 









Table 7.1 summarises the various analytical methods used in this research. The majority of these 
methods can be classed as rapid, with UV, DIP MS and SEM/EDX requiring a longer analysis 
time. ATR FTIR spectroscopy was able to both identify and quantify the API in a crushed a tablet, 
whereas Raman spectroscopy was able to identify the API in both a whole tablet and powdered 
sample. However, Raman spectroscopy was unable in this research to quantify the amount of API. 
Both types of MS analysis investigated in this research was able to identify the API in a powdered 
sample. Whereas SEM/EDX did not identify the API, however it was able to give the spatial 







Table 7.1: Comparison of various analytical methods with respect to tablet sample analysis 
Analytical Method Sample Technique Sampling 
Depth 
Detection Capability Analysis 
Time 




Bulk Able to quantify the amount of API in a tablet to 0.1% of 
tablet weight  
>30 minutes 
ATR FTIR Identification Powder Fingerprint Surface Identified all of the target API’s ~2 minutes 
Quantification Powder Peak Area Surface Detection limits are 5 % for atenolol & 10% for metformin 
hydrochloride 
< 5 minutes 




Identified all of the target API’s and some excipients ~2 minutes 
Quantification Powder Peak Height Sample 
dependent 
Calibration data gave poor linearity. Further work is required. < 5 minutes 
DIP MS Identification Powder m/z value Bulk Identified atenolol and the antimalarials chloroquine 
phosphate, quinine sulphate, lumefantrine, further work to 
alter the scan range would enable artemether, sulphadoxine 
and pyrimethamine to be detected. 
10 – 15 
minutes 
ASAP MS Identification Powder m/z value Bulk Identified atenolol, sulphadoxine and pyrimethamine. ~ 5 minutes 
SEM/EDX Elemental data Tablet  Surface Elemental spatial distribution over the surface of a cross 










Whilst it is important to consider what information the individual/ combined techniques give the 
analyst; significant consideration should be given to the application if these techniques to LIC’s 
and LMIC’s. Several factors need to be considered before any methodology could be 




 Specialist knowledge 
 Additional materials. 
The issue of the cost of the equipment is a significant factor in being able to apply any new 
methodology to identify SF medicines.  Table 7.2 shows the estimated cost for the equipment 
used in this study and for the equivalent handheld equipment; the costs shown exclude 
consumables and training. 
Table 7.2: Estimated cost of equipment in the UK 
Technique Cost (Excluding VAT) (£) 
Lab Based Benchtop (Portable) Handheld 
UV  10,000 – 15,000  
ATR FTIR  15,000 – 20,000  
Raman  ~70,000 35,000 – 65,000 
Raman Microscopy  160,000  
SEM/EDX 150,000 + 75,000 – 100,000  
GCMS with DIP 50,000 + 50,000  
 
The cost of equipment varies significantly ranging from the ‘relatively’ cheap UV spectrometers 
to the expensive SEM and Raman microscopes. The handheld Raman and benchtop ATR FTIR 
spectrometers are priced somewhere in the middle. The cost of any equipment used to detect SF 
medicines in LIC and LMIC would consume a large amount of capital, and all aspects would need 
to be considered before any purchase. The running costs and available infrastructure to support 
the equipment is another factor.  
Some countries in Africa do not have the infrastructure to support large pieces of equipment that 
would require a constant source of power, even in standby mode. Höllein et al., (2016) cited 
concerns with the lack of infrastructure in some African countries when setting up an analytical 
laboratory. In reality, not all LIC and LMIC have the infrastructure for a full-scale analytical 
laboratory, so ideally ‘portable’ and handheld equipment need to be considered. This would rule 





to ensure the system is continually kept under vacuum. A visit to the Pharmacy and Poisons Board 
in Kenya in 2017 by Tanna and Lawson indicated that laboratories were in fact available but with 
neither staff nor equipment. 
The issue of usage of solvents in a technique and the requirement of other consumables is 
important. The cost of solvents, availability, grade (analytical, ultra-pure) and cost of disposal 
should be considered. Some solvents are expensive in the UK and can sometimes be in short 
supply, for example acetonitrile in 2009. The availability and grade of solvents in LIC and LMIC 
cannot be guaranteed, for this reasoning UV analysis can be discounted as a technique to detect 
SF medicines in LIC and LMIC. 
The availability of expertise and specialist knowledge should be considered. Adequately trained 
personnel may not be available and as a result of this it is important that any technique 
implemented can essentially be ‘pass or fail’. ATR FTIR and Raman spectroscopy can be 
implemented as sample preparation is simple and the spectrum for any sample analysed can be 






Review of the results obtained from the current investigation into rapid screening methods to 




In the UK, there are significant price differences between proprietary and ‘super market own’, 
brands of common OTC medicines. Throughout much of the world, a similar situation is common 
in pharmacies for medicines normally available only on prescription in the UK. Recently in 
Nairobi (2017), for example, atenolol tablets were purchased from a pharmacy at different costs 
per tablet. This situation creates the opportunity for the replacement of one product by another 
and also the challenge to identify that this exchange of one formulation for another has occurred. 
The Raman, ATR FT/IR and EDX techniques, detailed in previous chapters, were used to identify 
examples of atenolol tablets mislabelled as a proprietary product. 
 
 Raman	Analyses	
67 tablet samples were analysed as detailed in Section 4.3.4 and the PCA plot derived from this 
data (Figure 8.1) is shown below. The yellow group on the right of the plot were a proprietary 
brand with 3 examples from 2 different countries within this grouping. The yellow group at the 
top of the diagram (AT/NEP/1) whilst packaged as the proprietary medicine were clearly different 
to the other samples. Within the much larger grouping in the centre of the diagram was the data 







Figure 8.1: PCA Plot of the Raman spectra for whole At/UK/7 (Yellow), At/SA/1 (Yellow), 
At/SA/2 (Yellow), At/NEP/1 (Yellow) and other generic atenolol tablets (Blue) 
Clearly, there is a difference between these two groups of supposedly the same proprietary 
formulation. Figure 8.2 clearly shows increased levels of titanium dioxide on the surface of the 
three proprietary tablet samples from the UK and Saudi Arabia. 
 

























The Raman spectroscopy of tablet formulations is frequently affected by fluorescence, the extent 
of which is dependent on the nature of the formulation i.e. the excipients present in the tablet. The 
fluorescence spectra of the tablets can therefore be used as an indicator of the excipients used in 
the tablets under investigation. The data in Figure 8.3 shows that the proprietary tablet examples 
have low but very reproducible fluorescence spectra whereas the spectra for all the other examples 
exhibited a much greater intensity across the spectral range studied. The ‘suspect’ proprietary 
labelled tablets showed a fluorescence spectrum similar to but somewhat different to the spectra 
for the general group of generic medicines. 
 
 
Figure 8.3: Raman Spectra of whole At/UK/7 (Yellow), At/SA/1 (Yellow), At/SA/2 (Yellow), 
and At/NEP/1 (Red) tablets 
 
 ATR‐FT/IR	Analyses	
Comparison of the ATR spectra showed little difference between the spectra of the crushed tablet 


























Figure 8.4: ATR FTIR Spectra of crushed At/SA/1 (Green), At/SA/2 (Blue), At/UK/7 (Purple) 
and At/NEP/1 (Yellow) samples 
 
 SEM/EDX	Analyses	
Elemental analysis also showed differences in the data. The results (Table 8.1) for At/NEP/1 show 
a similar elemental composition to other samples manufactured by the same company (At/UK/7, 
At/SA/1 and At/SA/2). However, it is not identical, the quantification results differ to the other 
samples, the carbon and oxygen ratio differs, and the presence of nitrogen alters this ratio. There 
is also a higher concentration of magnesium. Mapping indicates magnesium is distributed across 
the tablet; however, there appears to be an absence of any distinct titanium dioxide present in the 
coating. 
Table 8.1: EDX quantification data for cross-sectioned atenolol tablets by the same manufacturer 
Element Concentration (%) 
At/UK/7 At/SA/1 At/SA/2 At/NEP/1 
Carbon 58.53 61.81 59.33 48.47 
Oxygen 38.22 35.97 38.28 43.45 
Nitrogen    4.09 
Sodium  0.08 0.07 0.10 
Magnesium 3.20 2.10 2.28 3.89 







From this study it appears that sample  At/NEP/1may be either 
 A mislabelled tablet, 
 A falsified tablet. 
A tablet in the wrong box would give a Raman PCA signal in the main grouping. Clearly, this is 
not the case; the sample is clearly not simply mislabelled.  
DIP mass spectrometry confirmed only the target API to be present and UV/Vis analysis 
confirmed the expected level of API to be present. 
A deliberate or accidently change to the formulation cannot be determined. 
This is however, a clear indication of the values of the combined approach to the investigation of 
substandard and falsified medicines. 
The elemental analysis for substandard and falsified medicines is a novel concept. EDX 
spectroscopy has not yet been applied to this area of research. Raman and ATR FTIR analyses 
have been used extensively to investigate counterfeits by focussing on the identification of the 
API. One unique focus of this work is the use of these techniques to identify a falsified 






As a result of the experimental work performed and a review of the results obtained, the following 
areas have been identified where scope exists for future work: 
 Further analysis is required to confirm if the samples identified by this research are 
substandard or not. 
 
 To investigate the mixing issues presented for the quantification of an API by ATR FTIR 
and the selection of excipients for calibration mixtures. 
 
 Raman spectroscopy showed promising results, to enable this as a rapid screening method 
for atenolol and metformin hydrochloride, further work is required to investigate 
quantification of an API. 
 
 To apply ATR FTIR and Raman to other API’s and determine if it is possible to quantify 
the API.  
 
 To investigate the potential of SEM/EDX in deformulating a tablet and look to develop 
the novel technique. Also, investigate the use of cathodoluminscence in identifying SF 
medicines. 
 
 All new methods need to be proven, any potential rapid techniques need to be validated 
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Is it what it says on the packet? ATR FTIR
provides a rapid answer to counterfeit tablet
formulations
G Lawson, E Turay, R Armitage, L Goodyer and S Tanna
1. Introduction
How many people would question the reliability of a
packet of paracetamol or even atenolol bought whilst
away on holiday?
Counterfeiting of medicines is a global phenome-
non that affects both developed and developing
countries and especially in medicines sourced via the
internet.1 In the UK the level of counterfeit medicines
is thought to be between 1 and 2% whilst elsewhere in
the world figures as high as 40% are cited by the
WHO. A counterfeit medicine is a medicine which is
deliberately and fraudulently mislabelled in regards
to identity and source which apply to both branded
and generic products. Products may or may not have
the correct excipients, exclusion of active pharmaceu-
tical ingredient (API) or insufficient quantities of API
or fraudulent packaging. The effects of counterfeit
medicines on patients can range from the difficult
to detect and quantify to an important cause of
unnecessary morbidity, mortality and loss of public
confidence in medicines and the health systems.
In recent years more and more incidents of deaths
resulting from sub-standard or counterfeit medicines
have been reported. Recently in Pakistan, for example,
more than 400 deaths were thought to have resulted
from counterfeit cardiovascular medication. The iden-
tification of these materials causes problems for the
regulatory authorities both in the Healthcare Supply
Chain and also for Border Agency staff. The problem
with international visitors is particularly acute for
countries like Saudi Arabia, where large numbers of
pilgrims often bring excess medicines with them
which need to be rapidly assessed.
Rapid assessment implies a screening process
rather than the time consuming in depth analyses
offered by conventional laboratory equipment such as
GC-MS or NMR.2 The first step is a visual assessment
of barcodes or more frequently now the use of two
dimensional barcodes read by smart phones. This
provides rapid communication between supplier,
importer and the border agency but is however only
limited to assessing the packaging rather than the con-
tents. Chemical test kits are limited to specific active
ingredients, a problem not faced by a portable Raman
spectroscopy system which is being trialled in this
area and can be programmed for many APIs.3 Costs
and concerns about the robustness of the system have
raised some concerns. 
In this paper an alternative spectroscopic system
Fourier Transform Infra-Red (FTIR) spectroscopy
utilising Attenuated Total Reflection (ATR) sampling4
has been investigated. FTIR systems form the basis of
compound identification in the British Pharmacopoeia
(BP)5 and the combination with the ATR sampling
system removes the need for any prior solvent extrac-
tion to separate the API from the excipients. A tablet
formulation would simply be finely powdered and
a small sample of the API + excipients powder
placed on the ATR window and the resultant
spectrum produced. As can be seen from Figure 1
the spectrum obtained for caffeine from the tablet
formulation is virtually indistinguishable from the
spectrum obtained from the reference material.
Figure 1
Comparison of reference (red top) and tablet samples
for Caffeine.
This approach therefore appears to provide a
‘fingerprint method’ to rapidly assess if the expected
API is present in the dose format being tested. An
assessment of the API dose level may also be made
from the intensity of the peaks characteristic of the
API of concern. This determination would be depend-
ent on the detection capabilities of the ATR FTIR
system and very low dosage levels may not be
currently detectable.
2. Experimental    
2.1 Instrumentation
The ATR FTIR spectra were recorded using a Bruker
Alpha system equipped with a platinum diamond sin-
gle reflection sampling station. Spectra of each sample
were collected at a resolution of 2cm-1 over the range
400 – 4000cm-1. Replicate spectra, a minimum of three,
were collected for all calibration and trial samples.
The BP based analyses were run on a Thermo Electron
Helios Omega UV/Vis instrument using Vision Lite
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2.2 software.
2.2 Chemicals and sample preparation
The reference samples: caffeine, atenolol and parac-
etamol were > 99% analytical grade, whilst the
excipients used to prepare the calibration mixtures
were all pharmaceutical grade. The excipients used
included hydroxymethyl cellulose, titanium dioxide
and magnesium stearate.
Reference spectra of the authentic APIs were pro-
duced from finely ground samples placed on the ATR
sample station. The FTIR system was zeroed prior to
each sample series.
For the quantitative calibration samples several
single excipients were used for individual experi-
ments since the excipients in the test samples would
be unknown. Powder quantitative calibration and val-
idation samples were prepared by mixing suitable
amounts of the API and excipient to cover the nor-
mally encountered dosage range. These calibration
samples are expressed as a percentage by weight of
the API in the excipient. The anticipated ranges were:
Paracetamol 30-80% w/w and Atenolol 10-40% w/w
based on the tablets studied. After mixing using a pes-
tle and mortar to ensure homogenisation powder
samples were placed on the ATR station and replicate
spectra were recorded. This process was repeated for
several different samples taken from the calibration
mixture to ensure reproducibility. Quantitative data
was obtained from the Opus 6 software for spectral
peaks characteristic of the target APIs to produce
calibration data for the subsequent analyses.
Samples for the BP analyses were prepared as
detailed in the British Pharmacopoeia 2010 modified
for single tablet analysis.
Strips of tablets of both paracetamol and atenolol
were obtained adventitiously from pharmacies in the
UK, Pakistan, and India. These trial samples were
identified as follows:
• Paracetamol – UK: 4 x 500mg and
India: 5 x 500mg 
• Atenolol – UK: 3 x 50mg, Pakistan 3 x 50mg +
1 x 100, India 2 x 50mg + 1 x 25mg
3. Results and Discussion
3.1 Identification of the API
The overlay spectra in Figures 2 and 3 comparing the
spectrum of the neat API with that obtained from a
typical pill formulation, show that the anticipated API
can be readily identified to be present. The correlation
between the spectra confirms that no other API is
present at significant levels.
3.2 Determination of the dosage level
ATR measurements are affected by the degree of sur-
face contact between the sample and the sampling
diamond and a fine powder sample is therefore
important for reproducible data. Furthermore, as seen
by Mazurek,3 increasing the number of samples
analysed will improve the data as shown in Table 1
where the r2 regression coefficient from different
calibration diagrams demonstrates these effects.
Table 1
Methods to improve reproducibility
–––––––––––––––––––––––––––––––––––––––––––––––







ATR-FTIR spectrum in absorbance mode of UK tablet
(blue) and pure Paracetamol reference (red)
Figure 3
ATR-FTIR spectrum in transmission mode of UK tablet
(red) and pure Atenolol reference (blue)
Once suitable calibration data has been obtained
the percentage level in the tablet formulation can be
derived and the actual dosage level calculated from
the mass of the pill.
The results derived from this investigation are
shown in Table 2.
Once the calibration data has been prepared the
identification and quantification of the target API is
Is it what it says on the packet? continued
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generally available within 5 minutes of opening the
tablet packet. As can be seen the results for the UK
tablets show good agreement. Two of the paracetamol
samples from India are not as expected, one with a
low dose 438mg vs 500 and more surprisingly one at
628 vs 500mg. The measured doses in all the atenolol
samples from Pakistan were lower than stated on the
packet and these samples were analysed using the
BP method to confirm these findings. The results
obtained for the Pakistan atenolol samples were #A
34mg and #B 61mg confirming the ATR data.
Table 2
Quantitative analysis results
Note all results subject to a 10% error.
3.3 Discussion
The results demonstrate the potential of the ATR FTIR
approach to rapidly assess the actual components of a
medicine against those stated. This approach provides
a regulatory authority with the means to rapidly iden-
tify a suspect material using only bench top analytical
equipment with no consumables other than electricity.
Further analysis would be required to confirm the
presence of either a substandard or counterfeit
material.
The cardiovascular tablets were obtained from
Pakistan shortly after the problems in this area were
reported and the measured low levels of atenolol may
be related to these incidences. 
The substandard levels of paracetamol and
atenolol may well be the results of poor mixing at the
production stage and it is unlikely that these tablets
would provide therapeutic levels of the relevant drug
under the prescribed conditions.
The elevated paracetamol level found in one set of
samples from India would be of concern for people
prescribed 8 or more tablets a day where the total dose
would be around 5024 mg rather than the 4000
expected.
This work provides further evidence regarding the
poor quality of some of pharmaceuticals available in
many developing countries.6 It is quite likely that this
is due to issues relating to poor quality control of the
manufacturing processes and the impact on the health
of the population in such countries is hard to quantify.
For the traveller visiting such areas this data serves as
a warning that wherever possible medicines should be
purchased before departure, including items such as
paracetamol used to treat minor conditions.
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• The World Health Organisation (WHO) estimates that ~10% of medicines globally are either Substandard or Falsified (SF)1.
• To protect the public there is a genuine need for rapid “single tablet capable” qualitative and/or quantitative analytical method.
• Counterfeiters have been known to use low amounts of active pharmaceutical ingredient (API) in their products to enable them to pass 
qualitative screening tests. As a result, patients receive sub therapeutic doses of the drug, leading to ineffective treatment, therapeutic failure and 
even drug resistance2.
• Counterfeiters are finding ways to bypass established quality control (QC) techniques, therefore the development of new techniques is required.
• The overall aim of this project is to develop Attenuated Total Reflectance Fourier Transform Infrared  Spectroscopy (ATR FTIR), as a rapid 
instrumental method to identify and quantify the API in tablet formulations.
• This method (Figure 1) can be applied to the analysis of tablets available globally.
• UV analysis of single tablets was based on to the British Pharmacopeia 2017 methodology and used as a reference method.
• This research assessed quantitatively the level of either atenolol or metformin hydrochloride in tablets from various sources.
REFERENCES
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• This research demonstrates that ATR FTIR can be used as a rapid method for  identifying and quantifying the target API (atenolol and 
metformin hydrochloride) in a crushed tablet formulation using characteristic peaks.
• Both UV and ATR FTIR analyses identified tablets exhibiting API levels indicative of poor quality control.
• This methodology reduces sampling time per tablet from an hour using conventional techniques, such as UV to < 10 minutes.
• One limitation to this technique is the requirement of ensuring the crushed sample is sufficiently mixed/ homogenised.
Weigh and crush test
tablets
Prepare calibration mix 
samples





Two approaches to rapid detection:
A) QUALITATIVE – simple fingerprint 
match under the same analytical 
conditions
B) QUANTITATIVE – determination of 
the level of API or other components
Figure 1: Preparation and analysis of test sample 
Figure 2: Percentage of stated dose of atenolol for different tablets 
measured by ATR FTIR and UV
Figure 3: Percentage of stated dose of metformin for different tablets 
measured by ATR FTIR and UV
• Tablet samples are powdered using a pestle and mortar, analyses were run using a Bruker Alpha ATR FTIR system and measured over the 
range of 4000 – 400cm-1 with 2cm-1 resolution.
• Peak area measurements were taken at 858 – 758 cm-1 for atenolol and 1605 – 1501 cm-1 for metformin hydrochloride.
• Both methods identify substandard tablets, in particular the atenolol tablet  PAK1 (Figure 2). 
• Analysis of atenolol and metformin hydrochloride tablets was performed on individual tablets from the same batch.
• The API for the tablets analysed (atenolol and metformin hydrochloride) was identified in all test samples.
• Results shown are percentage of stated dose for atenolol (Figure 2) and metformin hydrochloride (Figure 3).
• In general, the ATR FTIR (X) and UV (X) agree for the tablet batches tested.
1. #DMUengage #DMUglobal visit to Kenya - June 2017
3. Types of counterfeit medicines
2. Counterfeit medicines - Introduction
4. Impact on patients of counterfeit medicines
7. DMU research on the rapid detection of counterfeit medicines
• The growing menace of fake or substandard medicines presents a serious
and increasing threat to patient safety and public health globally.
• Counterfeit medicines are a multibillion pound business, that increasingly
threatens the effective delivery of health care services.
• The WHO reports that ~10% of medicines worldwide are counterfeits and
this figure rises to ~30% in countries in Africa and ~50% for medicines pur-
chased via the internet.
• Both generic and branded medicines are targeted by counterfeiters.
• In Africa counterfeit medicines have flourished due to the emergence and
resurgence of many infectious diseases, particularly the three major killers:
malaria, HIV/AIDS and tuberculosis. 
• According to the WHO more than 120,000 people a year die in Africa as a re-
sult of fake or substandard anti-malarial drugs alone.
• Thus there is a need for a simple rapid screening process to identify suspect
medicines, especially in a tablet dosage form.
8. Outcomes to date
• #DMUengage award to Dr S. Tanna
• #DMUglobal for funding student bursaries and Dr S. Tanna
• Mr Peter Chimkupete (School of Allied Health) at DMU
• Dr Richard Njoroge - Chief Pathologist at the Kenya National Public Health
Laboratory
• Dr Shahin Sayed at the Aga Khan University Hospital, Nairobi, Kenya
#DMUengage - Helping people in Africa stay clear of
fake and substandard medicines
Sangeeta Tanna, Graham Lawson, Rachel Armitage, John Ogwu   




5. How is a counterfeit medicine identified? 6. Methods for the identification of counterfeit medicines
• DMU carries out research in all areas shown* in 6 above.
• ATR-FTIR / Raman are investigated for rapid medication investi-
gation.
• Mass spectrometry based techniques are used for confirmation
and therapeutic drug monitoring investigations.
DMU has two approaches to rapid detection:
(A) QUALITATIVE ANALYSIS
• Simple qualitative fingerprick match under similar analytical con-
ditions.
(B) QUANTITATIVE ANALYSIS
• Quantitative determination of the level of active pharmaceutical
ingredient (drug) or other components.
• Exchange of information on counterfeit/substandard medicines between DMU
and the following Kenya Ministry of Health departments:
• Pharmacy and Poisons Board
• National Quality Control Laboratory
• Student experience with Kenyan hospital pharmacy departments at:
• Aga Khan University Hospital
• Kenyatta National Hospital









• Counterfeit medicines are becoming a major global healthcare problem.
• In developed countries counterfeits constitute 1-2% of all medicines and
~50% from the internet.
• In sub-Saharan Africa 30-40% of all medicines are thought to be coun-
terfeit.
• Thus there is a need for a simple rapid screening process to identify sus-
pect medicines, especially in tablet form.
• Tablets are a complex mixture of the active pharmaceutical ingredient/s
(API/s) and many other materials, the excipients. The API/s constitute 1-
90% of the tablet w/w depending on the dose level.
• For screening purposes there is the need to confirm the presence of the
API/s with minimal sample work-up and specifically no solvent extraction in
order to increase throughput. 
• This research compares the direct mass spectrometer (MS) analysis of
ions produced from crushed tablet samples introduced into the analyser by
two different sampling probe techniques.
• The two systems are shown schematically in Figure 1(a) and (b).
METHODOLOGY
• Both systems have a demountabale probe with replaceable cups in the
tip to hold powder or liquid samples.
• Both systems have a simple quadrupole MS with unit mass resolution
scanning over the m/z range 50-500.
• The differences between the ease of use and the results from the sys-
tems are derived from the means of sample volatilisation and subsequent
production of positive ions.
Direct Insertion Probe (DIP)
• Bruker 300-MS, Bruker Instruments, UK.
• Once the sample is placed in the tip the probe has to be inserted into the
MS vacuum system via a vacuum lock.
• The probe tip was electrically heated over the range 40-300˚C.
• Volatilised material was ionised by 20eV electron impact.
• Ions were focussed into the Bruker 300-MS for analysis.
RESULTS
Atmospheric Solids Analysis Probe (ASAP)
• Advion Compact MS (CMS), Advion Ltd, UK.
• Once the sample is placed in the tip the probe is inserted directly into the
ionisation region and the flow of heated nitrogen volatilises the API/s.
• Ionisation occurs by protonation in the corona discharge field.
• Ions are focussed into the Advion Compact MS for analysis.
Materials
• Reference samples of paracetamol, caffeine, atenolol, chloroquine phos-
phate, sulfadoxine and the excipients magnesium stearate and lactose were
obtained from Sigma Aldrich, UK.
• Literature data was used for the identification of the MS data from art-
mether and lumifantrine tablets.
• Tablet samples were obtained from various ‘pharmacy’ sources in India,
Nigeria, Nepal, China and Rwanda and compared with samples from the
UK and Europe and with the reference data.
Fast identification of counterfeit medicines - a comparison of two MS methods
Graham Lawson1, John Ogwu1, Rachel Armitage1, Clive Alcroft2, Sangeeta Tanna1
1Leicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, The Gateway, Leicester LE1 9BH, UK
2Advion Ltd, Nottingham, UK
• Electron impact ionisation in the DIP process leads to molecular frag-
mentation with a consequent reduction in the intensity of the molecular ion.
• The fragmentation pattern is a characteristic fingerprint of that compound
which can be used for identification.
• Proton transfer, in the ASAP system, is a soft ionisation process which
should enhance the presence of the pseudo-molecular ion at M+H+ and
thereby produce a much simpler spectrum suitable for screening purposes.
Reference sample data
• Samples of the pure reference materials were analysed by both systems.
API RMM (MWt) m/z DIP m/z ASAP
Paracetamol 151 151, 109 152, 110
Caffeine 194 194 195
Chloroquine phosphate 516 319, 86 320, 247
Atenolol 266 222, 223 267,190, 225
Sulphadoxine 310 246, 245, 227 311, 156
• Tablet samples containing these API/s either singly or in combinations,
were collected and submitted to both analytical methods. 
Single API in a tablet




Two APIs in a tablet
• Both APIs in a single tablet can be identified. 
Figure 4. Mass spectra of tablets containing paracetamol and caffeine using DIP (a) and ASAP (b)
Figure 5. Mass spectra of sulphadoxine and pyrimethamine tablets using DIP (a) and ASAP (b)
• The ASAP mass spectra were very simple even from complex tablet for-
mulations. The presence of single and multiple APIs could be confirmed.
• The ASAP probe analysis of antimalarial tablets gave for chloroquine
phosphate m/z 320, 247 (RMM 516). Multicomponent tablets were more
challenging; lumifantrine gave m/z 530, 528 (RMM 529) and artemether
produced fragment ions at m/z 221 (RMM 298). Artensuate produced ions
at m/z 321, 325 (RMM 384) and amodiaquine at m/z 357 (RMM 356).
• The DIP probe relied on the more energetic electron impact ionisation
which produced some fragmentation of the parent molecule. In several
cases this resulted in less informative spectra. The EI observed signals
were: paracetamol m/z 151, 109; caffeine 194, 109; chloroquine phosphate
m/z 319, 86. 
• The multicomponent antimalaria tablets were difficult; lumifantrine and
artemether tablets produced a single fragment ion at m/z 142. Artensuate
produced ions at m/z 69, 81 (RMM 384) and amodiaquine at m/z 356, 357
(RMM 356).
(b)(a)
Figure 2. Mass spectra of genuine paracetamol tablets using DIP (a) and ASAP (b)
Figure 3. Mass spectra of suspect paracetamol tablets using DIP (a) and ASAP (b)
• Overall the ASAP probe system produced data more rapidly and with less
potential for contamination of the ionisation region. The ASAP mass spectra
were generally simpler which was ideal for use as a rapid screening
methodology to identify counterfeits in a QC scenario.
(a) (b)
(b)(a)
• Paracetamol samples from China and India giving inconsistent spectra. 
Figure 1. Schematic representaion of Direct Insertion Probe (DIP) (a) and Atmospheric Solids







• From ‘acceptable’ counterfeits of designer items to fake anti-cancer medicines
counterfeiting is a growing worldwide criminal trend that affects us all.
• The WHO estimate that ca. 10% of medicines sold worldwide are counterfeit1
whilst Pfizer estimates that 80% of all internet sales of Viagra are counterfeit2.
• More than 400 patients in Pakistan died as a result of poor quality heart disease
medicines and untold hundreds of Africans following treatment with substandard
anti-malarial medication.
• The authentification of in-dose medication forms usually relies on secure pack-
aging and tracking codes in combination with human senses. This approach is
necessary to maintain the volume of medicines imported into a country. Fake
packaging never hurt a patient.
• In reality it is the dosage form that must be acceptable and therefore a rapid
test taking only a few minutes to establish the quality of the dosage form would
be an extremely valuable tool.
• Some of the options for investigating a suspect counterfeit medicine are shown
in Fig. 1.
Figure 1. Options for investigating counterfeit medicines
• The time taken for each level increases from minutes for the top 2 to many
hours for the in depth analyses.
• Infrared (IR) techniques offer a convenient method for the identification of phar-
maceutical active ingredients (AI).
• The conventional approach uses solvent extraction followed by KBr disc prepa-
ration and IR transmission analysis. Whilst this approach is designed to remove
the AI from the excipients it is lengthy and has several drawbacks:
• KBr is hygroscopic and not easy to handle or store
• Difficult to make good KBr disc and need a hydraulic press
• Two much sample in the disc results in poor spectra
• These disadvantages can all be overcome by the use of the Attenuated Total
Reflection (ATR) IR mode. The basic principle is shown in Fig. 2.
• Examples of the agreement of the ATR spectra with reference spectra are
shown in Fig. 3.
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• The simple ATR approach provides a means of rapid assessment of the med-
ication in the presence of the excipients.
• Within the limits of the present study the presence of stated AIs can be con-
firmed.
• The ATR system is able to identify material for further investigation rapidly
based on dry powder analysis.
• The sample is placed on the top of the ATR crystal and the incident beam is at-
tenuated at the sample/crystal interface before detection.
• Any sample that can maintain an intimate contact with the crystal can therefore
be examined.
• The crucial questions in terms of the proposed application are:
• Will the ATR spectrum match the reference spectrum for the AI selected?
• Can a fingerprint IR spectrum be obtained in the presence of excipients?
• Can therapeutic levels of AIs be identified in tablet/liquid formulations?
• A range of tablets were used to examine the potential of the ATR technique.
Identification of counterfeit pills -
Is rapid instrumental analysis possible?
Sangeeta Tanna, Rachel Armitage, Graham Lawson  
Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK
Figure 2. ATR principle
• All of the analyses were run using the Bruker Alpha ATR FTIR system scanning
over the range 2000 - 600 cm-1 with 4 cm-1 resolution.
• Test materials were over-the-counter formulations or prescription dosage forms
from the NHS in the UK. These were tablets containing Aspirin, Caffeine, Parac-
etamol, Ibuprofen, Atenolol and Viagra.
• The general experimental approach was as follows:
• The test tablet was crushed and separate samples of the powder were 
individually analysed to test the reproducibility versus granule size.
• The resultant spectra were compared with reference data.
• The detection limit for the AIs was investigated by preparing known con-
centrations of the AI in a pre-prepared excipient mixture3.
Figure 4. Direct ATR analysis of crushed Viagra reference tablet
Ref              Test Ref Test
Figure 3. A comparison of the ATR spectrum for a caffeine tablet (red) and caffeine standard (blue)
Figure 5. Comparison of regions of the ATR spectra for reference and test Viagra tablets
• The results for the fingerprint determinations and the LODs of the AIs in excip-
ient mixtures are detailed in Table 1.
Table 1. Summary of quantitative data







• Pain relief tablets often contain several AIs. Such tablets were studied to see
if peaks characteristic of the stated components could be identified (Table 2).
Table 2. Summary of qualitative data for pain relief tablets
Pharmaceutical Active Ingredients (AIs) Result
Aspirin + Caffeine Characteristic peaks observed for both
Aspirin + Caffeine + Paracetamol Characteristic peaks observed for all three
• Fig. 4 shows the spectrum from a Viagra reference sample. Comparsion of re-
gions of the spectrum obtained from an ‘Internet Viagra’ sample with the reference
(Fig. 5) showed sufficient differences to raise questions of authenticity.
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A Microscopic Approach to a Big Problem...
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CONCLUSION AND FURTHER WORK
• The World Health Organisation (WHO) estimates up to 1% of all medicines in developed countries are likely to be 
counterfeit, whilst in developing countries it is estimated that 33% of medicines are counterfeit1.
• India is the leading supplier of low cost generic drugs to Africa2, and it has been reported that India leads all countries 
in producing and exporting counterfeit medicines3.
• As much as 35% of worldwide counterfeit sales comes from India, with Pakistan accounting for 13.3% of sales3.
• Counterfeit medicines have been known to use insufficient amounts of active ingredient in their products to enable 
them to pass qualitative screening tests. As a result, patients receive lower than expected doses of the drug, leading 
to ineffective treatment, therapeutic failure and even drug resistance.
• Counterfeiters are already finding ways to bypass established techniques, therefore the development of new 
techniques is required.
• The overall aim of this project is to develop a novel method for the rapid identification of counterfeit drugs.
• To achieve this, spectroscopic methods including Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray 
Spectroscopy (EDX) will be applied to dosage forms and compared to suitable references.
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• Samples of Atenolol (used for the treatment of high blood pressure) were obtained from Pakistan and India and were compared 
to UK manufactured samples.
• Cross sections of the Atenolol tablets were analysed using SEM/EDX to investigate if the spatial array of selected elements 
could provide a novel technique to fingerprint  tablets.
• Backscatter images of the UK and Indian sample show noticeable compositional and topographical differences. 
• EDX analysis confirms the compositional differences, in particular the absence of Titanium and Aluminium and presence of 
Phosphorus in the Indian sample.  
• Promising results have already indicated that other detectors on the SEM in conjunction with this work may be suitable to 
detect counterfeit medicines, further work is needed to develop and validate this novel method.
• Current published methods focus on a specific formulation, however this method has the potential for universal formulations.
Figure 1a - Backscatter image of UK sample Figure 1b - EDX map of UK sample
Figure 2a - Backscatter image of Indian sample Figure 2b - EDX map of Indian sample
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INTRODUCTION
• The World Health Organisation (WHO) estimates up to 1% of all medicines in developed countries are likely to be 
counterfeit, whilst in developing countries it is estimated that 33% of medicines are counterfeit1. 
• The figure for internet sales, may be as high as 50% from websites that conceal their physical address1& 2. It is 
believed 2.5 million men in Europe haven taken counterfeit Viagra, purchased online3.
• The United Nations (UN) estimates worldwide trade in counterfeit medicines is worth $500 billion with West Africa 
one of the key destinations4.
• Usage of counterfeit medicines can result in treatment failure, drug resistance or even death. The International 
Policy Network blames counterfeit medicines for 700,000 deaths worldwide from Malaria and Tuberculosis4.
• Forensic investigation of counterfeit medicines can be time consuming, costly and usually destructive.
AIMS AND OBJECTIVES
• The overall aim is to develop a novel method for the rapid identification of counterfeit drugs.
• To achieve this spectroscopic methods will be applied to packaging and dosage forms and compared to suitable references.
• Methods which eliminate the need for extensive sample preparation will also be developed.  
PRELIMINARY RESULTS
• Suspect samples of Atenolol were obtained from Pakistan and compared to genuine samples.
• Samples were visually analysed (Figure 1 a and b) and tested to BP standards using UV/Vis (Figure 2). 
• Cross sections of Ibuprofen tablets were analysed using SEM/EDX (Figure 3) to see if the spatial array of selected elements 
can provide a mechanism to fingerprint a tablet.
CONCLUSIONS
REFERENCES & ACKNOWLEDGEMENTS
• Visual inspection shows strong indications that one sample is counterfeit.
• Preliminary UV/Vis results show that Blokium tablets tested contained sub-therapeutic dose levels.
• UV/Vis results show that Zafa tablets tested did not contain uniform content of Active Pharmaceutical Ingredient (API).
• SEM/EDX has potential for identifying different tablet types and further work is aimed at differentiation of tablets of similar 
generic formulations.
1. World Health Organisation. Guidelines for the development of measures to combat counterfeit drugs. 1999.
2. MHRA. Counterfeit medicines and devices: MHRA. 2009.
3. http://www.nlm.nih.gov/medlineplus/news/fullstory_94707.html
4. http://www.policynetwork.net/health/media/awash-fake-drugs-nigerians-fight-back
Thanks go to Faheem Ahmed for collaborating on the UV/Vis analysis and to David Armitage for collaborating on the SEM/EDX analysis.
Genuine Sample Suspect Sample
The external packaging of genuine and suspect Tenormin branded Atenolol were 
visually compared. Results show that the suspect sample carries ICI’s logo in 
addition to AstraZeneca’s. 
Figure 1b – Visual Appearance (Tablet)
Genuine Sample Suspect Sample
Genuine and suspect Tenormin tablets were visually compared. Analysis of the 
images shows significant differences, the genuine sample has the brand name 
on one side. The ‘105’ on the reverse side is the manufacturer’s code for a 
50mg tablet. The suspect sample shows the brand name and dose level on 
one side and is blank on the reverse. In addition the score mark is missing 
from the suspect sample.
Figure 2 – UV/Vis Analysis of 50mg Atenolol Tablets
3 sets of Atenolol samples 
were acquired from 
Pakistan and dose levels 
were compared to a 
genuine sample from the 
UK (Teva). Results 
indicate that the Blokium
tablets tested were sub-
therapeutic. Zafa tablets 
exhibited poor uniformity, 
possibly as a result of 
inadequate mixing. 
Tenormin tablets and Teva
tablets are comparable. 






Results show the distribution of 
elements within the cross section 
of the tablet. 
Figure 1a – Visual Appearance (Packaging)
The presence of different elements 
can indicate certain excipients.
